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DETECTING AND EVALUATING THERAPY INDUCED CHANGES IN RADIOMICS
FEATURES MEASURED FROM NON-SMALL CELL LUNG CANCER TO
PREDICT PATIENT OUTCOMES

Xenia Janice Favè, B.S.
Advisory Professor: Laurence E. Court, Ph.D.

The purpose of this study was to investigate whether radiomics features
measured from weekly 4-dimensional computed tomography (4DCT) images of
non-small cell lung cancers (NSCLC) change during treatment and if those
changes are prognostic for patient outcomes or dependent on treatment modality.
Radiomics features are quantitative metrics designed to evaluate tumor
heterogeneity from routine medical imaging. Features that are prognostic for
patient outcome could be used to monitor tumor response and identify high-risk
patients for adaptive treatment. This would be especially valuable for NSCLC due
to the high prevalence and mortality of this disease.
A novel process was designed to select feature -specific image
preprocessing and remove features that were not robust to differences in CT
model or tumor volumes. These features were then measured from weekly 4DCT
images. These features were evaluated to determine at which point in treatment
they first begin changing if those changes were different for patients treated with
protons versus photons. A subset of features demonstrated significant changes
by the second or third week of treatment, however changes were never
significantly different between patient groups. Delta -radiomics features were
defined as relative net changes, linear regression slopes, and end of treatment
feature values. Features were then evaluated in univariate and multivariate
vi | P a g e

models for overall survival, distant metastases, and local -regional recurrence. In
general, the delta-radiomics features were not more prognostic than models built
using clinical factors or features at pre-treatment. However one shape descriptor
measured at pre-treatment significantly improved model fit and performance for
overall survival and distant metastases. Additionally for local-regional recurrence,
the only significant covariate was texture strength measured at the end of
treatment. A separate study characterized radiomics feature variability in cone beam CT images to increased scatter, increased motion, and different scanners.
Features were affected by all three parameters and specifically by motion
amplitudes greater than 1 cm.
This study resulted in strong evidence that a set of robust radiomics
features change significantly during treatment. While these changes were not
prognostic or dependent on treatment modality, future studies may benefit from
the methodologies described here to explore delta -radiomics in alternative tumor
sites or imaging modalities.
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Chapter 1 : Introduction
Lung cancer is responsible for the majority of cancer deaths in the United States for
both men and women1. In 2016 there were an estimated 224,390 new lung cancer cases1. Of
these, up to 85% were diagnosed as non-small cell lung cancer (NSCLC)1,2. While advances in
cancer care have substantially improved outcomes for particular tumor sites over the past 20
years, little change has been seen in the NSCLC patient outcomes3. Additionally, patients with
similar clinical factors and pathological characteristics can have very different outcomes4. As a
result, multiple studies have sought prognostic biomarkers that would identify high-risk patients
in order to tailor their treatment5–9. One novel approach for identifying high-risk NSCLC patients
is the use of radiomics features.
Radiomics is the process of calculating quantitative imaging features from medical
images and using these values to characterize the tumor or predict a clinical outcome10. These
features can be simple intensity-derived metrics such as the mean value or standard deviation
of the pixels within the tumor. More sophisticated metrics also exist that aim to capture the
spatial heterogeneity of pixels in the tumor. These include descriptive features such as contrast
or busyness and are measured from radiomics matrices such as the co-occurrence matrix11,12,
run length matrix13, or neighborhood difference matrix14. A variety of shape features also exist
to quantitatively describe how smooth or spiculated the tumor appears. Useful features are
believed to reflect tumor-specific phenotypes and biology. Radiomics features have the
advantage of measuring regional heterogeneity differences from the entire 3 dimensional tumor
which are known to vary spatially in solid tumors15–17. This advantage contrasts with biopsies
that can only sample specific points and may miss the heterogeneous areas linked to
malignancy. Additionally, repeated tumor biopsies can lead to patient complications and
particularly for lung cancer can result in pneumothorax18 while radiomics analyses are
inherently non-invasive. In fact, features are typically measured from medical images that are
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already routinely acquired so large datasets for radiomics analyses can be acquired without
interrupting the clinical workflow.
Radiomics studies have had success using computed tomography (CT),
fluorodeoxyglucose(FDG) positron emission tomography (PET), and magnetic resonance (MR)
images for a multitude of tumor sites. Radiomics has been particularly successful in studies
using CT images of NSCLC tumors. Much of the early groundwork for this area focused on
classifying tumors either by histology or malignancy. For example, an early study tested the
ability of 102 2D and 215 3D features to classify 74 lung tumors as adenocarcinoma or
squamous-cell carcinoma19. They achieved 68% classification accuracy by using a decisions
tree based classifier19. Song et al also investigated the ability of 592 radiomics features to
correctly classify histology and by using support vector machines were able to achieve 75%
classification accuracy20. Another study used radiomics features from 72 mediastinal lung
cancer nodes to classify the nodes as benign or malignant and achieved 81% sensitivity with
80% specificity21. A separate study also classified small nodules as benign or malignant using
radiomics features and identified five features from the co-occurrence matrix that could be used
as independent classifiers22.
There have also been a variety of radiomics studies focused on predicting outcomes for
NSCLC patients. The majority of these have examined predicting overall survival such as a
study by Aerts et al which developed and validated a radiomics signature in both lung cancer
and head and neck cancer patient cohorts23. Other studies have indicated that radiomics
features can act as independent predictors of overall survival24,25 and significantly improve risk
stratification compared to clinical factors alone26,27. Studies predicting risk of distant metastases
were able to develop a radiomics-signature with a c-index of 0.6128 and improve risk
stratification compared to clinical models alone26. Studies have also investigated radiomics for
predicting recurrence in NSCLC. One study used 101 early stage patients with
adenocarcinoma and predicted tumor recurrence with a c-index of 0.81 and AUC of 0.7929. Koo
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et al used radiomics features measured from the preoperative CT images to predict tumor
recurrence30 while Mattonen et al used the post-treatment follow-up CT images to predict if the
patient was developing radiation induced lung injury or recurrence31. In summary, many groups
have reported success in using radiomics features to either classify tumor types or predict
patient outcomes.
These studies have prompted research into the underlying biology that drives these
features. Recently genetic mutations in NSCLC tumors have been linked to radiomics features.
Specifically, kurtosis and skewness from the histogram were shown to be related to KRAS
mutations32 while features from the gray-level co-occurrence matrix were linked to EGFR
mutations33. Both of these mutations are connected to the MAPK pathway which is known to be
prognostic for survival34. These results suggest that there is a biological explanation for the
success of certain features measured from NSCLC in predicting patient outcomes or classifying
tumors.
In all of the afore-mentioned studies the radiomics features were measured at one time
point and typically prior to treatment. If these features are measuring tumor phenotypes then
the changes in the features during treatment may be useful as biomarkers of response.
Currently, tumor response is typically measured using the Response Evaluation Criteria In
Solid Tumor (RECIST) guidelines35,36. These guidelines primarily evaluate response through
the change in size of the tumor which is measured as either the largest diameter or overall
volume35. Studies using changes in radiomics features (delta-radiomics) have been used in
other areas of radiomics research. One study used delta-radiomics features to measure and
predict pneumonitis from CT images37. For CT images of colorectal liver metastases, the
relative differences in uniformity and entropy measured pre- and post- chemotherapy were
more prognostic of tumor response than changes in size or volume38. Another study examined
the role of a feature, mean of positive pixels, measured from contrast enhanced CT images of
soft tissue sarcomas to predict pathological response and showed that it outperformed size,
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density, and tumor blood flow39. However no study has yet examined the potential for deltaradiomics to assess NSCLC tumor response.
While radiomics features have been successfully used in a variety of studies, there are
also several challenges associated with their use. Because they are statistical metrics
calculated from the pixels of the tumor image, they are highly dependent on the parameters
used to acquire the images as well as any artifacts within the image. For CT images in
particular, features have been shown to be affected by the scanner used to acquire the
images40 and the imaging parameters41. Even in test-retest studies of the same patient on the
same scanner or studies using multiple contours on the same images, features have shown
variability42,43. Additionally, radiomics features can be calculated using different parameters or
image processing techniques, such as gray-level discretization, and the specific choice of
parameters can impact the feature reproducibility44. Controlling for these uncertainties is
challenging because of the lack of a ground truth for the feature values.
The main goal of this study was to evaluate whether delta-radiomics features measured
from CT images of NSCLC are independent, useful biomarkers of tumor response when
compared to clinical factors and radiomics features measured prior to treatment. An identified
subset of useful features would be beneficial for evaluating an individual patient’s tumor
response and potentially altering their treatment or follow-up care.
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Chapter 2 : Purpose and Central Hypothesis
Central Hypothesis
Radiomics features measured from NSCLC tumors change significantly during treatment, and
the magnitude of those changes are characteristic of treatment modality and prognostic for
outcome.
Specific Aim 1: Calculating Radiomics Features
Aim: Analyze the effect of image preprocessing on a set of radiomics features measured from
CT images and identify the optimal preprocessing for each.
Hypothesis: The image preprocessing technique used has a significant impact on the
prognostic ability and volume independence of radiomics features.
Project 1.1: Analyze the impact of image pre-processing on the volume dependence of
radiomics features.
Project 1.2: Analyze the impact of image pre-processing on the univariate significance
of radiomics features.
Project 1.3: Analyze the impact of image pre-processing on the scanner independence
of radiomics features.
Specific Aim 2: Prognostic Potential of Radiomics Features
Aim: Determine which radiomics features, measured from CT images, change significantly
during the course of radiation therapy and the relationship between these changes and
outcome.
Hypothesis: Radiomics features can be identified that change during the course of treatment
and are predictive for patient outcome.
Project 2.1: Identify radiomics features that change significantly with dose.
5|Page

Project 2.2: Determine the univariate significance of the radiomics features and clinical
factors in predicting 3 outcomes.
Project 2.3: Perform a multivariate analysis including radiomics features and clinical
factors in order to predict 3 outcomes.
Specific Aim 3: Reproducibility of Radiomics Features from CBCT Images
Aim: Identify which radiomics features can be reproducibly measured from cone-beam CT
(CBCT) images.
Hypothesis: A subset of radiomics features can be identified that are robust to the increased
scatter and motion present during CBCT imaging.
Project 3.1: Evaluate the impact of using different CBCT imagers to acquire images on
the extracted radiomics features.
Project 3.2: Evaluate the impact of different thicknesses of scatter material on the
extracted radiomics features.
Project 3.3: Evaluate the impact of motion during imaging on the extracted radiomics
features.
Specific Aim 4: Treatment Modality Dependence of Radiomics Features
Aim: Compare the changes in radiomics features from patients treated with intensity
modulated radiation therapy (IMRT) to those treated with passive scatter proton therapy
(PSPT).
Hypothesis: The changes in radiomics features measured from patients treated with protons
will occur earlier in treatment compared to those treated with photons due to the increased
RBE.
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Project 4.1: Compare the distribution of values at the beginning and end of treatment
for the two treatment modalities
Project 4.2: Quantify when in treatment radiomics features first exhibit significant
changes from baseline and if those changes are modality-dependent at any point in
treatment.
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Chapter 3 : General Methodology
Portions of this chapter are written or based on the following publications:
Fave, X, Mackin, D, Yang, J, Zhang, J, Fried, D, Balter, P, Followill, D. , Gomez, D, Jones, AK, Stingo, F,
Fontenot, J, and Court, L. Can radiomics features be reproducibly measured from CBCT images for
patients with non-small cell lung cancer? Medical Physics doi: 10.1118/1.4934826. Volume 42, Issue 12,
pages 6784-6797. 2015. ©John Wiley and Sons.
Fave X, Zhang L, Yang J, Mackin D, Balter P, Gomez D, Followill D, Jones AK< Stingo F, Court LE.
Impact of image preprocessing on the volume dependence and prognostic potential of radiomics
features in non-small cell lung cancer. Translational Cancer Research. Doi: 10.21037/tcr.2016.07.11.
Volume 5, Issue 4, pages 349-363.(c) AME Publishing Company.
The permission for reuse of this material was obtained from John Wiley and Sons © and AME Publishing
Company© respectively.

The typical workflow for any radiomics study is to gather a set of patient images, define
the region of interest (ROI) on each, extract a set of radiomics features from these ROIs, and
then perform the statistical analysis. In this chapter we describe these parts of the methodology
that were universal through the analyses for the 4 aims. First the initial patient cohort used in
this study and the exclusion criteria we used are described. Then our methodology for
delineating the tumor ROI on these patient’s images is explained. Finally details of the
radiomics software and radiomics features are given. Further details that are particular to a
specific study are described in the relevant subsequent chapters.

Patient Cohort
The following analyses were performed using the images, clinical factors, and outcomes
data from a set of 157 patients treated at the University of M.D. Anderson between 2009-2014
as part of an institutional review board (IRB) approved clinical trial comparing outcomes and
normal tissue toxicity between patients treated with intensity modulated radiation therapy
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(IMRT) and passive scatter proton therapy (PSPT)45. The retrospective review conducted for
this study was approved by the University of Texas M.D. Anderson Cancer Center IRB with a
waiver of informed consent. Patients on the original trial were treated with concurrent
chemotherapy. The inclusion criteria for patients on that trial were the presence of a
pathologically proven, unresected, locoregionally advanced, stage II-IIIB NSCLC tumor, a
Karnofsky performance score >70 or ECOG score 0-1, measurable disease on a chest x-ray,
contrast enhanced CT, or PET scan, a forced expiratory volume in the first second >/=1 liters,
acquisition of a fluorodeoxyglucose (FDG)-PET scan 3 months before trial registration,
between 18-85 years old, and a signed informed consent form45. The exclusion criteria were
diagnosis of small cell tumor histology, prior radiation to the treatment field, pregnancy, body
weight that exceeded the limits of the treatment couch, or being oxygen dependent due to
preexistent lung disease45. For the analyses in this dissertation, extra exclusion criteria were
implemented for each specific aim to ensure uniformity in the dataset and/or robustness of the
radiomics features. These specific criteria are addressed independently where they apply in
chapters 4-7 and are summarized in the Exclusion Criteria section below.

Imaging Parameters
As part of the aforementioned clinical trial, patients were imaged during each week of
their treatment with a 4 dimensional CT (4DCT) using the institutional protocol: peak tube
voltage of 120 kVp, tube current of 100 or 200 mA, and rotation time of 0.5 or 0.8 seconds.
Images were reconstructed into a 512x512 pixel matrix with an image thickness of 2.5 mm and
in-plane resolution of 0.98 mm. Additionally, a pre-treatment 4DCT was acquired for treatment
planning purposes using the same institutional protocol. Images were acquired using a GE
Discovery ST (GE Medical, Waukesha, WI), GE LightSpeed RT16, Phillips Brilliance Big Bore
(Philips Medical Systems, Cleveland, OH), or Philips Brilliance 64 CT scanner.
Patients also received cone-beam CT (CBCT) images for setup verification periodically
through treatment. All of the CBCT patient images were acquired using the thoracic imaging
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protocol on a Varian linac: peak tub voltage of 110 kVp, tube current of 20 mA, and exposure
time (total pulsed beam-on time) of 7-14 seconds. Images were reconstructed as a 512x512
grid with pixel dimensions of 0.8 mm and a 2.5mm slice thickness.

Tumor Region of Interest
In the subsequent analyses the end-of-exhale phase images for each 4DCT scan were
used for feature extraction. This phase was selected because it was considered the most
reproducible for patients and has been used in other radiomics studies26,46,41. Additionally, one
study demonstrated that radiomics features consistently order patients regardless of phase
from T20 to T90, where T50 represents the end of exhale phase41. The three-dimensional
gross tumor volume contour from the treatment plan was used as the region of interest (ROI)
for feature extraction. The gross tumor volume contour from the treatment plan was deformably
registered to each subsequent weekly 4DCT scan using a clinical software, CT-assisted
targeting, developed in-house47–49. During this step, only the contour is deformed, the images
themselves are not changed. Examples of deformed contours are in Figure 3.1. After the
contours were deformed, each image was examined to ensure consistency and make minor
adjustments. Adjustments were most frequently needed for tumors connected to the
mediastinum. In all cases, adjustments were made conservatively: that is, contouring only
tumor was prioritized over contouring anything that could be tumor. This approach was
successfully used in previous radiomics studies in our group26. Furthermore, to ensure that
normal lung and bone were excluded from the final ROI used for feature calculation, a
thresholding step was also applied to each CT image with a lower threshold of -100 Hounsfield
Units (HU) and upper threshold of 200 HU.
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Figure 3.1: Axial image slices for two patients at the beginning and end of treatment. The
contour from the pre-treatment CT was deformed to each subsequent weekly 4DCT image.
The two examples shown here demonstrate the robustness of this process to tumor shrinkage
(Patient A) and cavitation (Patient B).

Exclusion Criteria
Of the 157 patients, 29 never had their GTV contour deformed to the weekly images
and all of their images were left out of the analysis entirely following the following criteria:
1. The patient’s weekly images were acquired using breath hold instead of 4DCT, n=9
patients.
2. The patient had no GTVp in their plan (only nodal disease apparent), n=11 patients.
3. The patient’s primary tumor was very small at beginning of treatment and
disappeared before the end of imaging, n=9 patients.
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The remaining 128 patients had the GTV contour deformed to each of their weekly
images and radiomics features were calculated from each image. These patients had between
4-9 images each. The following extra exclusion criteria were applied by calculating the volume
of the deformed GTV on each image:
4. The patient was excluded if the measured tumor volume was <5cc at the beginning
of treatment, n=18 patients.
5. A patient’s particular weekly image was excluded if the measured tumor volume at
that week fell below 5 cc, n=28 images from 7 patients.
This left 110 patients with between 2-9 images each. When the methods included a
survival analysis then a landmark time point was used. This technique is explained in detail in
Chapter 5 and required the following extra criterion to be applied:
6. Patients who experienced the event in a survival analysis before the landmark time
were excluded, n=3 for overall survival, n=4 for time until distant metastases, and
n=4 for time until local-regional recurrence.
This left 107 or 106 patients for survival analyses.

Clinical Factors
Clinical factors were obtained through a retrospective review of the patient charts and
are listed in Table 3.1. These factors were used as clinical covariates in Aim 2 and thus are
tabulated for the patient subset of 107 patients that was used in Aim 2. Many of the clinical
factors were split into levels for ease of model building as well as to reflect actual clinical impact
(e.g. age>65 is more meaningful for treatment and outcome than that a patient’s age is exactly
68). The levels used for each covariate are also listed in Table 3.1.
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Radiomics Calculation Software
The Imaging Biomarker EXplorer (IBEX) software package version 1.0 was used for the
calculation of all radiomics features in this study50. This software is an open-source, MATLAB
based package that is freely available online at http://bit.ly/IBEX_MDAnderson. IBEX allows the
user a large amount of freedom in how the features are calculated. This includes the ability to
preprocess the image with different imaging filters, and the flexibility to adjust parameters of the
different radiomics matrices such as the co-occurrence matrix bin size and offset.
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Table 3.1: Clinical factors used in this study.
Clinical Factors
Sex
F
M
Age
<65
>=65
T stage
T1 or T2
T3 or T4
N stage
N0 or N1
N2 or N3
Overall disease stage
II
IIIa
IIIb
IV
Tumor histology
Squamous cell carcinoma
Adenocarcinoma or other
Smoking status
Current
Former
Never
Pack years (continuous)
0-24
25-49
50-74
75+
Karnofsky performance status
90-100
70-80
Total radiation dose
>70 Gy
<70 Gy

Number of Patients
(n=107)
45
62
45
62
49
58
24
83
12
44
49
2
46
61
34
64
9
20
37
28
22
52
55
72
35
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Image Preprocessing
Prior to radiomics feature calculation, images were often filtered with either a smoothing
filter such as the Butterworth filter or with bit depth resampling. In both cases, the aim of the
filtration was to reduce the noise in the image and thus produce more informative values for the
radiomics features. The impact of different filters on the features was explored as part of Aim 1
in Chapter 4 and full details of the filters are available there. The subsequent filtration selected
and used for each feature is detailed under each specific study.

Radiomics Features
The majority of features currently used in radiomics studies were designed to evaluate
visual perception characteristics (i.e. contrast) quantitatively. These include co-occurrence
matrix11,12, run-length matrix13, and neighborhood gray-tone difference matrix features14. Other
commonly used radiomics feature categories include those calculated from the histogram or
histogram features calculated after Laplacian of Gaussian filtration51,52. Each radiomics feature
category included in this study is explained in more depth below. Different feature subsets were
used within each aim and the particular feature selection criteria are thus described
independently in Chapters 4-7.
Histogram Features
Features derived from the histogram category are those that can be calculated from the
full distribution of intensities in the ROI with or without binning. These are commonly referred to
as first order statistics. Features included in this category are: energy, entropy, kurtosis,
maximum, mean, median, minimum, skewness, standard deviation, uniformity, and variance.
The majority of histogram features were calculated from the full distribution of intensities (e.g.
bin size=1). A few features require a histogram to be calculated (entropy and uniformity) and in
these cases the histogram bin size was 16. In both cases the full distribution of values in the
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ROI after thresholding was used. Full descriptions and algorithms for each of these features
are well documented in the literature23,53,54.
Co-occurrence Matrix Features
The co-occurrence matrix was first defined by Robert Haralick et al in 197312. The
matrix quantifies the frequency at which each gray-level intensity appears adjacent to each
other gray-level intensity in a particular direction. Thus the matrix represents spatial information
from the image and is designed to represent what an observer would perceive as the texture of
the image. The features derived from the matrix are considered second-order features because
they capture more information from the image than first-order histogram based features. In this
analysis the bin sizes for gray-level intensities were always set to 1, while the images were
often rescaled to 8 bit images prior to feature calculation, thus creating bins of size 16
Hounsfield units. The co-occurrence matrix was always calculated in the four 2D directions (0°,
45°, 90°, and 135°) for each axial slice. The co-occurrence matrices for a particular direction
are then summed over the set of axial slices. These direction-specific matrices are then
summed and averaged to create the final co-occurrence matrix for the 3D tumor ROI. These
steps are performed automatically by the IBEX software when calculating the co-occurrence
matrix. Features calculated from this matrix were auto-correlation, cluster prominence, cluster
shade, cluster tendency, contrast, correlation, difference entropy, dissimilarity, energy, entropy,
homogeneity, homogeneity 2, information measure correlation 1, information measure
correlation 2, inverse difference moment norm, inverse difference norm, inverse variance, max
probability, sum average, sum entropy, sum variance, and variance. Full descriptions and
algorithms for each of these features are well documented in the literature11,12,23,53,54.

Gray-Level Run-Length Matrix Features
The gray-level run-length matrix, hereafter described as the run-length matrix, was
defined by Mary Galloway in 197513 to classify images of terrain. Runs are defined as
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consecutive, collinear image pixels with the same gray level intensity value13. The run-length
matrix is a tally of the number of runs of each length versus each gray-level intensity. Similar to
the co-occurrence matrix, the run-length matrix is calculated for a particular direction (0°, 45°,
90°, or 135°). For this study, the run-length matrices in this study were calculated in the 0° and
90° direction and then summed and averaged to create a global 3D run-length matrix from
which to calculate the features. This step is automatically performed within IBEX. The other 2D
directions were not used because they have not yet been implemented within IBEX. Bins of
size 1 were used in all cases, although the images themselves were often resampled to 8 bits
resulting in a de facto bin size of 16 HU. In calculating features from this matrix, different areas
can be emphasized to highlight noise (short runs) or signal (long runs). The features calculated
from this matrix were short runs emphasis, long runs emphasis, gray level non-uniformity, run
length non-uniformity, run percentage, short run low gray level emphasis, short run high gray
level emphasis, long run low gray level emphasis, long run high gray level emphasis, low gray
level run emphasis, and high gray level run emphasis. Descriptions and algorithms for each of
these features are available in the literature23,13,53,54.
Neighborhood Gray-Tone Difference Matrix Features
The neighborhood gray-tone difference matrix, hereafter described as the neighborhood
difference matrix, was designed by Moses Amadasun in 1989 to accurately quantify human
perception of five visual characteristics: coarseness, contrast, busyness, complexity, and
texture strength14. The neighborhood difference matrix is a one-column matrix with an entry for
each gray-level intensity in the image. To obtain the values in the matrix, first the average
difference between each pixel and its neighbors is calculated. These average differences are
then summed for each pixel of the same gray-level intensity. The neighborhood is the set of
surrounding pixels at a specified offset (typically 1, 2, or 3 resulting in a square of 3x3, 5x5, or
7x7 centered on the pixel of interest). As a result, the pixels at the periphery of the image do
not contribute directly to the neighborhood difference matrix. In this study, gray-level bins of 1
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and a neighborhood size of 5x5 were typically used. All five of the defined features for the
neighborhood difference matrix were calculated: coarseness, contrast, busyness, complexity,
and texture strength. Algorithms and descriptions for each can be found in the literature14,53,54.
Laplacian of Gaussian Filtered Features
The Laplacian of Gaussian filtered features are features from the histogram that are
calculated from an image after a Laplacian of Gaussian filter has been applied to it. The
Laplacian of Gaussian filter smooths the image and then highlights the edges that remain. This
technique has been used in radiomics studies to potentially reveal structure in the tumor27,51,52.
Different filter scales (fine, medium, coarse) can be used to highlight features of different sizes.
Features that were calculated after filtration included the histogram maximum, mean, median,
minimum, standard deviation, entropy, skewness, and kurtosis.
Shape Features
Shape features are those that use only the ROI mask to calculate a quantitative metric
that describes the tumor. The shape features used in this study were volume, surface area,
surface area density, compactness1, compactness2, convex, convex hull volume, convex hull
volume 3D, mass, maximum 3D diameter, mean breadth, number of objects, orientation,
roundness, spherical disproportion, and sphericity. These are defined and described in the
literature23,55 as well as in the help documentation of IBEX.
Feature Naming Conventions
In subsequent tables and figures, features are named for the abbreviated feature
category and then the feature name (e.g. contrast from the co-occurrence matrix is listed as
COMcontrast). Features with longer names are abbreviated with the abbreviations listed in
Table 3.2 Table 3.2: Features used in this study and their abbreviations used in subsequent
tables and figures.(e.g. long run emphasis from the run length matrix is listed as RLMlre).
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Table 3.2: Features used in this study and their abbreviations used in subsequent tables and figures.

Category Name in IBEX

Feature Name in IBEX

Feature
Abbreviation

GrayLevelRunLengthMatrix25

GrayLevelNonuniformity

RLMglnu

GrayLevelRunLengthMatrix25

HighGrayLevelRunEmpha

RLMhglre

GrayLevelRunLengthMatrix25

LongRunEmphasis

RLMlre

GrayLevelRunLengthMatrix25

LongRunHighGrayLevelEmphasis

RLMlrhgle

GrayLevelRunLengthMatrix25

LongRunLowGrayLevelEmphasis

RLMlrlgle

GrayLevelRunLengthMatrix25

LowGrayLevelRunEmphasis

RLMlglre

GrayLevelRunLengthMatrix25

RunLengthNonuniformity

RLMrlnu

Run percentage

GrayLevelRunLengthMatrix25

RunPercentage

RLMrunperc

Short run emphasis

GrayLevelRunLengthMatrix25

ShortRunEmphasis

RLMsre

GrayLevelRunLengthMatrix25

ShortRunHighGrayLevelEmphasis RLMsrhgle

GrayLevelRunLengthMatrix25

ShortRunLowGrayLevelEmphasis

RLMsrlgle

NeighborIntensityDifference25

Busyness

NDMbusy

Feature Category

Full Feature Name

Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Gray-level run
length matrix
Neighborhood
gray-tone
difference matrix

Gray level nonuniformity
High gray level run
emphasis
Long run emphasis
Long run high gray
level emphasis
Long run low gray
level emphasis
Low gray level run
emphasis
Run length nonuniformity

Short run high gray
level emphasis
Short run low gray
level emphasis
Busyness
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Neighborhood
gray-tone
difference matrix
Neighborhood
gray-tone
difference matrix
Neighborhood
gray-tone
difference matrix
Neighborhood
gray-tone
difference matrix
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram
Intensity
Histogram

Coarseness

NeighborIntensityDifference25

Coarseness

NDMcoarse

Complexity

NeighborIntensityDifference25

Complexity

NDMcomp

Contrast

NeighborIntensityDifference25

Contrast

NDMcontrast

Texture strength

NeighborIntensityDifference25

TextureStrength

NDMtexstr

Energy

IntensityDirect

EnergyNorm

HISTenergy

Entropy

IntensityDirect

GlobalEntropy

HISTentropy

Kurtosis

IntensityDirect

Kurtosis

HISTkurt

Maximum

IntensityDirect

GlobalMax

HISTmax

Mean

IntensityDirect

GlobalMean

HISTmean

Median

IntensityDirect

GlobalMedian

HISTmed

Minimum

IntensityDirect

GlobalMin

HISTmin

Skewness

IntensityDirect

Skewness

HISTskew

Standard deviation

IntensityDirect

GlobalStd

HISTstd

Uniformity

IntensityDirect

GlobalUniformity

HISTunif
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Intensity
Histogram
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix

Variance

IntensityDirect

Variance

HISTvar

Auto-correlation

GrayLevelCooccurenceMatrix25

AutoCorrelation

COMautocorrel

Cluster prominence

GrayLevelCooccurenceMatrix25

ClusterProminence

COMclusprom

Cluster shade

GrayLevelCooccurenceMatrix25

ClusterShade

COMclusshade

Cluster tendency

GrayLevelCooccurenceMatrix25

ClusterTendency

COMclustend

Contrast

GrayLevelCooccurenceMatrix25

Contrast

COMcontrast

Correlation

GrayLevelCooccurenceMatrix25

Correlation

COMcorrel

Difference entropy

GrayLevelCooccurenceMatrix25

DifferenceEntropy

COMdifent

Dissimilarity

GrayLevelCooccurenceMatrix25

Dissimilarity

COMdissim

Energy

GrayLevelCooccurenceMatrix25

EnergyNorm

COMenergy

Entropy

GrayLevelCooccurenceMatrix25

Entropy

COMentropy
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Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix
Gray-level cooccurrence
matrix

Homogeneity

GrayLevelCooccurenceMatrix25

Homogeneity

COMhomog

Homogeneity 2

GrayLevelCooccurenceMatrix25

Homogeneity2

COMhomog2

Information measure
correlation 1

GrayLevelCooccurenceMatrix25

InformationMeasureCorr1

COMinfomc2

Information measure
correlation 2

GrayLevelCooccurenceMatrix25

InformationMeasureCorr2

COMinfomc2

Inverse difference
moment norm

GrayLevelCooccurenceMatrix25

InverseDiffMomentNorm

COMinvdifmn

Inverse difference
norm

GrayLevelCooccurenceMatrix25

InverseDiffNorm

COMinvdifn

Inverse variance

GrayLevelCooccurenceMatrix25

InverseVariance

COMinvvar

Maximum probability

GrayLevelCooccurenceMatrix25

MaxProbability

COMmaxprob

Sum average

GrayLevelCooccurenceMatrix25

SumAverage

COMsumavg

Sum entropy

GrayLevelCooccurenceMatrix25

SumEntropy

COMsument

Sum variance

GrayLevelCooccurenceMatrix25

SumVariance

COMsumvar
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Gray-level cooccurrence
matrix
Shape
Shape
Shape
Shape

Variance

GrayLevelCooccurenceMatrix25

Variance

COMvar

Compactness 1
Compactness 2
Convex
Convex hull volume
Convex hull volume
3D
Mass
Maximum 3D
diameter
Mean breadth
Number of objects
Orientation
Roundness
Spherical
disproportion
Sphericity
Surface area
Surface area density
Volume

Shape
Shape
Shape
Shape

Compactness1
Compactness2
Convex
ConvexHullVolume

SHAPEcompact
SHAPEcompact2
SHAPEconv
SHAPEconvhull

Shape

ConvexHullVolume3D

SHAPEconvhull3d

Shape

Mass

SHAPEmass

Shape

Max3DDiameter

SHAPEmaxdiam

Shape
Shape
Shape
Shape

MeanBreadth
NumberOfObjects
Orientation
Roundness

SHAPEmeanbre
SHAPEnumobj
SHAPEorien
SHAPEround

Shape

SphericalDisproportion

SHAPEspheredis

Shape
Shape
Shape
Shape

Sphericity
SurfaceArea
SurfaceAreaDensity
Volume

SHAPEsphericity
SHAPEsurfarea
SHAPEsurfareaden
Volume

Laplacian of
Gaussian Fine
Filter (size=5,
sigma=1)

Entropy

IntensityDirect

GlobalEntropy

LOGFFentropy

Laplacian of
Gaussian Fine
Filter (size=5,
sigma=1)

Mean

IntensityDirect

GlobalMean

LOGFFmean

Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
Shape
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Laplacian of
Gaussian Fine
Filter (size=5,
sigma=1)

Standard deviation

IntensityDirect

GlobalStd

LOGFFstd

Laplacian of
Gaussian Fine
Filter (size=5,
sigma=1)

Uniformity

IntensityDirect

GlobalUniformity

LOGFFunif

Laplacian of
Gaussian Fine
Filter (size=5,
sigma=1)

Kurtosis

IntensityDirect

Kurtosis

LOGFFkurt

Laplacian of
Gaussian Fine
Filter (size=5,
sigma=1)

Skewness

IntensityDirect

Skewness

LOGFFskew

Laplacian of
Gaussian
Medium Filter
(size=7,
sigma=1.5)

Entropy

IntensityDirect

GlobalEntropy

LOGMFentropy

Laplacian of
Gaussian
Medium Filter
(size=7,
sigma=1.5)

Mean

IntensityDirect

GlobalMean

LOGMFmean
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Laplacian of
Gaussian
Medium Filter
(size=7,
sigma=1.5)

Standard deviation

IntensityDirect

GlobalStd

LOGMFstd

Laplacian of
Gaussian
Medium Filter
(size=7,
sigma=1.5)

Uniformity

IntensityDirect

GlobalUniformity

LOGMFunif

Laplacian of
Gaussian
Medium Filter
(size=7,
sigma=1.5)

Kurtosis

IntensityDirect

Kurtosis

LOGMFkurt

Laplacian of
Gaussian
Medium Filter
(size=7,
sigma=1.5)

Skewness

IntensityDirect

Skewness

LOGMFskew
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Statistical Software
The analyses throughout this dissertation were performed using the R programming
environment 56 and the packages: “survival” 57, “survcomp”58, and “lme4”59 . Figures were also
created using the R programming environment and the packages: “ggplot” 60, “RColorBrewer”61,
“ggkm”62, and “gridExtra”63.

27 | P a g e

Chapter 4 : Calculating Radiomics Features
A substantial portion of this chapter is written or based on the following publications:
Fave X, Zhang L, Yang J, Mackin D, Balter P, Gomez D, Followill D, Jones AK, Stingo F, Court LE.
Impact of image preprocessing on the volume dependence and prognostic potential of radiomics
features in non-small cell lung cancer. Translational Cancer Research. Doi: 10.21037/tcr.2016.07.11.
Volume 5, Issue 4, pages 349-363.(c) AME Publishing Company.
Fave X, Zhang L, Yang J, Mackin D, Balter P, Gomez D, Followill D, Jones AK, Stingo F, Liao Z, Mohan
R, and Court L. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung
cancer. Scientific Reports. Doi: 10.1038/s41598-017-00665-z. Volume 7. © Nature Publishing Group.
Licensed under CC BY 4.0 available at https://creativecommons.org/licenses/by/4.0/legalcode.
The permissions for reuse of these materials were obtained from AME Publishing Company © and
Nature Publishing Group © respectively.

In this chapter we describe the results for Specific Aim 1: Analyze the effect of image
preprocessing on a set of radiomics features measured from CT images and identify the
optimal preprocessing for each. Our working hypothesis for this aim was that the image
preprocessing technique used would have a significant impact on the prognostic ability and
volume independence of radiomics features.

Introduction
The body of literature suggesting that radiomics features may be prognostic in patients
with non-small cell lung cancer (NSCLC) has been steadily growing over the past few years.
Although these results are intriguing, the rush to determine whether radiomics features have a
useful role in tumor analysis has left many of the fundamental questions surrounding them
overlooked or only partially answered. Chief among these is how to determine whether a
feature is being calculated correctly. In radiomics, no ground truth exists for the features
themselves, and as a consequence most studies have settled for selecting features with high
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reproducibility in patient test-retest sets and then using statistical tests or a machine-learning
algorithm to determine which features are useful for a particular research question42,64–67.
However, this approach can lead to high false-positive rates68, and has resulted in variability in
both the features that are used and how they are calculated (e.g., feature parameters and
image preprocessing).
Further, while a feature should be reproducible, reproducibility itself does not guarantee
that a feature is informative. For example, a highly smoothed image is much more likely to
return the same value for a feature on a retest, but it may also have lost the original spatial
differences that the feature was selected to identify. Also, because most of the quantitative
imaging features used in radiomics today were initially developed to analyze aerial
photographs12–14, in which only two-dimensional rectangular photographic images of the same
pixel dimensions were compared, normalization for area or volume differences was not
originally necessary. However, in tumor analysis, the regions of interest (ROIs) are the irregular
contours of three-dimensional tumors. As a result, the volumes of tumor ROIs have substantial
inter-patient variability. A feature that is correlated with volume would be likely to have high
reproducibility when tested and retested in a set of patients with a wide range of ROI volumes.
This correlation can dominate the useful spatial distribution or intensity information in the
feature that we hope to measure. The impact of these volume differences on features
measured from computed tomography (CT) images has never been systematically
investigated. However, two recent studies have demonstrated the effects of volume on features
in fluorodeoxyglucose-positron emission tomography (FDG-PET) images in which the total
number of voxels per tumor was much smaller, and concluded that radiomics features offer
complementary information only above volume thresholds as large as 10 or 45 cm3
respectively69,70.
Radiomics features have also been shown to demonstrate wide variability when the
imaging parameters used for acquisition of CT images are changed41 or when a different CT
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scanner is used with the same imaging protocol40. The gray-level intensities in CT images are
carefully calibrated to the Hounsfield Unit scale. Thus this variability in the features suggests
the features may be susceptible to noise in the image, differences between scanners due to
differences in the reconstruction kernel and algorithm, or differences in beam quality. In order
for features to be useful, the difference between CT scanners must be negated. One option
would be to standardize the imaging parameters, especially the tube current, between
machines before acquiring the images so that the results are more similar. However when
working with retrospective data it would be more convenient to apply smoothing filters to the
image or use a bit depth resample that can reduce the impact of noise in the image and
potentially help homogenize images acquired on different scanners. Reducing the image noise
would also increase the likelihood that the feature values are representative of the actual tumor
heterogeneity and not image noise.
In order to determine how best to calculate features, it is first necessary to determine
which features are susceptible to changes in image preprocessing or wide variations in tumor
volume. This chapter investigates this issue by assessing changes in the correlations between
features and volume, the univariate prognostic potential of features, and the CT model
dependence as a function of different image preprocessing techniques.

Methods
Images
The pre-treatment 4DCT images acquired for treatment planning of the patient cohort
described in Chapter 3 were used in this analysis and followed all of the exclusion criteria
described in Chapter 3 which left 107 images for analysis. The characteristics for the resulting
study population are summarized in Table 4.1.
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Table 4.1: Summary of the clinical characteristics of the study population, n=107.

Characteristic
Median age (range)
Median gross tumor volume (range)
Sex
Male
Female
Tumor stage
II
III
IV
Tumor histologic findings
Squamous cell carcinoma
Adenocarcinoma/other

No. (%)
66 years (47-80 years)
39.6 cm3 (5.4-567 cm3)
62 (58)
45 (42)
12 (11)
93 (87)
2 (2)
46 (43)
61 (57)

Exploratory Analysis of Image Pre-processing Techniques
Initially, three different types of image pre-processing techniques were considered for
this study: resampling the image bit depth, smoothing the images, or both smoothing and
resampling the image. As part of an exploratory analysis, different filters under each of these
categories were examined for their relative ability to change the feature values. A default filter
in each category was chosen for comparison to the other filters of the same category then each
of these default filters was compared to using no image preprocessing at all.
Resampling the image bit depth was evaluated because it had been used in previously
published works26,70–72 and because it allows for a simple way to control the bin size of the
radiomics matrices (co-occurrence matrix, run-length matrix, and neighborhood difference
matrix). For example resampling the bit depth from 12 bit to 8 bit, reduces the number of
possible intensity values from 212 = 4096 to 28 = 256, and thus the pixels have been binned by
bins of size 4096/256 = 16. Because several of the radiomics features are calculated from
matrices that track how often pixels of one intensity are next to each of the other intensities,
this resample removes the need to select an appropriate bin size for these matrices, and
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instead bins of 1 can be used when calculating the matrix from an image that has already been
bit depth resampled. Continuing with the example, the original 12 bit image would have had a
co-occurrence matrix of 4096 by 4096 while an 8 bit image would have a co-occurrence matrix
of 256 by 256. The range of values in NSCLC tumors is typically much less than the range of
values in the entire image. Thus for a hypothetical tumor with values from only 1 to 100 HU,
only a 100 by 100 subsection of the 12 bit co-occurrence matrix would be used to calculate the
feature since the rest of the co-occurrence matrix would be filled with zeros. For the 8 bit
image, the 1-100 HU range would be resampled to 1-7, and the informative subsection of the
co-occurrence matrix would thus be a 7 by 7 matrix. By using resampling, the 7 by 7 cooccurrence matrix would be less likely to be sparsely populated than the 100 by 100 cooccurrence matrix especially if the tumor is small and thus may better represent the spatial
patterns in the image and be more informative. The CT images used in this analysis were
stored as 12 bit images so images were resampled for bit depths ranging from 11 to 6 bits.
Then the values for each feature at each bit depth were compared to the original 12 bit image
using a Pearson correlation test. This was done to evaluate if the specific choice of bit depth
had an impact on the relative order of the patients.
The second category of filters that was examined in this exploratory analysis was the
use of smoothing filters. Smoothing filters are designed to reduce image noise and thus were
expected to improve the ability of the radiomics features to measure the tumor heterogeneity.
Three different types of smoothing filters were examined: a Gaussian filter of size 3 with a
sigma of 0.5, a 3D edge preserving smoothing filter with a kappa of 70, and four Butterworth
filters with orders of 2 and cutoff frequencies of 75,100, 125, and 150 respectively. The
Gaussian filter is an isotropic filter that acts in the spatial domain. It has been used in other
radiomics studies43,51,70,73 and works by smoothing evenly across the entire image. However
this technique can lead to blurring along edges. The edge preserving smoothing filter also acts
in the spatial domain but is an anisotropic diffusion filter which means it can smooth along
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different directions when it detects an edge so as not to blur the edge74. The parameter, kappa,
determines the strength of the edges that it can detect74. Larger values of kappa mean the filter
is more likely to smooth over an edge than preserve it. The Butterworth smoothing filter acts as
a low pass filter to remove high frequency noise. This filter has the advantage of acting in the
frequency domain, so it is not limited by the size of the filter matrix. Additionally, Butterworth
filters have the benefits of reduced ringing and gradual attenuation of higher frequencies. The
larger the value for the order, the steeper the cutoff will be for the Butterworth filter. Research
within our own group has shown that using Gaussian filters with a sigma between 0.5 and 1.1
result in a significantly lower value for uniformity in tumors with necrosis versus those without 75.
In the same study it was also determined that using the 3D edge preserving smoothing filter
with a kappa>=60 resulted in a significantly lower value for skewness in the tumors with
necrosis75. A separate analysis found that using a Butterworth filter with a cutoff frequency of
125 reduced the dependence of texture features from CT images on the reconstruction FOV76.
The Pearson correlation coefficient was calculated between the radiomics features calculated
from images preprocessed with each smoothing filter and the features calculated from the
images preprocessed with the Butterworth filter that had a cutoff frequency of 125. This was
done to determine whether the choice of smoothing filter had a substantial impact on the
relative order of the patients.
Then using both smoothing and bit depth resampling before feature calculation was
examined to combine the advantages of both of these techniques. For this set, images were
preprocessed with each of the examined smoothing filters (Gaussian, edge preserving
smoothing, and Butterworth with cutoff frequencies of 75, 100, 125, and 150) and an 8 bit depth
resample. The choice of 8 bit was selected because the effect of noise in CT for soft tissue
and tumor should be less than 16 HU and because this value had been used in other radiomics
analyses26,70–72. The Pearson correlation coefficient was calculated between each filter and bit
depth combination and the Butterworth filter with a cutoff frequency of 125 and 8 bit depth
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resample. The Butterworth filter was chosen as the default filter to be used with the 8 bit depth
resample in order to stay consistent with the different filter comparisons. This test was done to
determine whether the choice of smoothing filter when combined with an 8 bit depth resample
had a substantial impact on the relative order of the patients.
The goal of this exploratory analysis was to evaluate the impact of specific
preprocessing parameters on the resulting radiomics feature values with the intention of
selecting one image preprocessing technique of each type for full investigation of the features’
volume dependence, CT model dependence, and prognostic potential. The Pearson correlation
coefficient was used to compare different combinations of preprocessed features to the default
versions selected in each group. The Pearson correlation coefficient was used because if
feature values changed in scale but not rank (e.g. patients with high contrast still had high
contrast but all of the values are 1/10 of the values without image preprocessing) then their
impact on eventual prognostic models would remain the same. The different bit depth
resamples were compared to using no bit depth resample. The different smoothing filters were
compared to the Butterworth smoothing filter with a cutoff frequency of 125. The different
smoothing and bit depth combinations were compared to the combination of a Butterworth filter
with a cutoff frequency of 125 and 8 bit depth resample. Finally an 8 bit depth resample,
Butterworth filter with a cutoff frequency of 125, and combination of Butterworth filter with a
cutoff frequency of 125 and an 8 bit depth resample were compared to using no extra image
preprocessing to evaluate whether these different combinations yielded radiomics features that
were different from their original non-preprocessed versions and thus potentially more
informative.
A lower intensity threshold of -100 and upper intensity threshold of 200 Hounsfield Units
were applied to all images before feature calculation to ensure that no voxels of the
surrounding normal lung tissue or bone were included in the GTV. These thresholds have been
used in previous studies of radiomics features extracted from CT images of lung cancer26,43.
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This threshold was performed after smoothing but before a bit depth resample. The threshold
was performed after smoothing because the radiomics software IBEX applies the smoothing
over the entire bounding box and not just the pixels within the contour. Thus if the image had
been thresholded and then smoothed, the smoothing would blur pixels with values of 0 into the
contour GTV and artificially decrease the values. Thus images were either (i) thresholded and
then resampled, (ii) smoothed and then thresholded, or (iii) smoothed, thresholded, and then
resampled.
Image Pre-processing
After the exploratory analysis, four of the examined image preprocessing techniques
were selected for in-depth analysis of their impact on the radiomics features. As in the
exploratory analysis, a lower intensity threshold of -100 and upper intensity threshold of 200
Hounsfield Units were applied to all images before feature calculation to ensure that no voxels
of the surrounding normal lung tissue or bone were included in the GTV. Images were then
further pre-processed with either (i) 8 bit depth resampling, (ii) a Butterworth smoothing filter
with an order of 2 and a cutoff frequency of 125, (iii) both Butterworth smoothing (order of 2 and
cutoff frequency of 125) and 8 bit depth resampling, or (iv) no additional pre-processing. When
both Butterworth smoothing and 8 bit depth resample were used, the Butterworth smoothing
was performed first. The radiomics features were calculated from the tumor ROIs after each of
these pre-processing techniques had been applied. The general effect of each of these
techniques should be to reduce noise in the image and thus improve the overall signal to noise
ratio of any radiomics feature. These particular preprocessing options were selected based on
the results of the exploratory analysis. Figure 4.1 shows the visible result of each of these preprocessing techniques on a sample tumor ROI. The impact of these four techniques on the cooccurrence matrix for the tumor in Figure 4.1 is illustrated in Figure 4.2.
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Figure 4.1: Sample image of a patient tumor ROI using each preprocessing technique.

Figure 4.2: Visualization of the co-occurrence matrix for the same tumor ROI after four different
image preprocessing techniques. The axes in these figures are the ranges of intensity values.
Thus for the No Preprocessing and Butterworth Smoothing co-occurrence matrices, the values
range from 1 to 4096 for both the x and y axis as these are 12 bit images. For the 8 bit depth
resample and 8 bit depth resample and Butterworth Smoothing images the axes range from 1
to 256. Additionally all four of the images are zoomed in on the useful part of the matrix since in
all 4 cases, most of the co-occurrence matrix is filled with zeros due to the image threshold
used. The dark blue represents values of zero in the matrix while dark red is scaled to the
highest frequency in the matrix. Note that using Butterworth smoothing tends to make the cooccurrence matrix distribution more linear.
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Features
For both the exploratory analysis and in-depth analysis, 45 radiomics features from the
histogram, co-occurrence matrix, neighborhood difference matrix, and run-length matrix were
calculated and are summarized in Table 4.2. The histogram features summarize characteristics
of the intensity distribution for each tumor. The co-occurrence matrix, neighborhood difference
matrix, and run-length matrix features all contain information about the spatial distribution of the
pixel intensities within a tumor. Full descriptions of these feature categories is available in
Chapter 3. Also, all features were calculated using the open-source Imaging Biomarker
Explorer (IBEX) software50 as discussed in Chapter 3.
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Table 4.2: The radiomics features used in the analysis of image preprocessing techniques.

Histogram
Energy
Entropy
Kurtosis
Maximum
Mean
Median
Minimum
Skewness
Standard
deviation
Uniformity
Variance

Co-occurrence
Matrix
Autocorrelation
Cluster
prominence
Cluster shade
Cluster
tendency
Contrast
Correlation
Difference
entropy
Dissimilarity
Energy
Entropy
Homogeneity
Homogeneity 2
Information
measure
correlation
Information
measure
correlation 2
Inverse
difference
moment norm
Inverse
difference
norm
Inverse
variance
Max probability
Sum average
Sum entropy
Sum variance
Variance

Run Length Matrix
Gray-level
nonuniformity
High gray-level
run emphasis
Long run
emphasis
Long run high
gray level
emphasis
Long run low
gray level
emphasis
Low gray-level
run emphasis
Run
percentage
Run-length
nonuniformity
Short run
emphasis
Short run low
gray-level
emphasis
Short run high
gray-level
emphasis

Neighborhood
Difference Matrix
Busyness
Coarseness
Complexity
Contrast
Texture Strength

38 | P a g e

Volume-Dependence
To determine whether the features became more or less correlated with volume as a
result of image pre-processing, we used the spearman rank correlation coefficient (rs) to
calculate the correlation with volume of each feature after each preprocessing technique. The
Spearman rank correlation coefficient ranges from -1 to 1 and evaluates whether a value
decreases or increases monotonically; 1 and -1 represent a perfect correlation and 0
represents no correlation.
Because the feature algorithms used for tumor analysis in current radiomics studies
were originally designed for comparing equally sized photographs12, it was possible that some
algorithms might be inherently dependent on volume and may require correction for the number
of voxels in the image. Features with extremely high values (rs > 0.95) for all four preprocessing
techniques were identified and new normalized versions of the algorithms for these features
were created and added to the feature set for analysis. The Spearman correlation coefficient
for these normalized features were then calculated for each preprocessing technique. For
completeness, we did not remove the features that exhibited the extremely strong correlations
with volume from the remainder of the analysis in this chapter.
To evaluate the corrected versions of the volume-dependent features, two datasets of
spherical digital phantoms were created using MATLAB (The Mathworks, Inc., Natick, MA) and
saved as DICOM images. Digital phantom images had an in-plane resolution of 0.98 mm and
slice thickness of 2.5 mm. Axial images of the digital phantoms can be seen in Figure 4.3. The
first phantom dataset represented a texture of pure noise. Three sets of five spheres (12, 90,
175, 320, 445 cm3) were used. Each set of five spheres was filled with intensity values from a
Gaussian distribution with a mean of 1025 and standard deviation of 25, 50, or 75 respectively.
This dataset was used to check that the volume-corrected features did not change with
increasing volume and more importantly confirm that the corrected feature values increased or
decreased in the expected order as the standard deviation in the digital phantoms increased.
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For example, when measuring busyness, the values from the spheres with the larger standard
deviation should have higher values for busyness. The second phantom dataset represented a
defined texture of pure signal (i.e., no noise). Three sets of five spheres were used again but
were filled with a checkerboard pattern. Each set had checkerboard cubes with a side length of
2, 5, or 10 voxels where alternating cubes had an intensity of either 1 or 2. Thus, when viewed
in either the axial, sagittal, or coronal plane, a checkerboard pattern was apparent. This second
pattern was used to confirm that the corrected features were independent from volume and
able to correctly order the phantoms with increasing checkerboard square size.
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Figure 4.3: Axial views of the 3D spherical digital phantoms created for this study. Two patterns
were used: (i) spheres filled with Gaussian noise with increasing standard deviation and (ii)
spheres filled with a checkerboard pattern with increasing checkerboard square sizes. For each
pattern five spheres of increasing radii were created. These phantoms could then be used to
check any volume dependencies were removed when corrected feature algorithms were used
and that the new form of the feature was informative (e.g. feature values increased or
decreased as the pattern was changed in the expected order).
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CT Model Dependence
To determine whether the feature values significantly varied with the CT model used to
acquire the images, a Wilcoxon rank sum test between two scanners was performed for each
feature and pre-processing combination. The overwhelming majority of images had been
acquired on either a GE Discovery ST or a GE Lightspeed RT16 (755 of the 785 images). The
remaining images were acquired on either a Philips Brilliance 64 (n=21) or Philips Brilliance Big
Bore (n=9). This test was performed because CT scanner model has been demonstrated to be
an important factor in feature reproducibility40. A patient subset that had images available from
the first week of treatment (n=81) was used for this test because at this time point the patients
were roughly split between the two CT scanners (37 patients imaged with the GE Discovery ST
and 44 patients imaged with the GE Lightspeed RT16) and their tumors were not expected to
have already shown any therapy-induced changes. The Wilcoxon rank sum test evaluates the
null hypothesis that two populations have the same distribution of values. P-values were
corrected for multiplicity testing using the Benjamini-Hochberg method77 and were considered
significant if the value was less than 0.05 after correction.
Prognostic Potential
To determine the impact of preprocessing on the usefulness of radiomics features,
univariate Cox proportional hazards models were fitted for overall survival. P-values for the fit
using the likelihood-ratio test were calculated for each model. P-values were corrected using
the Benjamini-Hochberg process to control for the false discovery rate (type 1 error). Corrected
p-values<0.05 were considered significant.
Each univariate model was then recalculated using leave-one-out cross validation to
generate predictions for each patient in each model. In this framework, each patient’s
prediction is calculated using a model in which that patient was left out of the coefficient fitting
process. Harrell’s concordance index (c-index) was then calculated using the predicted risks.
The c-index is similar to the area under the curve and evaluates, for each combination of two
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patient predictions, how often the patient with the higher predicted risk actually experiences the
event (death) before the patient with the lower predicted risk. A c-index value of ≤0.5 indicates
that the model does not perform better than random chance and a value of 1.0 indicates a
perfect model. The c-index for a model with volume as the only covariate was also calculated
for comparison.
Lastly, to determine whether features actually outperformed volume alone, the loglikelihood ratios between Cox proportional hazards models for overall survival fitted with
volume only and models fitted with volume and one radiomics feature at a time were
calculated. The p-values for the log-likelihood ratios were then determined and corrected using
the Benjamini-Hochberg process. A p-value <0.05 would mean that including that particular
feature significantly improved the model’s fit to the data when compared with the fit of a model
using volume only.

Results
Exploratory Analysis of Image Preprocessing Techniques
The goal of the exploratory analysis was to determine if the specific parameters for
three types of filters (bit depth resampling, smoothing, and smoothing with bit depth
resampling) played a large role in the impact of that filter on the relative radiomics feature
values. Results for the Pearson correlation coefficients comparing the different bit depth
resampling levels to no bit depth resampling, and thus images with 12 bit depth, are in Figure
4.4. When the bit depth resampling level was decreased, the strength of the Pearson
correlation coefficient decreased for approximately half of the features (21 of the 46).
Regardless of the specific bit depth level used, most features remained weakly correlated (r≥
0.6) with their values measured from the default images. The features that had the largest
decreases in their correlation strength as bit depth decreased were short run high gray level
emphasis, long run length gray level emphasis, and gray level non-uniformity from the runlength matrix, and inverse variance and information measure correlation 1 from the co43 | P a g e

occurrence matrix. Of the features whose correlation decreased below 0.9 at one or more bit
depths: 2 demonstrated a decrease at 11 bit depth, 4 at 10 bit depth, 3 at 9 bit depth, 3 at 9 bit
depth, 2 at 8 bit depths, 4 at 7 bit depths, and 10 at only 6 bit depths.
Results for the Pearson correlation coefficients comparing the different smoothing filters
are in Figure 4.5. In this analysis the Pearson correlation coefficient was calculated between
the radiomics feature values after each filter and the feature values obtained after the image
was preprocessed with a Butterworth filter with an order of 2 and a cutoff frequency of 125.
Changing the cutoff frequency to 150 or 100 resulted in features that were all still highly
correlated (r ≥ 0.9) to the default Butterworth filter. Reducing the cutoff frequency to 75 also
resulted in the majority of features still being highly correlated to the default values but 14 of the
correlations decreased to be between 0.8 and 0.89 and 2 of the features had correlations
between 0.7 and 0.79. Using a Gaussian filter instead of a Butterworth filter resulted in very
highly correlated features as well with only one feature (information measure correlation 1 from
the co-occurrence matrix) having the lowest value of 0.77 but most features were above 0.9.
Similarly for the edge preserve smoothing filter, only 6 features did not have a correlation
higher than 0.9. The lowest correlation was still a moderate value of 0.62. Thus in almost all
cases the specific choice of smoothing filter does not strongly affect the relative feature values.
Results for the Pearson correlation coefficients comparing the combination of different
smoothing filters with an 8 bit depth resample to using a Butterworth filter with an order of 2 and
a cutoff frequency of 125 with an 8 bit depth resample are in Figure 4.6. As with the
comparison of the different smoothing filters, the overwhelming majority of features were highly
correlated when the only change was the Butterworth frequency cutoff to 100 or 150. When the
cutoff frequency was decreased to 75, some of the features did begin to show a large change,
with 3 (gray level nonuniformity from the run-length matrix, complexity from the neighborhood
difference matrix, and inverse variance from the co-occurrence matrix) having a coefficient less
than 0.7. The feature that showed the most change was gray level non-uniformity from the run44 | P a g e

length matrix. Using a Gaussian filter instead also resulted in highly correlated features with the
exception of gray level non-uniformity from the run-length matrix and inverse variance from the
co-occurrence matrix. When features were calculated with an edge preserve smoothing filter,
the correlation coefficients decreased below 0.9 for 19 features but the majority were still
between 0.7 and 0.9 with only 2 features (inverse variance and correlation from the cooccurrence matrix) having coefficients below 0.7. There was a lot of overlap between the
features whose correlation coefficients decreased with a cutoff frequency of 75 and those that
decreased when the edge preserve smoothing filter was used.
One of the filters of each type (8 bit depth resample, Butterworth smoothing with a cutoff
frequency of 125, and both Butterworth smoothing with a cutoff frequency of 125 and an 8 bit
depth resample) was then compared to using no image preprocessing and the results are
shown in Figure 4.7. A few features were always highly correlated regardless of which image
preprocessing was used; these included long gray level run emphasis, high gray level run
emphasis, and gray level non-uniformity from the run-length matrix, the mean and median from
the histogram, and 8 features from the co-occurrence matrix. For the remainder of the features,
if the correlation decreased with bit depth resampling or smoothing then it also decreased
below 0.9 when both bit depth and smoothing were used.
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Figure 4.4: Correlation between features calculated after bit depth resampling between 11 and
6 bits and their default values without any bit depth resampling (BD12). Approximately half of
the features (21/46) remained highly correlated to their original values even as the bit depth
was resampled to 6 bits. For the remaining features, their correlation decreased as the bit
depth was decreased with two features showing changes even with only a minor resampling to
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11 bit depths and 10 features remaining correlated until a major resampling to 6 bit depths.
Abbreviations: BDXX=Bit depth resampling to XX, (e.g. BD8= 8 bit depth resample).
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Figure 4.5: Correlation between features calculated after different smoothing filters to their
default values from images smoothed with a Butterworth filter with a cutoff of 125. The majority
of radiomics features were highly correlated (r>0.9) to their values after a Butterworth filter with
a cutoff of 125 was used to when they were calculated with different smoothing filters for
comparison. Thus the choice of cutoff or specific smoothing filter does not play a substantial
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role in the feature values. Abbreviations: BW125=Butterworth filter with a cutoff value of 125,
Gauss=Gaussian filter with size 3 and sigma of 0.5, EP=Edge preserve smoothing filter with a
kappa of 70.
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Figure 4.6: Correlation between features calculated after Butterworth smoothing filters with
different cutoffs (75,100,150) and an 8 bit depth resample to their default values from images
smoothed with a Butterworth filter with a cutoff of 125 and an 8 bit depth resample. The
majority of radiomics features were highly correlated (r>0.9) to their default values when
calculated with different frequency cutoffs. Even with a much lower frequency cutoff of 75, the
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overwhelming majority of features had Pearson correlation coefficients>0.8. Thus the choice a
specific cutoff frequency does not play a substantial role in the relative patients’ feature values.
Abbreviations: BWXX+BD8=Images filtered with a Butterworth filter with a cutoff value of XX
and an 8 bit depth resample, (e.g. BW125+BD8, is a Butterworth filter with a cutoff frequency of
125 and 8 bit depth resample).
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Figure 4.7: Correlation between features calculated after three filters to their default values
from images without any image preprocessing (BD12). Features were calculated after either an
8 bit depth resample (BD8), smoothing with a Butterworth filter that had a cutoff frequency of
125 (BW124), or both smoothing with a Butterworth filter with a cutoff frequency of 125 and an
8 bit depth resample (BW125+BD8). Only 13 of the radiomics features were highly correlated
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(r>0.9) regardless of the image processing. The combination of smoothing and resampling was
most likely to substantially decrease the correlation.
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Volume Dependence
The absolute values of the Spearman correlation coefficients for each feature after each
tested preprocessing technique are plotted in Figure 4.8. In general, features were more
correlated with volume after either Butterworth smoothing or both Butterworth smoothing and
bit depth resampling, and were less correlated with volume after bit depth resampling, Figure
4.9. A few features demonstrated strong (rs >0.85) correlations with volume for only one or two
pre-processing techniques. Both information measure correlation and information measure
correlation 2 from the co-occurrence matrix had high correlations with volume after no
preprocessing or Butterworth smoothing (>0.90), but were not correlated with volume when bit
depth resampling was used, either alone or with Butterworth smoothing (rs < 0.5). Inverse
difference moment norm from the co-occurrence matrix had a correlation of 0.88 with volume
after Butterworth smoothing or after Butterworth smoothing and bit depth resampling. Texture
strength from the neighborhood difference matrix had correlation coefficients of -0.94, -0.87,0.90, for Butterworth smoothing, bit depth resampling, and both Butterworth smoothing and bit
depth resampling respectively, but when no pre-processing was used the coefficient was less
than 0.5.
Five features demonstrated a very strong volume correlation, with Spearman correlation
coefficients absolute values >0.95 regardless of which preprocessing technique was used.
These features included energy from the histogram, coarseness and busyness from the
neighborhood difference matrix, and grey-level non-uniformity and run-length non-uniformity
from the run-length matrix. After close investigation, we found that these high levels of volume
correlation were due to the feature algorithms, which did not normalize for the number of voxels
or matrix elements summed. This means that if these features were measured from two ROIs
of different sizes but with pixels of only one intensity, two different values would be obtained.
Factors that mitigate this source of volume dependence were introduced for each of these
feature algorithms (Table 4.3), and new Spearman correlation coefficients were calculated. The
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algorithms for energy, grey-level non-uniformity, and run-length non-uniformity were edited by
dividing their values by the total number of voxels in the ROI. The algorithms for busyness and
coarseness were changed by normalizing the sums of the average difference around each
intensity (the neighborhood difference matrix values, s(i)) by the number of voxels of that
intensity. The maximum of the Spearman correlation coefficients for the normalized features
was 0.79, Figure 4.8 . All of the normalized features preprocessed with resampling had
correlations <0.5.
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Figure 4.8: The volume correlation for the features measured using the spearman rank
correlation coefficient. The absolute value of the coefficients for each feature and
preprocessing technique are plotted here. The volume correlation for most of the features was
substantially changed with different image pre-processing. Five features were extremely
correlated with volume regardless of the preprocessing technique used and were recalculated
with a normalizing factor. The normalized version of these algorithms are noted with an
asterisk.
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Table 4.3: The original and normalized algorithms for the volume-dependent features. The
original algorithms for the volume-dependent features from the literature were changed by
introducing a normalization term for the number of voxels of each intensity, i, in the image, N(i),
or the total number of voxels Nv. Other terms are: pi-probability of intensity i in the image; s(i)sum of the average difference value around voxels of intensity i; Gh-Highest gray-level intensity;
Ng-Number of gray levels; Nr-Number of run levels; p(i,j)- probability of gray-level i having a run
of length j; X(i)-the intensity of the ith voxel in the image, X.
Feature
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Figure 4.9: The absolute value of Spearman correlation coefficients plotted as a histogram for
each preprocessing technique. Butterworth smoothing either alone or combined with bit depth
resample increased the strength of the correlation between most of the features and volume.
When only bit depth resample was used, the overall volume correlation decreased for the
features.
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To evaluate whether the corrected feature equations were still informative, the features
were calculated from a series of digital phantoms. Each of the corrected features was able to
correctly order both of the digital phantom patterns (Gaussian noise with increasing standard
deviation and a checkerboard pattern with increasing size of the checkerboard squares). The
variation between the values for the three Gaussian noise patterns was substantially less than
for the three checkerboard patterns. The values calculated from these phantoms for both the
original and corrected version of the five volume dependent features are plotted in Figure 4.10.
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Figure 4.10: Radiomics feature values measured from digital phantoms before and after
volume normalization of the feature algorithms. Digital phantoms were filled with either a
checkerboard (CB) pattern with squares of 10x10, 5x5, or 2x2 voxels or by Gaussian noise with
a standard deviation (SD) of 25, 50, or 75 units. Prior to volume normalization, the values from
both phantoms demonstrated a strong volume dependence as seen in the plots on the left side
of the figure. After normalization, the values measured from the digital phantoms were
independent of volume. Additionally, the feature values were correctly ordered for the digital
phantoms.
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CT Model Dependence
The results of the Wilcoxon rank sum test to determine if features were significantly
associated with the CT model used to acquire the images before and after image
preprocessing are shown in Figure 4.11. No features were always significantly associated with
the CT model used to acquire the images regardless of which image preprocessing was used.
24 features were never significantly associated with CT model regardless of which image
preprocessing was used. These features included 7 features from the histogram, 8 from the cooccurrence matrix, 4 from the neighborhood difference matrix, and 5 from the run-length matrix.
For the remaining 31 features, 2 were not significantly associated with CT Model when they
were calculated after bit depth resampling was used, 28 when smoothing was used, 27 when
smoothing and bit depth resampling were used together, and 6 when no preprocessing was
used. So in general smoothing used either alone or in conjunction with bit depth resampling
reduced the likelihood that a feature would be dependent on CT model.
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Figure 4.11: The Benjamini-hochberg corrected p-values for the Wilcoxon rank-sum test
comparing values measured on two different CT models. Approximately half of the features
were always independent of the CT model used to acquire the image. The remaining features
were most likely to not be significantly different between CT models when smoothing or
smoothing with bit depth resampling was used. The green area highlights features whose pvalue was <.05 and thus significant.
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Prognostic Potential
The p-values for the Cox proportional hazard models are plotted in Figure 4.12 for each
feature and pre-processing combination, as well as for volume. Almost every feature (39/55)
had at least one preprocessing technique that resulted in statistically significant stratification (pvalue < 0.05 after Benjamini-Hochberg correction). A few features from each category were
never significant in this univariate analysis: normalized busyness, the original (volumedependent) busyness, complexity, and contrast from the neighborhood difference matrix;
maximum, minimum, and the original energy from the histogram; long-run emphasis, run
percentage, and the original forms of grey-level non-uniformity and run-length non-uniformity
from the run-length matrix; correlation, energy, information measure correlation 2, and max
probability from the co-occurrence matrix; and volume. Features that were always significant
regardless of the preprocessing technique were high and low gray-level run emphasis from the
run-length matrix, mean from the histogram, and the original algorithm for coarseness. In
general features were more likely to have a significant p-value after Butterworth smoothing or
both Butterworth smoothing and 8 bit depth resampling were used.
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Figure 4.12: The p-values after Benjamini-Hochberg correction for the univariate cox
proportional hazards model for each feature and preprocessing combination. The green region
of the plot indicates significant values: p-value<0.05. Volume was included in the feature set for
comparison.
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The c-indices calculated from the predicted values for each univariate model are plotted
in Figure 4.13. The c-index for volume was 0.56. The largest calculated c-index was 0.65 for
the median from the histogram after both Butterworth smoothing and 8 bit depth resampling.
The next highest c-index was 0.60 for both high gray-level run emphasis and short run high
gray-level run emphasis from the run-length matrix. In general, using Butterworth smoothing
either alone or with 8 bit depth resampling resulted in c-indices close to or slightly larger than
the c-index for volume, whereas using 8 bit depth resampling on its own or not using any image
pre-processing resulted in c-indices < 0.5. With the exception of minimum intensity, for every
feature at least one preprocessing technique resulted in a c-index greater than 0.5.
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Figure 4.13: Harrell’s concordance index (c-index) for each feature and preprocessing
combinations. Predictions were generated for each patient during leave-one out cross
validation. With the exception of minimum intensity, for every feature at least one
preprocessing technique resulted in a c-index value greater than 0.5, though only one was
larger than 0.6.
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The Benjamini-Hochberg corrected p-values for the log-likelihood ratios comparing Cox
proportional hazards models for overall survival fitted with volume only and fitted with volume
and one of the radiomics features are plotted in Figure 4.14. Of the 54 features, 25 had at least
one significant p-value from this test. Most of the significant features were calculated with either
Butterworth smoothing or Butterworth smoothing and 8 bit depth resampling. Short run high
gray-level emphasis energy added significant value to the model when no preprocessing was
used, texture strength from the neighborhood difference matrix added significant value when 8
bit depth resampling was used, and the volume-corrected version of energy from the histogram
was significant when either no preprocessing or 8 bit depth resampling was used.
Approximately half of the features (29/54) were not significant regardless of which
preprocessing technique was used. This subset included at least one feature from each of the
feature categories and all 5 of the uncorrected, volume correlated features identified in the
previous section.
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Figure 4.14: The Benjamini-Hochberg corrected p-values for the log-likelihood ratio between
cox proportional hazards models with only volume as a covariate and models with volume and
one radiomics feature at a time. The region in green highlights significant p-values<0.05.
Features were most likely to be significant if they had been preprocessed with Butterworth
smoothing either alone or in conjunction with 8 bit depth resample.
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Prognostic Potential versus Volume Dependence
The corrected p-values for the log-likelihood ratio between Cox proportional hazards
models fit with volume as their only covariate and models fit with both volume and one
radiomics feature are plotted against the volume correlation for each feature after each
preprocessing technique, Figure 4.15. All but one of the features with a significant p-value for
the log-likelihood ratio had at least a slight correlation with volume (rs > 0.5). However, many
features with equally high or higher correlations with volume did not have significant p-values.
Thus, features with significant p-values and some correlation with volume are likely providing
complementary information. The only feature with a significant p-value and a correlation
coefficient less than 0.5 was the minimum of the histogram after Butterworth smoothing.
Features with very high volume (rs > 0.95) correlations were not able to add significant value to
models built using volume. These features included all of the preprocessing versions of the five
original, volume correlated algorithms from the first section of the results, as well as the
unpreprocessed versions of the information measure correlation and information measure
correlation 2 from the co-occurrence matrix and the smoothed version of the information
measure correlation 2.
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Figure 4.15: Effect of preprocessing on the volume correlation versus the added prognostic
value of the features. Volume dependence was measured with the spearman correlation
coefficient and the added prognostic value of the features was measured with the log-likelihood
ratio between cox proportional hazards models for overall survival using only volume and
models using volume and one radiomics feature. The green area highlights features whose pvalue was <.05 and thus significant.

Discussion
This analysis demonstrated that preprocessing can have a strong impact on the volume
dependence and univariate significance of many radiomics features. Specifically, Butterworth
smoothing increased the likelihood that a feature was significant in univariate Cox proportional
hazards models and significantly improved the model fit in Cox proportional hazards models
that included volume as a second covariate. This may be because smoothing removes some of
the noise in the image and thus allows the measured features to better represent the tumor’s
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relative heterogeneity and thus its likelihood of responding to treatment. However, this
preprocessing technique also increased the correlation with volume of a feature, suggesting
that preprocessing techniques must be chosen carefully.
Although various studies have identified features that on their own or as part of a model
may yield prognostic information, very little research has been done on the physical basis for
high or low feature values. As observed in this study, one tumor characteristic that can
influence feature values is tumor volume. We identified 5 features that were highly correlated
with volume owing to terms in the feature algorithms that are directly affected by the number of
voxels in the entire image. This dependence would not have been an issue in the original
design of these features, which were used only to compare aerial photographs that were the
same size. However, in tumor analysis, patients with the same relative heterogeneity can have
substantially different tumor sizes and thus widely different values for a radiomics feature if it is
dependent on the number of voxels. In our analysis, simple normalizations of the original
algorithms were able to lower these correlations. Additionally, we showed that the original
versions of the algorithms for these 5 features were not able to add significant value to
outcome models that already had volume as a covariate. While for two of these features
(energy and grey-level non-uniformity), normalizing them did result in significant p-values.
Because the direct dependencies we discovered were inherent to the texture equations and not
the images, the same relationships are likely to exist in images of different types of cancer,
especially those that span a large range of volumes. Similarly, although we used threedimensional ROIs to capture the full heterogeneity of the tumor, several previous studies have
used only the largest axial image slice when determining their ROI21,37. The strong
dependencies we found for these five features will also apply to two-dimensional slice studies
because the algorithms are inherently volume-dependent. Thus, we recommend that future
studies consider including these modified algorithms in their future feature sets in place of the
original volume-dependent features.
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This work also presented a simple but highly versatile technique for studying the merit
of individual texture features independently of the confounding variables inherent to patient
data. Digital phantoms with either a defined pattern or random values from a Gaussian
distribution were useful for demonstrating the possible range of values and volume
dependencies of a particular texture. The digital phantoms could also allow users to assess
whether their understanding of the image characteristics that lead to relatively high or low
texture values is correct. It may be possible for users to extend that understanding to predict
whether a tumor will have a relatively high or low texture value. As demonstrated in these
results, this methodology could also be used to identify other weaknesses in features, test the
ability of features to differentiate data, and potentially establish the most useful parameters for
the calculation of features.
A large fraction of the features studied in this work both with and without image
preprocessing were at least slightly (rs > 0.5) correlated with volume. These relationships are
not necessarily problematic, as the features may still provide information that is complementary
to volume. For example, surface area is known to be correlated with volume, yet provides
important new information. This idea was supported by the fact that almost all of the features
with a significant p-value for the log-likelihood test comparing models with volume as a
covariate to models with volume and a radiomics feature were at least slightly correlated to
volume (rs>0.5). These correlations may be due to actual differences in the heterogeneities of
large versus small tumors on average which the features are designed to measure. To
reiterate, a feature correlated with volume should not necessarily be excluded from a dataset,
but a feature calculated with an algorithm that is inherently dependent on the number of voxels
should be changed or removed. Otherwise, that feature would return two different values when
measured from two ROIs of different sizes even if both have the same intensity in each pixel,
e.g. two circles filled with pixels of intensity 20 but one has a radius of 5 pixels and one has a
radius of 10 pixels.
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In this study we also examined the impact of different preprocessing techniques on both
the correlation with volume and prognostic significance of each radiomics feature. For some
features an increase in the correlation with volume due to preprocessing may represent the
amount of information lost in the image. For example, an image that has been overly smoothed
eventually has only one intensity value in all of its voxels. Then, because all of the texture
information captured by radiomics features has been erased, the feature could represent only
the volume information, which is not affected by image preprocessing. However, using no
preprocessing at all can also result in meaningless feature values because the values can be
dominated by noise in the image. The ideal preprocessing technique for a particular feature
would reduce this image noise while maintaining the tumor’s actual relative heterogeneity to
generate useful information for modeling. Because a ground truth is not known for radiomics
features, we used the significance of the features in univariate analysis to evaluate the
usefulness of each feature. If a feature was significant in the univariate analysis, then the
preprocessing was concluded to have helped it. We found that, in general, using a Butterworth
smoothing filter, either on its own or in conjunction with 8 bit depth resampling, resulted in the
ability to extract statistically significant features from tumor ROIs. However, the specific trends
were feature- dependent. Thus, feature-specific image preprocessing may be required to
maximize the usefulness of each radiomics feature. This is perhaps not surprising considering
the differences in specific features. For example, the mean intensity from the histogram would
change less with smoothing than a feature from the co-occurrence matrix, which could benefit
from appropriate bin sizes in the calculation of the matrix and thus the right choice for bit depth
rescale.
One limitation of the current study is that only 3 different preprocessing techniques were
evaluated in-depth. It is possible that superior preprocessing techniques could exist, such as
using voxel size resampling or edge-detection filtering, or that fine-tuning the parameters could
improve these techniques. However we did perform an exploratory analysis of the impact of
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fine tuning certain filter parameters prior to the in-depth analysis. Each of the eventually
selected preprocessing techniques was compared to various related filter iterations. For
example the impact of the 8 bit depth resample on features was compared to using bit depths
between 6 and 11 instead and the impact of different Butterworth frequency cutoffs was
investigated both with and without the added 8 bit depth resample. This exploratory analysis
suggested that using any smoothing filter had a bigger impact on the relative feature values
than the difference between two smoothing filters or two different Butterworth frequency cutoffs.
Similarly resampling the bit depth affected the feature values but the difference between two
specific bit depth levels such as 10 bit and 8 bit were minor. Thus the preprocessing techniques
that were finally selected for use in the in-depth analysis portion of this study did not comprise
an exhaustive set but instead were selected to demonstrate the large changes in a feature’s
univariate significance that can occur by using different methods for noise-reduction before
feature calculation. Because studies have been published with the same features but different
preprocessing techniques and parameters for their feature matrices (co-occurrence matrix,
neighborhood difference matrix, and run-length matrix) this is an important result that must be
investigated in order for these features to eventually be standardized and used clinically.
Another limitation of this study is that it is likely that many of the specific trends
described here will be different for other image modalities or tumor sites. However the overall
conclusion that image preprocessing can substantially affect the overall usefulness of a feature
should apply in any case. Thus, we highly recommend that future studies examine the most
appropriate features to be used for a particular patient population and the calculation
parameters accompanying those features before including the features in prognostic models.

Conclusions
Radiomics features calculated from a variety of imaging modalities are being widely
studied for potential to help predict patient outcomes or aid physicians in diagnosis. However,
so far studies have calculated features using a wide range of software, parameters, and pre74 | P a g e

processing techniques. The goal of this aim was to demonstrate the effect that different preprocessing techniques can have on the usefulness of radiomics features by measuring the
volume-dependence and prognostic value of each feature in univariate models. We proposed
normalization factors for five features that were highly volume-dependent regardless of the
preprocessing technique used. Additionally, we found that most features benefited from image
smoothing using a Butterworth filter, either alone or in conjunction with 8 bit depth resampling.
While smoothing was more likely to make a feature statistically significant in a univariate model,
smoothing also tends to increase the volume dependence of the feature. It is important to
balance these two effects in order to determine the optimal preprocessing technique for each
feature.
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Chapter 5 : Prognostic Potential of Radiomics Features
A substantial portion of this chapter is written or based on the following publication:
Fave X, Zhang L, Yang J, Mackin D, Balter P, Gomez D, Followill D, Jones AK, Stingo F, Liao Z, Mohan
R, and Court L. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung
cancer. Scientific Reports. Doi: 10.1038/s41598-017-00665-z. Volume 7. © Nature Publishing Group.
Licensed under CC BY 4.0 available at https://creativecommons.org/licenses/by/4.0/legalcode.
The permission for reuse of this material was obtained from Nature Publishing Group ©.

In this chapter we describe the results for Specific Aim 2: Determine which radiomics
features, measured from CT images, change significantly during the course of radiation therapy
and the relationship between these changes and outcome. Our working hypothesis for this aim
was that radiomics features can be identified that change during the course of treatment and
are predictive for patient outcome.

Introduction
Most NSCLC radiomics studies have focused on identifying heterogeneous tumors
before treatment to identify high-risk patients with potentially more aggressive tumors.
However, a challenge that remains to be addressed is the fact that tumors of the same
phenotype can respond very differently to treatment34. A model that could effectively identify
patients whose tumors are not responding to treatment would be beneficial and could be used
to recommend patients for adjuvant chemotherapy or a radiation boost. Measuring radiomics
features over the course of radiation therapy may allow for the identification and quantification
of therapy-induced changes in the tumor. These changes in radiomics features, defined here
as delta-radiomics features, may indicate which patients are responding to treatment. A large
change in the value of a radiomics feature could indicate better response and potentially better
long-term outcomes, while the value of the feature at the end of treatment may be indicative of
the treatment’s success.
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This study had several goals. The first was to identify radiomics features that
demonstrate significant changes during radiation therapy. Next, the prognostic value of
univariate models using radiomics features measured at the beginning of treatment, end of
treatment, or the net changes or slopes during treatment were compared for the outcomes of
overall survival, freedom from distant metastases, and local-regional control. Finally
multivariate models were built to determine whether pretreatment or delta-radiomics features
could improve the prognostic ability of models built using only clinical factors.

Methods
Patient Data
For this study, we retrospectively reviewed the images and medical records for the
patient cohort discussed in Chapter 3. This cohort was comprised of 107 NSCLC patients that
were treated at the University of Texas MD Anderson Cancer center as part of an IRB
approved clinical trial45. The retrospective analysis performed for this study was approved by
our IRB with a waiver of informed consent. The patients were treated with radiation therapy and
concurrent chemotherapy. They had been randomized to receive treatment with either photons
or protons to 66 or 74 Gy. Because of their participation on this trial the patients were imaged
weekly during treatment with a four-dimensional CT (4DCT)45. For this retrospective analysis,
the medical records of these patients were reviewed to determine their clinical factors: sex,
age, smoking status, pack years, tumor histology, overall disease stage, T stage, N stage,
Karnofsky performance status (KPS), and total prescribed radiation dose. In this analysis,
treatment modality was not considered for classification purposes although the impact of
modality on radiomics features was investigated separately in Chapter 7.
The primary endpoints for this analysis were overall survival, freedom from distant
metastases, and local-regional control. For this analysis, a local-regional recurrence was
defined as evidence of disease inside the treatment field, adjacent to the treatment field, or in
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the regional lymph nodes. A distant metastasis was defined as evidence of disease anywhere
else in the body including the contralateral lung. Patients were censored at their last date of
follow-up if they did not reach the endpoint.
Table 5.1: Clinical characteristics of the NSCLC patient population used for modeling.
Clinical Factors
Sex
F
M
Age
<65
>=65
T stage
T1 or T2
T3 or T4
N stage
N0 or N1
N2 or N3
Overall disease stage
II
IIIa
IIIb
IV
Tumor histology
Squamous cell carcinoma
Adenocarcinoma or other
Smoking status
Current
Former
Never
Pack years (continuous)
0-24
25-49
50-74
75+
Karnofsky performance status
90-100
70-80
Total radiation dose
>70 Gy
<70 Gy

Number of Patients
(n=107)
45
62
45
62
49
58
24
83
12
44
49
2
46
61
34
64
9
20
37
28
22
52
55
72
35
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Landmark Analysis
Survival studies using measures of response that are calculated at multiple time points,
such as the radiomics features measured at weekly intervals in this study, require a landmark
time point to be used for calculating the time until the endpoint is reached78,79. Otherwise a bias
can be introduced by responders since they must have already survived to the time of
treatment to be classified as responders78,79. In this study, patients were classified as high or
low risk using multivariate models that included clinical factors (recorded at the time of entrance
to the study), pre-treatment radiomics features (measured from the treatment planning images),
and delta-radiomics features (measured from the different weekly images through treatment).
Because a variable number of days occurred for each patient between when they entered the
trial and when their pre-treatment images were acquired and between their pre-treatment
images and last weekly images, a landmark time point was required to measure survival. For
this study, endpoints were defined from a landmark time point of 90 days from the day the
patient was entered on the clinical trial until one of the endpoints of death, presence of distant
metastases, or local-regional failure was met. Patients not reaching the endpoint were
censored at their last follow-up date. The landmark point was calculated by determining the
total number of days from entering the trial to end of treatment for each patient. The maximum
interval (by which all measures of response had been determined) was 83 days, which was
rounded to 90 days for simplicity. This ensures that the time until the endpoint is reached or the
patient is censored is uniformly measured across all patients and not biased by the number of
days they have already survived to reach the end of treatment.
Features
Features included in this analysis were shape features (n=16), intensity histogram
features (n=11), co-occurrence matrix features (n=22)11,12, neighborhood difference matrix
features (n=5)14, and run-length matrix features (n=11)13,Table 5.2. To determine the best
parameters for the non-shape features, each feature was calculated four times: (i) with no
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image preprocessing other than thresholding, (ii) with smoothing using a Butterworth filter with
an order of 2 and a cutoff of 125 followed by thresholding,(iii) with thresholding followed by an
8-bit depth resample, and (iv) with Butterworth smoothing, thresholding, and an 8-bit depth
resample80. The Butterworth smoothing acts to remove Gaussian noise from the images, which
may obscure the lower frequency biological variations that radiomics features are designed to
measure. The 8-bit depth resample is used as an alternative to modifying the binning
parameter for the histogram and radiomics matrices. Using 8-bit depth images results in a bin
width of 16 HU and thus is more likely to reflect actual density changes in neighboring pixels
than bins with a width of 1 HU, which largely reflect image noise. More details on these image
processing techniques is available in Chapter 4 where we examined their impact on common
radiomics features in detail.
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Table 5.2: List of features used in the analysis of univariate and multivariate prognostic
potential.

Histogram
Energy
Entropy
Kurtosis
Maximum
Mean
Median
Minimum
Skewness
Standard
deviation
Uniformity
Variance

Co-occurrence
Matrix
Autocorrelation
Cluster
prominence
Cluster shade
Cluster
tendency
Contrast
Correlation
Difference
entropy
Dissimilarity
Energy
Entropy
Homogeneity
Homogeneity 2
Information
measure
correlation
Information
measure
correlation 2
Inverse
difference
moment norm
Inverse
difference
norm
Inverse
variance
Max probability
Sum average
Sum entropy
Sum variance
Variance

Run Length
Matrix
Gray-level
nonuniformity
High gray-level
run emphasis
Long run
emphasis
Long run high
gray level
emphasis
Long run low
gray level
emphasis
Low gray-level
run emphasis
Run
percentage
Run-length
nonuniformity
Short run
emphasis
Short run low
gray-level
emphasis
Short run high
gray-level
emphasis

Neighborhood
Difference Matrix
Busyness
Coarseness
Complexity
Contrast
Texture Strength

Shape
Compactness1
Compactness2
Convex
Convex hull
volume
Convex hull
volume 3D
Mass
Max 3D
diameter
Mean breadth
Number of
objects
Orientation
Roundness
Spherical
disproportion
Sphericity
Surface area
Surface area
density
Volume
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Optimal image pre-processing was determined on a feature-specific basis using the
following steps, which are also illustrated in Figure 5.1. First a univariate Cox regression model
for overall survival was fitted for each preprocessed version of each feature using only the
pretreatment images for each patient. The significance of the feature in the model was
calculated to determine whether a model built on only this feature was a better fit than the null
model. This step identified radiomics features that were predictive and therefore might be
useful for calculating delta-radiomics features. Next a Wilcoxon rank sum test was performed
for each feature and pre-processing combination to determine if the feature values were
significantly different when images were acquired on the GE Discovery ST versus the GE
Lightspeed RT16, as CT scanner model has been demonstrated to be an important factor in
feature reproducibility40 and the overwhelming majority of images had been acquired on these
two scanners (755 of the 785 images). The remaining images were acquired on either a Philips
Brilliance 64 (n=21) or Philips Brilliance Big Bore (n=9). A patient subset that had images
available from the first week of treatment was used for this test because at this time point the
patients were roughly split between the two CT scanners used in this study (37 patients imaged
with the GE Discovery ST and 44 patients imaged with the GE Lightspeed RT16) and their
tumors would not yet have shown any therapy-induced changes. Finally, the correlation
between each feature and the gross tumor volume was calculated using Spearman’s rank
correlation coefficient. The feature values and gross tumor volumes were calculated from the
pretreatment images for this step. For each feature, the pre-processed version that was
significant in univariate analysis for survival (p-value <0.10) and did not have a significant value
(p-value >0.05) for the Wilcoxon rank sum test between CT scanners was included in the final
feature set. Features that never met these two criteria regardless of the image pre-processing
used were excluded from the feature set. If a feature met both criteria for more than one image
pre-processing type, the version of the feature that had the smallest correlation with volume
was selected. A p-value of 0.10 was used as the threshold for significance in this pre-analysis
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because the p-values were used only for feature selection, not hypothesis testing, and thus the
filtering need not be overly stringent. This choice was balanced against the need to remain
conservative so that the feature dimensionality is decreased during this step. For the same
reason, no multiplicity correction was used at this stage.
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Figure 5.1: Workflow for the selection of feature specific image preprocessing. The images are
all processed in four ways: no extra processing, smoothing with a Butterworth filter, resampling
to an 8 bit depth, and both smoothing with a Butterworth filter and resampling with an 8 bit
depth. Each feature is calculated from the four sets of processed images. Then the best
processing is determined on a feature specific basis by evaluating the univariate significance,
dependence on the CT model used to acquire the images, and volume dependence. Based on
the results of these tests, one image preprocessing is selected for that feature. Then the
process is repeated for the next feature. If no image preprocessing for a feature allows it to
pass the tests, then the feature is removed entirely.
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Delta-radiomics Features
Two tests were conducted to determine which of the optimized features changed during
treatment and thus might be useful indicators of tumor response. First a linear mixed effects
model with random intercepts for each patient was built for each feature in the form,
Δ𝐹𝑒𝑎𝑡𝑢𝑟𝑒 ~ Δ𝑡𝑖𝑚𝑒 + (1|𝑃𝑎𝑡𝐼𝐷)
Equation 5.1
Here, ∆Feature was the feature value measured from each weekly 4DCT, ∆time was
the number of days from the commencement of treatment before the image was acquired, and
PatID was a patient-specific identifier that allows the model to account for the fact that we had
multiple, longitudinal measurements of each feature for each patient by assigning each patient
their own intercept. The p-value of the log-likelihood ratio for each model was calculated. Pvalues were corrected for multiple comparisons using the Benjamini-Hochberg method77. If the
corrected p-value was less than 0.05, the model was considered significant and indicated that
the changes in the feature were significantly associated with the time since treatment had
begun. For each feature with a significant p-value in this test, simplified measures of the overall
change were calculated and defined as delta-radiomics features. The delta-radiomics features
were defined as the percent net change, Equation 5.2, the linear regression slope, and the
value of the feature at the last week of treatment for each patient.
% 𝑁𝑒𝑡 𝐶ℎ𝑎𝑛𝑔𝑒 = (𝐹𝑒𝑎𝑡𝑢𝑟𝑒𝑊𝑒𝑒𝑘𝐹𝑖𝑛𝑎𝑙 − 𝐹𝑒𝑎𝑡𝑢𝑟𝑒𝑊𝑒𝑒𝑘1 )/𝐹𝑒𝑎𝑡𝑢𝑟𝑒𝑊𝑒𝑒𝑘1
Equation 5.2
Here, FeatureWeekFinal was the value of the feature at the end of treatment and FeatureWeek1 was
the value at the first weekly 4DCT for each patient. A one-sample, two-tailed t-test was
conducted for the percent net change and linear regression slope delta-radiomics features to
determine whether the overall changes for the group were significantly different from 0, and
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values were again corrected using the Benjamini-Hochberg method. Features that passed both
the linear mixed effects and t-test analyses (corrected p-value <0.05) were considered to
demonstrate significant therapy-induced changes and were included as potential deltaradiomics covariates in both univariate and multivariate model building.
Univariate Analysis
Covariates examined for the univariate analysis were the clinical factors listed in Table
5.1 and the radiomics and delta-radiomics features that passed the previous tests. For each of
the radiomics features, four versions were tested: the values at pre-treatment (pre-TX), the
percent net change over the course of treatment (% net change), the linear regression slope
(slope) over the course of treatment, and the values at the end of treatment (end-TX).
For each of these covariates, the univariate model fit and predictive performance were
assessed for each outcome (overall survival, freedom from distant metastases, and localregional recurrence) using two tests:
(i)

P-value of the log-likelihood ratio: Univariate cox proportional hazards models
were fit to the data using the entire patient set. The log-likelihood ratio of the fit
was calculated to determine whether or not the fit was significantly better than
the null model. P-values were corrected for multiplicity using the Bonferroni
correction. The Bonferroni correction was used because the different versions of
the radiomics features are not independent from each other.

(ii)

C-index: Univariate cox proportional hazards models were then generated in a
leave-one-out cross validation (LOOCV) loop. On each iteration of the loop, the
coefficient for the single covariate was refitted and then a prediction for the leftout patient was calculated using the model. The predictions generated from the
LOOCV were used to calculate Harrell’s concordance index81 (c-index). The cindex is analogous to the area under the curve but is designed for survival data
86 | P a g e

instead of binary data. Values of the c-index can range from 0 to 1 with a value
of 1 indicating perfect prediction and a value ≤0.5 indicating that a model
performs no better or worse than a random guess. Thus, the overall c-index is a
more likely representation of how the model would perform on new patients.
Multivariate Analysis
Multivariate Cox regression models were built for each of the primary endpoints using
leave-one-out cross validation (LOOCV) and Akaike Information Criterion (AIC) with the
following procedure, which is also illustrated in Figure 5.2. First, one patient was removed from
the dataset and a Cox proportional hazards model was built using all of the clinical factors and
the remaining patients. The covariates were reduced using stepwise AIC in both directions.
Next, all of the pretreatment radiomics features were added to this model individually and the
log-likelihood ratio was calculated to determine if they had significantly improved the model.
Then the subset of features that had significantly improved the model fit (p-value <0.05) were
all added together to the clinical model. Stepwise AIC was repeated in both directions with
forced nesting of the clinical covariates to select the best pretreatment features. These steps
were then repeated with the delta-radiomics features with forced nesting of the clinical and
pretreatment radiomics covariates. The delta-radiomics versions of the features were identified
by the suffixes “netPercentChange”, “Slope”, or “WeekLast”, while the pretreatment radiomics
features are indicated by the suffix “Week0”. This process was repeated with each patient left
out in turn so that at the end there were three models for each left-out patient: one with only
clinical factors, one with clinical factors and pretreatment radiomics features, and one with
clinical factors, pretreatment radiomics features, and delta-radiomics features. The total
number of times each covariate was selected for the three models over all of the LOOCV
iterations was calculated. Covariates that were selected in more than half of the iterations were
retained and considered high-performing. Final versions of the three models using only these
frequently selected covariates were then calculated and compared using the log-likelihood ratio
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to determine whether the radiomics and/or delta-radiomics features significantly (p-value <0.05)
improved the fit of the model to the data. If no feature was selected in more than half of the
iterations for a particular model, then the null model or the nested model from the previous
iteration was used.
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Figure 5.2: Workflow for building of multivariate models. A LOOCV loop is used to generate 3
models on each iteration: (1) Only clinical factors, (2) clinical factors and pre-treatment (TX)
features, and (3) clinical factors, pre-TX features, and delta-radiomics features. After the three
models have been built with each patient left out once, the number of times each covariate was
selected is tabulated. Then those covariates that are selected in greater than 50% of the
iterations are kept. These are then used to fit final versions of the 3 models.
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To evaluate the prognostic potential of these features, a new LOOCV was performed.
For this analysis, the three models were built on each iteration using only the high-performing
clinical, radiomics, and delta-radiomics covariates from the original LOOCV. No covariate
reduction was performed, but the coefficients were refit on each iteration. On each iteration of
the loop, a prediction for the left-out patient was calculated using each of the three models.
Because the patient was left out of the coefficient fitting process, predictions generated for the
left out patient were unbiased. Once the loop was complete, and each patient had a prediction
for each model, the c-index was calculated for each model. The c-indices allowed for the
comparison of the predictive accuracy of models that included radiomics and delta-radiomics
features to models incorporating only clinical factors. Finally, patients were stratified as high or
low risk based on whether their prediction was above or below the median prediction for each
model. Kaplan-Meier curves were plotted using this patient stratification, and the log-rank test
was used to determine whether the stratifications were significant (p-value <0.05).
All statistical analyses were performed in R language56 using the survival57,
lme459,MASS82, and ggplot260 analysis packages.

Results
Feature Selection
The initial feature set had 49 texture features measured before treatment, with four
different image preprocessing types and 16 shape features, for a total of 212 feature and
preprocessing combinations. Of these, 75 were significant in univariate analysis (p <0.10), and
123 were not significantly different between different CT scanners (p <0.05). These results are
shown in Figure 5.3-Figure 5.6. Using the feature selection process described in the methods,
this feature set was reduced to 31 features. Of these, 9 were calculated with no extra
preprocessing, 15 were calculated with Butterworth smoothing, and 7 were calculated with
Butterworth smoothing and 8-bit depth resampling, Figure 5.6. No features were calculated
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using just 8 bit depth resample. At least one feature from every feature category was
represented in this final feature set.
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Figure 5.3: Impact of image preprocessing on the univariate significance of radiomics features.
This figure plots each radiomics feature versus the image preprocessing styles used to
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calculate it. Blue triangles signify that the Feature-Preprocessing combination resulted in a
significant fit for a univariate Cox regression using only the features measured at pretreatment
(p-value <0.10). Red circles indicate that the univariate fit was not significant and thus that the
feature should not be measured with that preprocessing style. Note that the shape features do
not change with image preprocessing and so were calculated only with the basic thresholding
step. For the image preprocessing styles: None means that the feature was calculated with
only a simple thresholding step, Smooth that the feature was calculated with Butterworth
smoothing and thresholding, Resample that the feature was calculated with thresholding and 8bit depth resampling, and Both that the feature was calculated with Butterworth smoothing,
thresholding, and 8-bit depth resampling.
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Figure 5.4: Impact of image preprocessing on the significance of CT Model in a Wilcoxon rank
sum test for each radiomics feature. This figure plots each radiomics feature versus the image
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preprocessing styles used to calculate it. Blue triangles signify that the Feature-Preprocessing
combination did not have a significant p-value (i.e., <0.05) in the Wilcoxon rank sum test for the
impact of the CT Model (GE Lightspeed RT16 vs GE Discovery ST). Red circles indicate that
the p-value was significant and thus that the feature calculated with that preprocessing style
was significantly affected by the CT scanner model with which the images were acquired. Note
that the shape features do not change with image preprocessing and so were calculated only
with the basic thresholding step. None means that the feature was calculated with only a simple
thresholding step, Smooth that the feature was calculated with Butterworth smoothing and
thresholding, Resample that the feature was calculated with thresholding and 8-bit depth
resampling, and Both that the feature was calculated with Butterworth smoothing, thresholding,
and 8-bit depth resampling.
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Figure 5.5: Impact of image preprocessing on the univariate significance and significance of the
CT Model in a Wilcoxon rank sum test for each radiomics feature. This figure plots each
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radiomics feature versus the image preprocessing styles used to calculate it. Blue triangles
signify that the Feature-Preprocessing combination passed both tests (had a significant p-value
[<0.1] in the univariate analysis and did not have a significant p-value [<0.05] in the Wilcoxon
rank sum test analyzing the impact of CT scanner model). Red circles indicate that the feature
failed at least one test. Note that the shape features do not change with image preprocessing
and so were calculated only with the basic thresholding step. None means that the feature was
calculated with only a simple thresholding step, Smooth that the feature was calculated with
Butterworth smoothing and thresholding, Resample that the feature was calculated with
thresholding and 8-bit depth resampling, and Both that the feature was calculated with
Butterworth smoothing, thresholding, and 8-bit depth resampling.
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Figure 5.6: Final image preprocessing that was selected for each radiomics feature used in the
prognostic analysis. This figure shows the final set of features that remained after our entire
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feature selection process along with the feature-specific image preprocessing chosen for each.
None means that the feature was calculated with only a simple thresholding step, Smooth that
the feature was calculated with Butterworth smoothing and thresholding, Resample that the
feature was calculated with thresholding and 8-bit depth resampling, and Both that the feature
was calculated with Butterworth smoothing, thresholding, and 8-bit depth resampling. No
features were selected using just an 8-bit depth resample so this column does not appear in
the figure.
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Delta-radiomics Features
All 31 features had significant p-values for the log-likelihood ratio of their linear mixed
effects model, with time since beginning of treatment as the covariate and random intercepts
for each patient, even after Benjamini-Hochberg correction for multiplicity. The net changes and
slope in each feature were also significant in t-tests comparing their means to 0 after multiplicity
correction for every feature. Thus a total of 31 features were available for feature selection in
the multivariate model building.
Univariate Analysis
For overall survival, 67 of the 107 patients reached the endpoint of death. The median
survival time was 638 days. 50 patients had a distant metastases with a median time until
reaching the endpoint or censoring of 311 days. 23 patients had a local-regional recurrence
with a median time until reaching the endpoint or censoring of 420 days.
For the univariate analysis of clinical factors, none of the univariate models using
clinical factors had a significantly better fit than the null model after multiplicity correction,
Figure 5.7. Then when the c-indices were calculated, the majority of features had a c-index
below 0.5, and the highest c-index for any of the outcomes was only 0.56, Figure 5.8. Thus,
overall the clinical factors did not appear to be highly significant predictors of outcome when
used on their own in cox proportional hazards models.
For the univariate analysis of radiomics features, none of the univariate models had a
significantly better fit than the null model after multiplicity correction regardless of outcome,
Figure 5.9. However, when the c-indices were calculated, many of them were above 0.5, Figure
5.10. For overall survival, the features measured at pre-treatment were most likely to be
prognostic. The lowest c-index for a feature measured at pre-treatment was 0.54 for entropy
from the histogram while the maximum was 0.69 for median from the histogram. The highest cindices for the features’ end of treatment values, net percent change, and slope were 0.58,
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0.58, and 0.60 respectively for information measure correlation from the co-occurrence matrix,
sphericity, and compactness.
For distant metastases, the c-index results were similar. The features measured at pretreatment were most likely to be prognostic with the highest c-index of 0.72 occurring again for
the median from the histogram. The highest c-index for the values at the end of treatment was
0.60 for kurtosis from the histogram; for the net percent changes was 0.57 for information
measure correlation 2 from the co-occurrence matrix; and for the slopes was 0.58 for
compactness.
For local-regional recurrence, the c-indices were relatively low. The highest c-index was
only 0.55 and occurred for the values at the end of treatment of texture strength from the
neighborhood difference matrix. The highest c-indices for the other feature types were 0.52 for
roundness at pre-treatment, 0.52 for the net percent change in inverse difference moment norm
from the co-occurrence matrix, and 0.49 for the slope in roundness.
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Figure 5.7: The Benjamini-Hochberg corrected p-values for the log-likelihood ratio of each
univariate model using one of the clinical factors. None of the univariate models was
significantly better than the null model.
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Figure 5.8: C-indices for univariate clinical models calculated using a LOOCV loop to generate
patient-specific predictions for three outcomes. The overwhelming majority of the c-indices
were below 0.5 and the highest c-index was only 0.56 for overall survival.
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Figure 5.9: The Bonferroni corrected p-values for the log-likelihood ratio of each univariate
model using four different versions of each radiomics feature. None of the univariate models
was significantly better than the null model after multiplicity correction.

104 | P a g e

Figure 5.10: C-indices for univariate radiomics models calculated using a LOOCV loop to
generate patient-specific predictions for three outcomes. The maximum c-indices for overall
survival and distant metastases were 0.69 and 0.72 respectively and were both calculated
using the median from the histogram measured at pre-treatment. For local-regional recurrence
the highest c-index was 0.55 calculated using texture strength from the neighborhood
difference matrix measured at the end of treatment.
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Multivariate analysis
The final results of the multivariate analysis are summarized in Table 5.3 for all three
outcomes and all three models. The number of times each clinical factor and radiomics feature
was selected in the first LOOCV is described in Table 5.4 for each outcome.
Table 5.3: Final comparison of the three models for each outcome. For the c-indices and logrank test p-values, a value of NA indicates that no extra covariates were selected for this model
and thus the value cannot be evaluated. Similarly, a value of NA for the log-likelihood ratio pvalue implies that the two models being compared had the same covariates and thus the loglikelihood ratio cannot be computed. Model 1 is the model with only clinical factors. Model 2 is
the model with clinical factors and pretreatment features. Model 3 is the model with clinical
factors, pretreatment features, and delta-radiomics features. *significant at p<0.05; ** significant
at p<0.005; *** significant at p<0.001.

Outcome
C-index
Model 1
Model 2
Model 3
Log-likelihood
ratio p-value
Model 1 vs model 2
Model 1 vs model 3
Model 2 vs model 3

Overall
Survival

Distant
Metastases

Local-Regional
Recurrence

0.597
0.672
0.675

0.539
0.632
NA

NA
NA
0.558

4.20 x 10-5***
2.10 x 10-5***
0.020*

4.87 x 10-4***
NA
NA

NA
NA
NA

5.27 x 10-3 ***

0.38

NA

Log-rank test
p-value
Model 1
Model 2
Model 3

-6

1.56 x 10 ***

NA

-5

NA

0.0269*

2.40 x 10 ***
1.30 x 10 ***

-3
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Table 5.4: The number of times each clinical factor and radiomics feature was selected in the first leave-one-out cross validation for each
outcome. Features included in the final model have their model coefficients included in the table. Abbreviations: LOOCV, leave one out
cross validation; SCC, squamous cell carcinoma; KPS, Karnofsky Performance Status; WK0, week 0 (i.e., pretreatment)
Model

Feature
Type

Covariates

Overall Survival

Clinical
Factors

WK0
Features
Delta
Features

Distant Metastases

Clinical
Factors

WK0
Features

Included
in final
model
Yes
Yes
Yes
Yes
No
No
Yes

Model Coefficient

T stage (T stage 3-4)
Sex (male)
Histology (SCC)
Total radiation dose (>70 Gy)
KPS
Pack years
SHAPEcompact2.Week0

No. of times
selected in
LOOCV
107
107
107
107
1
1
107

RLMglnu.Slope
NDMtexstr.Slope
HISTkurt.netPercentChange
NDMtexstr.WeekLast
HistKurt.WeekLast
Age (65 years)
Sex (male)
Overall stage (IIIB)
T stage (T stage 3-4)
Smoking status (former)
Smoking status (current)
Total radiation dose
KPS
SHAPEcompact2.Week0
COMsumvar.Week0
SHAPEcompact.Week0
HISTkurt.Week0

96
67
26
13
3
93
86
61
59
58
58
46
11
105
13
1
1

Yes
Yes
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
No
No
No

-0.240
-0.330

-0.933
0.866
0.772
-0.652

0.546

-0.467
0.492
0.552
-0.490
-0.062
0.060

0.585

107 | P a g e

Delta
Features

Local-regional
Recurrence

Clinical
Factors

WK0
Features
Delta
Features

COMautocorrel.Week0
COMcorrel.netPercentChange
COMinfomc2.WeekLast
COMinvdifmn.WeekLast
COMinvdifmn.Slope
COMinvdifmn.netPercentChang
e
Smoking status (former)
Smoking status (current)
KPS
Pack years
NDMtexstr.Week0
SHAPEspheredis.Week0
NDMtexstr.WeekLast
SHAPEround.netpercentChang
e
HISTkurt.WeekLast

1
7
6
2
1
1

No
No
No
No
No
No

19
19
15
3
17
1
88
13
1

No
No
No
No
No
No
Yes
No
No

-0.517
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For overall survival, the clinical factors included in the final model were T stage, patient
sex, tumor histology, and total radiation dose. The pretreatment feature that was included was
compactness2 from the shape category. The delta-radiomics features that were included were
the slopes in grey-level non-uniformity from the run-length matrix and texture strength
calculated from the neighborhood difference matrix. Adding the single selected pretreatment
feature compactness2 increased the c-index from 0.597 to 0.672 for overall survival. The loglikelihood ratio between these two models was significant. However, further addition of deltaradiomics features made a negligible difference to the c-index and did not substantially affect
the patient stratification by the Kaplan-Meier curves as can be seen in Figure 5.11, Figure 5.12,
and Figure 5.13. The log-likelihood ratio between model 2 (with clinical factors and
pretreatment radiomics features) and model 3 (with clinical factors, pretreatment radiomics
features, and delta-radiomics features) was significant, indicating an improved fit.
For distant metastases, no delta-radiomics features were included in the final model.
The final clinical factors included in the model were tumor T stage, overall disease stage, and
patient age, sex, and smoking status. Adding a pretreatment feature, compactness2 from the
shape category, did result in an increase in the c-index from 0.539 to 0.632. The log-likelihood
ratio between model 1 (clinical factors only) and model 2 (clinical factors and pretreatment
radiomics features) was highly significant. Furthermore, patient stratification was significant
when the pretreatment radiomics feature was added, while it was not significant for the purely
clinical model, see Figure 5.14 and Figure 5.15.
For local-regional recurrence, no clinical factors or pretreatment radiomics features
were selected in more than half of the LOOCV iterations. As a result, none were considered
high-performing or were available for use in the final models for local-regional recurrence.
However, the delta-radiomics feature texture strength from the neighborhood difference matrix
measured at the end of treatment was selected in a majority of the LOOCV iterations. As a
result, only the model including delta-radiomics features was built. This univariate model
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resulted in a low value for the c-index (0.558) but a statistically significant stratification of the
patients (p-value = 0.0269) as can be seen in Figure 5.16. In lieu of calculating the loglikelihood ratio between this model and model 1 (clinical features only) or model 3 (clinical,
pretreatment radiomics, and delta-radiomics factors), the log-likelihood ratio between this
model and the null model was calculated (p-value = 0.0725).
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Figure 5.11: Kaplan-Meier curves for overall survival using clinical factors alone to generate
Cox proportional hazards models. Models were built within a LOOCV loop, and on each
iteration of the loop, the model was used to generate a prediction for the left out patient.
Patients were classified as high or low risk based on if their prediction was above or below the
median prediction value. The p-value for the log-rank test was less than 0.05 and thus the
stratification was significant.
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Figure 5.12: Kaplan-Meier curves for overall survival using clinical factors and pre-treatment
radiomics features to generate Cox proportional hazards models. Models were built within a
LOOCV loop, and on each iteration of the loop, the model was used to generate a prediction for
the left out patient. Patients were classified as high or low risk based on if their prediction was
above or below the median prediction value. The p-value for the log-rank test was less than
0.05 and thus the stratification was significant.
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Figure 5.13: Kaplan-Meier curves for overall survival using clinical factors, pre-treatment
features, and delta-radiomics features to generate Cox proportional hazards models. Models
were built within a LOOCV loop, and on each iteration of the loop, the model was used to
generate a prediction for the left out patient. Patients were classified as high or low risk based
on if their prediction was above or below the median prediction value. The p-value for the logrank test was less than 0.05 and thus the stratification was significant.

113 | P a g e

Figure 5.14: Kaplan-Meier curves for distant metastases using clinical factors alone to generate
Cox proportional hazards models. Models were built within a LOOCV loop, and on each
iteration of the loop, the model was used to generate a prediction for the left out patient.
Patients were classified as high or low risk based on if their prediction was above or below the
median prediction value. The p-value for the log-rank test was not less than 0.05 and thus the
stratification was not significant.
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Figure 5.15: Kaplan-Meier curves for distant metastases using clinical factors and pretreatment features to generate Cox proportional hazards models. Models were built within a
LOOCV loop, and on each iteration of the loop, the model was used to generate a prediction for
the left out patient. Patients were classified as high or low risk based on if their prediction was
above or below the median prediction value. The p-value for the log-rank test was less than
0.05 and thus the stratification was significant.
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Figure 5.16: Kaplan-Meier curves for local-regional recurrence using clinical factors, pretreatment features, and delta-radiomics features to generate Cox proportional hazards models.
Models were built within a LOOCV loop, and on each iteration of the loop, the model was used
to generate a prediction for the left out patient. Patients were classified as high or low risk
based on if their prediction was above or below the median prediction value. The p-value for
the log-rank test was less than 0.05 and thus the stratification was significant.
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Discussion
The first part of this analysis was to select the best image-preprocessing technique for
each feature and to exclude features that could not meet two requirements (significance in
univariate models and no significance between CT scanner models). This step resulted in
feature-specific image preprocessing such as having certain features from the co-occurrence
matrix calculated with 8 bit depth resampling and thus from a co-occurrence matrix with bins of
16 HU while other co-occurrence matrix features were calculated with only smoothing and thus
from a co-occurrence matrix with bins of 1 HU. Previous studies using features from texture
matrices have always calculated the features from a matrix with the same parameters. We
chose to use this feature-specific selection process instead because it is not known which
parameters for the texture matrices or for a specific feature are best. Additionally, it is possible
that different features are most useful for measuring tumor heterogeneity at different intensity
scales which is evaluated by this method. Over half of the features did not pass the minimum
requirements for any of the image preprocessing techniques and thus the feature set was also
reduced from 65 features to 31. This step was important because in the subsequent univariate
analysis a heavy penalization for multiplicity correction was implemented and so reducing the
number of features to those that could plausibly be useful aided in reducing the strength of that
penalization.
In addition to passing the feature-specific image preprocessing criteria, all 31 of the final
features also passed two tests that evaluated whether they changed consistently during
treatment. First the p-values of the log rank test comparing univariate linear mixed effects
models to the null model for each radiomics feature were evaluated. The fact that all 31 of
these features passed this test suggests that the values change in a general positive or
negative direction for each feature. This conclusion was supported by the results of the t-tests
that compared the mean of the slopes and relative net changes in the features to a normal
distribution with a mean at 0. If a feature had failed these tests it would have been either
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because it did not change at all for any of the patients (and is probably measuring image noise)
or because for some patients it increased while for some it decreased and the net result for the
cohort was 0. We wanted to exclude features that changed in both directions because that
would indicate the changes were unlikely to be due from treatment and we were specifically
looking for therapy-induced changes in the features.
Two different metrics were then evaluated for the univariate analysis: the significance of
a univariate cox proportional hazards model fit and the c-index. For the clinical factors, pretreatment radiomics features, and delta-radiomics features the results were largely negative.
No clinical factor or radiomics feature had a significant univariate fit after multiplicity correction.
This suggests the overwhelming majority of covariates we tested are not prognostic for any of
the endpoints being measured. This was supported by the fact that when the prognostic ability
of the features was tested individually using the c-index, most of the clinical factors and
radiomics features had c-indices less than 0.5. However for the clinical factors, the number of
pack years did have a c-index higher than 0.5 for all three end points, while for the radiomics
features the best performing feature was the median from the histogram which had a c-index
close to 0.7 for both overall survival and distant metastases when the value at the beginning of
treatment was used. In general the best version of any selected radiomics feature was the
value at pre-treatment for overall survival or distant metastases. This may have been due to
our initial selection criteria for the features which only selected features that were prognostic for
overall survival when measured at pre-treatment (p-value<0.1 without multiplicity correction).
Interestingly for local recurrence, the best version of the features that had at least one c-index
greater than 0.5 was the values at the end of treatment and this was the only feature that got
selected in the later multivariate analysis. While the results of the univariate analysis were not
strongly supportive of the prognostic potential of the delta-radiomics features, there was a
possibility that when used in conjunction with clinical factors or radiomics features measured at
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pre-treatment they could add an incremental improvement and so were still included in the
multivariate analysis
While the inclusion of delta-radiomics features had a statistically significant impact on
the overall likelihood of a model for overall survival compared to a model with only clinical and
pretreatment radiomics features, the impact on the model’s prognostic abilities was negligible.
For distant metastases, no delta-radiomics features were selected in the final round of model
building. This suggests that delta-radiomics features do not offer substantially new prognostic
information for these outcomes though they were still prognostic for overall survival. The same
pretreatment radiomics feature, compactness2, was selected for both the overall survival and
time to distant metastases models and improved their prognostic potential. For both overall
survival and distant metastases, the coefficient for this feature was positive, meaning a patient
had a higher predicted risk of experiencing the outcome if the value for compactness2 from
their ROI was relatively large. This feature was related to the volume and shape of the tumor
ROI, i.e. how spiculated it may appear. The feature values were also affected by the tumor
location, since a tumor attached to the chest wall was contoured with at least one smooth side
compared to a tumor surrounded by lung which ranged anywhere between fully smooth or fully
spiculated. Compactness 2 was also found to be predictive in a radiomics study by Aerts et al
where it was included as part of a four feature radiomics signature23. This study is unique in
that it demonstrated that compactness 2 added significant new information to a variety of
clinical factors already routinely obtained, as opposed to only TNM staging and tumor volume.
In this study, the clinical model was built first and then radiomics features were added to it
rather than building a purely radiomics model and assessing its capabilities. This is important
because the introduction of radiomics features into a routine clinical workflow is unlikely to be
accepted unless models built using radiomics features outperform models built using only
routinely acquired clinical factors.
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Interestingly, in the models for local-regional recurrence, the only covariate that was
predictive for outcomes was a radiomics feature, texture strength from the neighborhood
difference matrix, measured from images acquired during the last week of treatment. This
feature was designed to quantify whether an image has clear, perceivable characteristics that
can be considered as texture and the overall strength of that signal14. Further work is needed to
identify what this feature may represent in the context of NSCLC tumor analysis. This result
may be evidence that, although it is not possible to predict local-regional recurrence prior to
treatment, the state of the tumor at the end of the treatment can be assessed using radiomics.
One possible cause of the poor selection of delta-radiomics features in the models may
be due to the initial feature preselection process. The full feature set was first reduced to
features whose pretreatment values were at least prognostic in univariate models for overall
survival. It is possible that the results would differ if this requirement was changed to instead
select for delta-radiomics features that are significant in univariate models. The original
requirement was chosen for two reasons: first, because several publications have shown that
pretreatment radiomics features have informative value and thus changes in the features that
are already prognostic may reflect actual biological changes in the tumor, and second, if model
building was limited to delta-radiomics features that were significant in univariate analyses the
results could be biased and overly optimistic.
One limitation of this study was the lack of a dataset for independent model validation
due to the fact that patients are not routinely imaged weekly during their treatment. This
limitation was mitigated by using cross validation, which has been shown to be an effective
method for creating unbiased patient-specific predictions83,84. Another limitation of this study
was that the median predicted value was used as the cut-off point for high- and low-risk
patients. This is not an optimized approach, and it is very likely that a different model-specific
value would yield different results. However, testing multiple cutoffs to find the best one without
an independent validation dataset to test it in has been repeatedly shown to yield overly
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optimistic results68,85,86. By using the median, this source of bias is avoided and the conclusions
remained conservative. Lastly, because the images used in this analysis were non-contrast CT
images, vessels passing through the lesion could not be segmented from the contour. Thus the
contours for the tumor ROIs may contain vasculature along with the solid tumor component we
are interested in. The inclusion of vasculature in the tumor ROIs may affect the radiomics
features and the calculated tumor volume.
Radiomics is in some ways fundamentally limited because the features are not
inherently descriptive. This is in contrast to clinical covariates which, when selected in
prognostic models, lend themselves to hypotheses, e.g., age is likely to affect survival because
a younger person is statistically likelier to live longer than an older person. For radiomics
features, this type of reasoning is difficult and instead new studies must be undertaken to
correlate feature values with biological characteristics such as genetic mutations. Radiomics
features also suffer from lack of robustness, as they have been demonstrated to vary with
imaging equipment, ROI contouring, and imaging parameters. Thus the implementation of
radiomics features in a clinical setting would require substantial effort to standardize both
imaging and measurement parameters. This study identified two features, compactness2 and
texture strength, which may be of clinical significance. The first step in determining their
robustness will be to examine the impact of segmentation on both features’ values and
prognostic potentials. This is especially critical for compactness2 since it is a shape based
feature and thus could be substantially impacted by segmentation

Conclusions
This study found evidence that radiomics features change during the course of radiation
therapy for NSCLC. However, these changes in features did not significantly outperform
features measured before treatment in multivariate models for overall survival and distant
metastases. Thus it may be more important to focus efforts on improving the standardization of
features measured before treatment and identifying a biological or molecular explanation for
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their predictive values. One radiomics feature measured at the end of treatment did outperform
both clinical factors and pretreatment radiomics features for prediction of local-regional
recurrence. This feature, texture-strength, could become an indicator for tumor response since
it was only prognostic when measured at the end of treatment. Despite the fact that this study
did not find strong evidence supporting the prognostic potential of delta-radiomics features, the
results of this study are important because the potential of tracking radiomics features
throughout treatment for NSCLC was investigated. Furthermore, while other studies have used
delta-radiomics features for other treatment sites or for normal tissue toxicity, they have used
only the relative net change in their models37,39,87. This study included both the slope of a linear
regression for the features of each patient, which may be less susceptible to noise than the
relative net change, and the feature values at the end of treatment, which may reflect tumor
response.
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Chapter 6 : Reproducibility of Radiomics Features from CBCT
Images
A substantial portion of this chapter is written or based on the following publication:
Fave, X, Mackin, D, Yang, J, Zhang, J, Fried, D, Balter, P, Followill, D. , Gomez, D, Jones, AK, Stingo, F,
Fontenot, J, and Court, L. Can radiomics features be reproducibly measured from CBCT images for
patients with non-small cell lung cancer? Medical Physics doi: 10.1118/1.4934826. Volume 42, Issue 12,
pages 6784-6797. 2015. ©John Wiley and Sons.
The permission for reuse of this material was obtained from John Wiley and Sons ©.

In this chapter we describe the results for Specific Aim 3: Identify which radiomics
features can be reproducibly measured from CBCT images. Our working hypothesis for this
aim was that a subset of radiomics features can be identified that are robust to the increased
scatter and motion present during CBCT imaging.

Introduction
In future studies, it would be valuable to measure delta-radiomics features through
treatment for larger patient cohorts. While it may be possible for another IRB-approved study to
acquire weekly 4DCT images, it would be far easier to use the low-dose cone-beam CT
(CBCT) images that are already routinely acquired for patient setup verification. Using these
images would allow for the collection of larger patient cohorts, as well as more frequent
imaging because CBCT images are typically acquired before every treatment fraction or at
least weekly during treatment. However, CBCT images are known to have worse image quality
than regular CT due to their use of a flat-panel detector and larger cone angle which results in
larger amounts of scatter being detected. Additionally, CBCT imaging requires a longer scan
time than CT images (~1 minute) and patients are not usually asked to hold their breath. As a
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result, motion artifacts are more likely in CBCT images. This is of special concern for NSCLC
patients whose tumors may move with respiration.
The purpose of this study was to individually investigate sources of error in CBCT
images (different imaging protocols, scatter, and motion) on a typical set of radiomics features
in order to determine the features’ susceptibility to each. Once these different impacts have
been characterized, guidelines can be developed for obtaining CBCT images that will render
consistent radiomics features for use in future studies.

Methods
Patient Test-Retest CBCT Images
CBCT images were acquired from a subset of patients that were part of the main cohort
discussed in Chapter 3. We retrospectively searched the imaging history for each of the
patients in the cohort for repeat CBCT images. From this search, only ten patients were found
who had two sets of CBCT images obtained within 15 minutes of each other using the same
imager. This retrospective analysis was approved by the University of Texas M.D. Anderson
Cancer Center IRB with a waiver of informed consent. Characteristics for these 10 patients are
tabulated in Table 6.1.
Table 6.1: Clinical characteristics for the test-retest CBCT patient population.
Characteristic
n, number of patients
Median age (range)
Median GTV volume (range)
Gender
Male
Female
Tumor stage
II
III
Tumor histology
Squamous cell carcinoma
Adenocarcinoma/other

Number of Patients
10
65.5 (49-80)
77.5 cm3 (17-315 cm3)

Percent of Patients
NA
NA
NA

3
7

30%
70%

1
9

10%
90%

2
8

20%
80%
124 | P a g e

All CBCT patient images were acquired using the thoracic imaging protocol on a Varian
linac: peak tube voltage of 110 kVp, tube current of 20 mA, and exposure time (total pulsed
beam-on time) of 7-14 sec. Images were reconstructed as a 512 x 512 grid with pixel
dimensions of 0.8 mm and a 2.5 mm slice thickness. For each of these 10 patients, we
deformably transferred the GTV contour from the treatment plan to their two CBCT image sets
using an in-house deformation image registration software, CT-assisted targeting47,48. The
images and contours were imported into the IBEX radiomics software to extract the values for
the imaging features.
The concordance correlation coefficient (CCC) was calculated for each feature using
this test-retest image set. Features whose CCC<0.9 were not considered reproducible and
were excluded from the rest of the analysis43,88. This test removed features that were not
reproducible even when measured in images obtained from the same patient within 15 minutes
using the same imager. The cutoff value of 0.9 was chosen based on the recommended criteria
of McBride et al that considered a correlation of 0.9 to reflect moderate strength-of-agreement
and all correlations<0.9 to be poor. The Spearman correlation coefficient (rs) was also
calculated between each feature and the region-of-interest (ROI) volume. The Spearman
coefficient was calculated for the test and retest image volumes individually. Any feature with
rs>0.85 in both image sets was excluded from the rest of the analysis in order to remove
features whose CCC was high only because of that feature’s strong correlation with
volume89,90. The cutoff value of 0.85 is within the range of values of that has been cited in the
literature as representative of strong correlations such as Zou et al89 who considered any rs
>0.8 to be strongly correlated and Mukaka et al90 who interpreted only rs>0.9 to have very high
correlations. Because the purpose of this step was to reduce the likelihood of false positives in
the following experiments where each feature was independently examined for its
reproducibility under different conditions and not to establish an explicit volume-dependence, a
relatively high cutoff was selected to remove only strong relationships.
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For the remaining features, the mean intra-patient test-retest differences were
calculated with Equation 6.1. These values were used as benchmarks for reproducibility in the
subsequent phantom studies. This criterion was used because the phantom was expected to
change substantially less from scan to scan than a patient. In Equation 6.1, Npats is the number
of patients and 𝑥𝑛,𝑡 and 𝑥𝑛,𝑟 are the nth patient’s test and retest values respectively.
𝑁

Mean intrapatient difference =

𝑝𝑎𝑡𝑠
∑𝑛=1
|(𝑥𝑛,𝑡 − 𝑥𝑛,𝑟 )|

𝑁𝑝𝑎𝑡𝑠

Equation 6.1
Texture Phantom
The Credence Cartridge Radiomics phantom was used to evaluate the impact of
different scanners, protocols, scatter levels, and amounts of motion on texture values extracted
from CBCT images, Figure 6.1. This phantom was designed at our institution specifically for
investigating the reproducibility of texture features40. The phantom is a hollow, acrylic,
rectangular prism. Inside are cartridges of 10.1 x 10.1 x 3.2 cm3 made of different materials:
wood, dense cork, regular cork, shredded rubber, acrylic, and resin. The phantom also contains
four 3D printed cartridges with tessellated hexagons of different sizes. A previous analysis of
the phantom imaging characteristics conducted at our institution using CT scans demonstrated
that the texture values extracted from the shredded rubber and dense cork cartridges were
closest to values obtained from patient tumors40. For this reason, only these two materials were
used in this analysis. An ROI of 6.0 x 6.0 x 2.0 cm3 was positioned at the center of these two
materials for feature extraction in each image, Figure 6.1. This size was used because it was
close to the median size of the patient GTV volumes (77.5 cm3) and to avoid including the
edges of the phantom in the ROI.
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A

B

C

D

Figure 6.1: The Credence Cartridge Radiomics Phantom. (A) Photograph of the radiomics
phantom used in this study and (B-D) CBCT images of the phantom with the ROIs used. Only
the (B) shredded rubber and (C) dense cork cartridges were used for the current analysis.
Texture Features & Pre-Processing
For this study, a comprehensive set of 68 radiomics features were initially selected,
Table 6.2Table 6.2. Features were selected to cover the diverse range of features that have
been used in previous texture feature studies using CT images of NSCLC23,26–28,43,91. Selected
features included first-order descriptors from the intensity histogram; second-order features to
describe spatial relationships in gray level intensities from the co-occurrence matrix12,23, runlength matrix13, and neighborhood gray-tone difference matrix14; and Laplacian of Gaussian
(LoG) filtered features, which can highlight tumor characteristics not visible in the original
image27,51.
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Table 6.2: Features that were included in the analysis of CBCT feature reproducibility.

Histogram
without rescaling
Max
Mean
Median
Entropy
Energy
Standard
deviation
Uniformity
Kurtosis
Skewness
Variance
with rescaling
Max
Mean
Median
Entropy
Energy
Standard
deviation
Uniformity
Kurtosis
Skewness
Variance

Co-occurrence
Matrix
Autocorrelation
Cluster
prominence
Cluster shade
Cluster tendency
Contrast
Correlation
Difference
entropy
Dissimilarity
Energy
Entropy
Homogeneity
Homogeneity2
Information
measure
correlation
Information
measure
correlation2
Inverse
difference
moment norm
Inverse
difference norm
Inverse variance
Max probability
Sum average
Sum entropy
Sum variance
Variance

Run Length
Matrix
Gray-level
nonuniformity
High gray-level
run emphasis
Long run
emphasis
Long run high
gray-level
emphasis
Long run low
gray-level
emphasis
Low gray-level
run emphasis
Run length
nonuniformity
Run percentage
Short run
emphasis
Short run high
gray-level
emphasis

Neighborhood
Difference Matrix
Busyness
Coarseness
Complexity
Contrast

LoG Filtered
Features
fine filter
Entropy
Mean
Standard
deviation
Uniformity
Kurtosis
Skewness

medium filter
Entropy
Mean
Standard
deviation
Uniformity
Kurtosis
Skewness

128 | P a g e

The patient ROIs were pre-processed with a thresholding step to exclude air, bones,
and normal lung tissue. Values less than -150 HU or greater than 200 HU were excluded for
the patient images. For the motion phantom a lower threshold of -700 HU was used to ensure
none of the surrounding lung-equivalent material was included in the ROI. Thresholds were not
used for the texture phantom ROIs in order to ensure that all of the voxels within the ROI would
be included.
All the images were also rescaled to 8-bit images before calculating the co-occurrence
matrix, run-length matrix, and neighborhood difference matrix features; this was done to reduce
the effect of noise on the texture features and prevent sparsely populated matrices from being
produced. The histogram features were calculated both with and without 8-bit rescaling. The
LoG features were calculated without the rescaling step because the Gaussian filter already
acts to smooth the images and reduce noise. The LoG features were calculated at two different
scales: a fine filter (fineFilt) with a window size of 5 and sigma of 1 and a medium filter
(medFilt) with a window size of 7 and sigma of 1.5. Note this analysis was performed prior to
the in-depth analysis of image preprocessing on features in Chapter 4 and thus feature-specific
image-preprocessing was not used.
Effect of Scanners
During the course of treatment, a patient may receive some of his or her dose fractions
on a different linac than the one used for the first fraction, and thus the daily or weekly CBCT
images would be acquired from separate machines. Additionally, images from different patients
that are accumulated for a radiomics study are likely to come from different imagers. To
determine whether these differences have an influence on the resulting texture values, the
texture phantom was imaged with the CBCT imagers on 19 linacs, including 9 Elekta linacs and
10 Varian linacs. Two scans were acquired per machine: one with the default head protocol
and one with the default thoracic protocol for that machine. The standard image reconstruction
was used for all scans. The characteristics of these linacs and scans are described in Table
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6.3 Each scan was classified as a Varian head scan (V-Head), Varian thorax scan (V-Thorax),
Elekta head scan (E-Head), or Elekta thorax scan (E-Thorax). For each texture feature the
absolute difference between values measured from every possible pair of scanners was
calculated. These differences were then categorized by the types of scans being compared
(e.g. V-Thorax scan vs. E-Head). The differences were compared individually to the mean
intra-patient difference for each feature. If the difference between two scans was less than the
mean intra-patient difference, the comparison passed and the feature was considered
reproducible between those two scans. The mean intra-patient difference was used as the
criteria, because it was assumed that the phantom would demonstrate substantially less
variation than the patients when scanned under different conditions. The overall percentage of
passing scans for each comparison category was recorded. A high percentage of passing
scans implies that the feature is reproducible between that subset of linacs.
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Table 6.3: Scan characteristics for the phantom CBCT images used in this study. *For Elekta
machines the exposure time represents the pulse length, for Varian machines the exposure
time represents the full beam-on time.

ID

Manufacturer

Protocol

1
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
10
11
12
13
14
15
16
17
18
19

Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Elekta
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian
Varian

Head
Head
Head
Head
Head
Head
Head
Head
Head
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Head
Head
Head
Head
Head
Head
Head
Head
Head
Head
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax
Thorax

Image
Size
(pixels)
410
410
410
410
410
410
410
410
410
270
270
270
270
270
270
270
270
270
512
512
384
512
512
512
512
512
512
512
512
512
384
512
512
512
512
512
512
512

Pixel
Size
(mm)
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
0.5
0.5
0.7
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.9
0.9
1.2
0.9
0.9
0.9
0.9
0.9
0.9
0.9

Slice
Thickness
(mm)
5.00
3.00
4.00
4.00
5.00
4.00
4.00
2.00
2.00
5.00
3.00
4.00
4.00
5.00
4.00
4.00
2.00
2.00
2.50
2.50
2.50
2.50
2.50
2.50
2.50
1.98
1.98
1.98
2.50
2.50
2.50
2.50
2.50
2.50
2.50
1.98
1.98
1.98

Tube
Voltage
(kVp)
120
120
120
120
120
120
120
120
120
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
110
100
100
100
110
110
110
110
110
110
110
125
125
125

Exposure
Time*
(ms)
20
20
20
20
20
20
20
40
40
10
10
10
10
10
10
10
10
10
7300
7480
7160
7460
7560
7300
13180
7470
7350
7350
13160
13480
12900
13600
13660
12980
13180
13395
13275
13275

Tube
Current
(mA)
32
32
32
32
32
32
32
40
40
10
10
10
10
10
10
10
10
10
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
20
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Effect of Scatter
CBCT image quality is largely limited by the amount of scatter created by the volume
being imaged. The impact of different amounts of scatter from different sized patients on
radiomics values is unknown. The texture phantom used in this study is relatively small and
does not well approximate the amount of scatter created by a patient. To determine whether
increased scatter would substantially change texture feature values, the texture phantom was
imaged on its own, then with one layer (thickness of 2.5-8 cm on each side) of scatter material
(solid water equivalent and sandwich size Ziploc bags of rice), and then with two layers
(thickness of 5-11 cm on each side) of scatter material, Figure 6.2. These three setups were
imaged with both the head and thoracic protocols on a Varian linac.
The absolute differences in each of the features for both protocols with either one layer
or two layers of scatter material versus no surrounding scatter material and the difference
between one layer of scatter and two layers of scatter were calculated. The log of the ratio of
these differences in phantom values to the mean intra-patient differences was then calculated
as the metric for this test, Equation 6.2. A negative value for the log of the ratio implies the
phantom differences were less than the mean intra-patient difference and passed while a
positive value implies the phantom differences were larger and thus that the feature failed.

𝑝ℎ𝑎𝑛𝑡𝑜𝑚 𝑑𝑖𝑓𝑓
𝑙𝑜𝑔10 (
)
𝑚𝑒𝑎𝑛 𝑖𝑛𝑡𝑟𝑎𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑑𝑖𝑓𝑓
Equation 6.2
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A

B

C

Figure 6.2: Axial images of the radiomics phantom with added scatter material. To measure the
effect of scatter, the texture phantom was imaged with and without surrounding scatter material
of various thicknesses.
Effect of Motion
A third source of uncertainty in texture values obtained from CBCT images is the effect
of motion. Motion has a larger effect on values measured from CBCT images than conventional
CT images because the scans take longer to acquire. To analyze the effect of this motion, a
CIRS dynamic motion phantom was used, Figure 6.3 (CIRS, Virginia). This motion phantom
has a width of 30 cm, height of 20 cm, and length of 15 cm. These thicknesses provide some
scatter and were on par with the overall thicknesses created in the previous section studying
only scatter. No extra scatter material was added around the phantom.
This anthropomorphic phantom has a rod made of lung-equivalent material that can be
programmed to move cyclically with different respiratory rates through the phantom lungs. This
rod has a cavity designed for the placement of different tumor-equivalent or dose measurement
inserts. For our analysis, we created a block of the shredded rubber material that had the size
and shape of this cavity (height of 4.5 cm and diameter of 4.1 cm). Then the phantom was
programmed to move the rod using a 1-2cos4(t) waveform with peak-to-peak amplitudes of
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either 0, 2, 4, 6, 8, 10, 15, 20, or 25 mm. This waveform has been shown to be representative
of respiratory motion46,92. A new CBCT scan was acquired using the same thoracic protocol on
a Varian linac for each programmed motion.
A 3D ROI encapsulating the shredded rubber material was delineated manually on the
images of the phantom acquired with no motion. This ROI was copied to the images with
motion. Radiomics values were then calculated for each image set. Equation 6.2Equation 6.2
was used to determine at which amplitude of motion features ceased being reproducible. Here
the absolute difference between the texture value measured from images with motion and the
values measured without motion were calculated and used as the phantom difference values in
the numerator of Equation 6.2. The values were compared to the mean intra-patient difference
values, and as before, negative values implied passing, while positive values implied failing.
This test was repeated using only the center slice of the motion phantom’s original 3D ROI. The
values from only the center slice were expected to be more reproducible because the average
density change in the center of the image is less than at the edges, especially as the tumor
motion increases. This test was done to determine if texture features could be reliably
measured from tumors with large motion if the edges were excluded.
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A

B

C

Figure 6.3: Images of the CIRS dynamic motion phantom. (A) Setup for taking CBCT images of
the phantom with the shredded rubber insert in place. (B) An axial slice of the CBCT scan of
the phantom with the insert visible and (C) a zoomed-in coronal slice of the insert with the
largest motion of 25 mm.

Results
Patient Test-Retest CBCT Images
In the first part of this study we examined whether any features should be excluded
because they were not reproducible even when measured from two images of the same patient
acquired on the same scanner within 15 minutes. Of the original 68 features, 23 had a
CCC<0.9 and were excluded from further analysis, Table 6.4Table 6.4. Of the remaining 45
features, 8 were excluded because the absolute value of their rs with volume was greater than
0.85 for both the test and retest image sets, and thus might only be reproducible because they
are volume-dependent, Table 6.4. Thus, a total of 37 features remained for the subsequent
analyses. These included 5 features from the histogram without 8-bit scaling, 5 features from
the histogram with 8-bit scaling, 16 features from the co-occurrence matrix, 8 features from the
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run-length matrix, 1 feature from the neighborhood difference matrix, and 2 features filtered
with the medium LoG filter.
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Table 6.4: The results of the CCC and rs tests for the patient test-retest data. * Indicates
features that have passed all three of these initial tests and were used in the rest of the
analysis. VolDepA is the spearman correlation coefficient with volume using the first group of
patient images, VolDepB uses the second group of patient images.

Feature

CCC

VolDepA

VolDepB

CCC

VolDepA

VolDepB

RLMsrlgle

0.986

-0.964

-0.964

HISTSCmed

0.965

0.841

0.902

RLMsrhgle

0.968

0.358

0.358

HISTSCmean

0.980

0.842

0.915

RLMsre

0.984

-0.818

-0.891

HISTSCmax

0.909

0.830

0.834

RLMrunperc

0.991

-0.867

-0.891

HISTSCkurt

0.728

-0.115

0.164

RLMrlnu

0.986

-0.830

-0.891

HISTSCentropy

0.885

0.430

0.467

RLMlrlgle

0.977

0.782

0.600

HISTSCenergy

0.992

1.000

0.988

RLMlrhgle

0.990

0.939

0.939

HISTmed

0.982

0.782

0.903

RLMlre

0.988

0.891

0.842

HISTmean

0.980

0.891

0.915

RLMlglre

0.981

-0.830

-0.915

HISTmax

0.908

0.689

0.693

RLMhglre

0.982

0.842

0.915

HISTkurt

0.697

-0.176

0.200

RLMglnu

0.900

-0.758

-0.697

HISTentropy

0.926

0.624

0.539

NDMtexstr

0.765

-0.950

-0.950

HISTenergy

0.992

1.000

0.988

NDMcontrast

0.838

-0.867

-0.867

*

COMvar

0.981

0.491

0.406

NDMcomp

0.764

0.433

0.317

*

COMsumvar

0.980

0.745

0.745

NDMcoarse

0.943

0.750

0.667

*

COMsument

0.903

0.491

0.503

NDMbusy

0.609

-0.933

-0.933

COMsumavg

0.965

0.782

0.903

LOGMFunif

0.780

-0.095

-0.238

COMmaxprob

0.531

-0.091

-0.103

LOGMFstd

0.118

-0.548

-0.405

COMinvvar

0.984

0.709

0.673

LOGMFskew

0.895

0.810

0.762

COMinvdifn

0.936

0.952

0.964

LOGMFmean

0.969

-0.857

-0.690

COMinvdifmn

0.885

0.939

0.952

LOGMFkurt

0.932

0.833

0.786

*

COMinfomc2

0.933

0.842

0.818

LOGMFentropy

0.815

0.190

0.167

*

COMinfomc

0.944

-0.770

-0.624

LOGFFunif

0.736

-0.033

-0.217

*

COMhomog2

0.983

0.733

0.733

LOGFFstd

0.703

-0.667

-0.583

*

COMhomog

0.980

0.733
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Effect of Different Scanners
In the second part of this study we examined whether changing the scanner or protocol
resulted in changes in the texture features that were larger than the mean intra-patient
difference. Features that changed less than the mean intra-patient difference passed a
comparison and the overall passing percentages were recorded for each scanner/protocol
combination. The results of the inter-scanner analysis for each feature are shown in Table 6.5
for the shredded rubber cartridge and in Table 6.6 for the dense cork cartridge. Features were
most likely to be reproducible when scans using the same protocol and the same manufacturer
were compared. This result is highlighted in

Intra-Patient
Difference

Figure 6.4, where the results for entropy measured from the histogram are shown as an
illustrative example.
For shredded rubber, when the same protocol and manufacturer were used, 3 features
had a passing percentage of 100%, the average across all features was 31%, and 3 features
had a 0% passing percentage. When scans from the same manufacturer but different protocols
were compared, the highest passing percentage was 90%, the average was only 19%, and 23
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features had a 0% passing percentage. When scans from different manufacturers were
compared, the highest passing percentage was only 36%, the average was less than 1%, and
36 features had a 0% passing percentage.
For dense cork, the results were slightly better for each category and 1 feature, cluster
shade from the co-occurrence matrix, had a 100% passing percentage for every category.
When the same protocol and manufacturer were used, 6 features had a passing percentage of
100%, the average across all features was 43%, and 2 features had a 0% passing percentage.
When scans from the same manufacturer but different protocols were compared, 4 features
had a passing percentage of 100%, the average was 26%, and 13 features had a 0% passing
percentage. When scans from different manufacturers were compared, 2 features had a
passing percentage of 100%, the average was 10%, and 33 features had a 0% passing
percentage.

Intra-Patient
Difference

Figure 6.4: The absolute differences between pairs of scans plotted by the types of groups
being compared. Scans from machines of different manufacturers had the largest absolute
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differences which were above our criteria of the mean intra-patient difference (the horizontal
green line).
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Table 6.5: Results of the inter-scanner variability test for the shredded rubber ROI. When
categories from different manufacturers (E=Elekta and V=Varian) were compared, essentially
no comparisons passed the mean intra-patient difference threshold. When both the
manufacturer and protocol were the same, many of the features had a passing rate above
50%.

RLMsrhgle
RLMsre
RLMrlnu
RLMlrlgle
RLMlre
RLMlglre
RLMhglre
RLMglnu
NDMcoarse
LOGMFmean
LOGMFkurt
HISTstd
HISTskew
HISTSCstd
HISTSCskew
HISTSCmed
HISTSCmean
HISTSCmax
HISTmed
HISTmax
HISTentropy
COMvar
COMsumvar
COMsument
COMsumavg
COMinvvar
COMinfomc2
COMinfomc
COMhomog2
COMhomog
COMdissim
COMdifent
COMcontrast
COMclustend

E-Head E-Head E-Head E-Head E-ThoraxE-Thorax E-Thorax V-Head V-Head V-Thorax
vs
vs
vs
vs
vs
vs
vs
vs
vs
vs
E-Head E-Thorax V-HeadV-Thorax E-Thorax V-Head V-ThoraxV-HeadV-Thorax V-Thorax
13.9% 0.0% 0.0% 0.0%
2.8%
0.0%
0.0% 11.1% 6.0%
8.9%
16.7% 14.8% 0.0% 0.0% 11.1% 0.0%
0.0% 44.4% 54.0% 73.3%
22.2% 16.1% 0.0% 0.0% 13.9% 0.0%
0.0% 35.6% 40.0% 51.1%
16.7% 0.0% 0.0% 0.0% 11.1% 23.3% 16.7% 37.8% 25.0% 20.0%
13.9% 12.4% 0.0% 0.0% 11.1% 0.0%
0.0% 48.9% 60.0% 84.4%
5.6%
0.0% 0.0% 0.0% 16.7% 0.0%
0.0% 8.9% 13.0% 6.7%
22.2% 0.0% 0.0% 0.0% 11.1% 0.0%
0.0% 11.1% 10.0% 13.3%
61.1% 49.4% 0.0% 0.0% 44.4% 0.0%
0.0% 100.0% 0.0% 91.1%
36.1% 27.2% 0.0% 0.0% 22.2% 0.0%
0.0% 86.7% 56.0% 100.0%
47.2% 39.5% 0.0% 0.0% 25.0% 0.0%
0.0% 26.7% 0.0% 37.8%
36.1% 11.1% 15.6% 12.2% 16.7% 1.1% 16.7% 91.1% 0.0% 75.6%
44.4% 33.3% 0.0% 0.0% 22.2% 0.0%
0.0% 20.0% 0.0% 28.9%
83.3% 49.4% 0.0% 21.1% 50.0% 0.0%
6.7% 80.0% 39.0% 51.1%
44.4% 33.3% 0.0% 0.0% 22.2% 0.0%
0.0% 17.8% 0.0% 28.9%
83.3% 53.1% 0.0% 21.1% 50.0% 0.0%
6.7% 80.0% 43.0% 53.3%
27.8% 0.0% 0.0% 0.0% 11.1% 0.0%
0.0% 17.8% 10.0% 20.0%
16.7% 0.0% 0.0% 0.0% 13.9% 0.0%
0.0% 8.9% 8.0% 11.1%
0.0%
0.0% 0.0% 0.0%
5.6%
1.1%
3.3% 11.1% 0.0%
4.4%
16.7% 0.0% 0.0% 0.0% 11.1% 0.0%
0.0% 8.9% 10.0% 8.9%
2.8%
0.0% 0.0% 0.0%
5.6%
3.3%
3.3% 13.3% 0.0% 11.1%
55.6% 44.4% 0.0% 0.0% 38.9% 0.0%
0.0% 84.4% 0.0% 80.0%
44.4% 37.0% 0.0% 0.0% 19.4% 0.0%
0.0% 15.6% 0.0% 13.3%
8.3%
4.9% 0.0% 0.0%
2.8%
0.0%
0.0% 4.4% 0.0%
0.0%
47.2% 38.3% 0.0% 0.0% 27.8% 0.0%
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2.8%
0.0%
0.0% 13.3% 0.0%
6.7%
16.7% 12.4% 0.0% 0.0% 11.1% 0.0%
0.0% 26.7% 24.0% 44.4%
77.8% 69.1% 35.6% 0.0% 61.1% 31.1% 0.0% 35.6% 6.0% 57.8%
58.3% 55.6% 0.0% 0.0% 38.9% 0.0%
0.0% 35.6% 9.0% 84.4%
13.9% 13.6% 0.0% 0.0% 11.1% 0.0%
0.0% 31.1% 26.0% 51.1%
16.7% 16.1% 0.0% 0.0% 11.1% 0.0%
0.0% 28.9% 25.0% 42.2%
30.6% 23.5% 0.0% 0.0% 13.9% 0.0%
0.0% 4.4% 9.0% 24.4%
16.7% 18.5% 0.0% 0.0% 11.1% 0.0%
0.0% 20.0% 17.0% 42.2%
47.2% 32.1% 0.0% 0.0% 16.7% 0.0%
0.0% 4.4% 5.0% 11.1%
44.4% 37.0% 0.0% 0.0% 19.4% 0.0%
0.0% 15.6% 0.0% 13.3%
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Table 6.6: Results of the inter-scanner variability test for the dense cork ROI. Each value
represents the percentage of comparisons for that category of comparisons that were less than
the mean intra-patient difference value.

RLMsrhgle
RLMsre
RLMrlnu
RLMlrlgle
RLMlre
RLMlglre
RLMhglre
RLMglnu
NDMcoarse
LOGMFmean
LOGMFkurt
HISTstd
HISTskew
HISTSCstd
HISTSCskew
HISTSCmed
HISTSCmean
HISTSCmax
HISTmed
HISTmax
HISTentropy
COMvar
COMsumvar
COMsument
COMsumavg
COMinvvar
COMinfomc2
COMinfomc
COMhomog2
COMhomog
COMdissim
COMdifent
COMcontrast
COMclustend

E-Head E-Head E-Head E-Head E-ThoraxE-Thorax E-Thorax V-Head V-Head V-Thorax
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vs
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vs
vs
vs
E-Head E-Thorax V-HeadV-Thorax E-Thorax V-Head V-ThoraxV-HeadV-Thorax V-Thorax
25.0% 0.0% 0.0% 4.4% 21.4% 0.0%
0.0% 17.8% 20.0% 22.2%
16.7% 5.6% 0.0% 0.0% 17.9% 0.0%
0.0% 15.6% 25.0% 48.9%
30.6% 11.1% 0.0% 0.0% 17.9% 0.0%
0.0% 15.6% 25.0% 44.4%
0.0%
0.0% 0.0% 0.0%
7.1%
0.0%
0.0% 0.0% 1.0%
0.0%
2.8%
1.4% 0.0% 0.0%
7.1%
0.0%
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0.0%
0.0% 1.1% 0.0%
7.1%
0.0%
0.0% 2.2% 0.0%
0.0%
25.0% 0.0% 10.0% 15.6% 28.6% 0.0%
0.0% 17.8% 20.0% 26.7%
94.4% 69.4% 0.0% 0.0% 67.9% 0.0%
0.0% 77.8% 2.0% 95.6%
25.0% 9.7% 0.0% 0.0% 17.9% 0.0%
0.0% 22.2% 40.0% 77.8%
88.9% 54.2% 0.0% 0.0% 75.0% 0.0%
0.0% 40.0% 27.0% 80.0%
44.4% 43.1% 67.8% 51.1% 46.4% 57.5% 70.0% 95.6% 66.0% 88.9%
86.1% 50.0% 0.0% 0.0% 53.6% 0.0%
0.0% 33.3% 2.0% 71.1%
100.0% 100.0% 78.9% 97.8% 100.0% 72.5% 97.5% 100.0% 86.0% 93.3%
83.3% 48.6% 0.0% 0.0% 60.7% 0.0%
0.0% 33.3% 3.0% 71.1%
100.0% 100.0% 90.0% 100.0% 100.0% 66.3% 90.0% 100.0% 88.0% 95.6%
13.9% 0.0% 6.7% 5.6% 25.0% 0.0%
0.0% 11.1% 8.0% 15.6%
16.7% 0.0% 3.3% 5.6% 21.4% 0.0%
0.0% 6.7% 6.0% 13.3%
11.1% 0.0% 0.0% 0.0% 25.0% 0.0%
0.0% 17.8% 6.0% 11.1%
13.9% 0.0% 3.3% 5.6% 17.9% 0.0%
0.0% 6.7% 6.0% 11.1%
30.6% 0.0% 0.0% 0.0% 42.9% 0.0%
0.0% 42.2% 9.0% 26.7%
83.3% 50.0% 0.0% 0.0% 60.7% 0.0%
0.0% 53.3% 11.0% 95.6%
97.2% 66.7% 0.0% 0.0% 67.9% 0.0%
0.0% 22.2% 0.0% 60.0%
41.7% 11.1% 0.0% 0.0% 21.4% 0.0%
0.0% 4.4% 3.0%
4.4%
66.7% 38.9% 0.0% 0.0% 46.4% 0.0%
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47.2% 16.7% 0.0% 0.0% 21.4% 0.0%
0.0% 15.6% 4.0% 13.3%
72.2% 19.4% 0.0% 0.0% 21.4% 0.0%
0.0% 11.1% 19.0% 24.4%
88.9% 75.0% 51.1% 0.0% 100.0% 13.8% 0.0% 31.1% 1.0% 64.4%
58.3% 12.5% 14.4% 0.0% 60.7% 21.3% 0.0% 33.3% 9.0% 71.1%
19.4% 8.3% 0.0% 0.0% 17.9% 0.0%
0.0% 11.1% 18.0% 31.1%
22.2% 9.7% 0.0% 0.0% 17.9% 0.0%
0.0% 13.3% 19.0% 33.3%
63.9% 26.4% 0.0% 0.0% 35.7% 0.0%
0.0% 15.6% 23.0% 42.2%
33.3% 18.1% 0.0% 0.0% 17.9% 0.0%
0.0% 13.3% 22.0% 40.0%
100.0% 68.1% 0.0% 0.0% 92.9% 0.0%
0.0% 15.6% 27.0% 53.3%
97.2% 66.7% 0.0% 0.0% 67.9% 0.0%
0.0% 22.2% 0.0% 60.0%
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Effect of Scatter
In the third part of this study we examined whether adding scatter material created
changes in the texture features that were larger than the mean intra-patient difference.
Features that changed less than the mean intra-patient difference passed the comparison.
Results from the comparisons of features calculated with and without scatter material are in
Figure 6.5 and Figure 6.6. For the dense cork cartridge imaged with the thoracic protocol, 25 of
the 37 features were reproducible with 1 layer of scatter material. When a second layer of
scatter material was added, 16 features were still reproducible. However, for the shredded
rubber cartridge imaged with the thoracic protocol only 4 features were reproducible
(regardless of the amount of scatter material added).
For the head protocol, only 10 features from dense cork and 11 features from shredded
rubber were reproducible with 1 layer of scatter material. These features were not consistent,
and only 4 appeared in both groups. With 2 layers of scatter material, the number of
reproducible features from dense cork dropped to 4, while the number of reproducible features
from shredded rubber remained at 11, 9 of which were the same as before. The most
reproducible feature was skewness from the histogram.
The differences between 1 and 2 layers of scatter were smaller than the patient testretest differences for 23 of the features measured from the thoracic scan of dense cork and 11
for the head scan of dense cork. For the thoracic scan of shredded rubber only 5 features
passed and for the head scan of shredded rubber only 8 features passed.
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Figure 6.5: The impact of scatter on the reproducibility of radiomics features extracted from the
shredded rubber cartridge. For each comparison and feature, the base 10 log ratio of the
difference in phantom measurements to the mean intra-patient difference is plotted.
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Comparisons are described by the imaging protocol (head or thorax) and the amount of
surrounding scatter material (e.g. 1 layer versus no scatter material). Negative values are
highlighted in blue and imply smaller differences in the phantom measurements than in the
patient test-retest values and thus a “pass.” Positive values are highlighted in red and imply
that the phantom difference was larger than the mean intra-patient difference and thus a “fail.”
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Figure 6.6: The impact of scatter on the reproducibility of radiomics features extracted from the
dense cork cartridge. For each comparison and feature, the base 10 log ratio of the difference
in phantom measurements to the mean intra-patient difference is plotted. Comparisons are
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described by the imaging protocol (head or thorax) and the amount of surrounding scatter
material (e.g. 1 layer versus no scatter material).Negative values are highlighted in blue and
imply smaller differences in the phantom measurements than in the patient test-retest values
and thus a “pass.” Positive values are highlighted in red and imply that the phantom difference
was larger than the mean intra-patient difference and thus a “fail.”
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Effect of Motion
In the fourth part of this study we examined whether adding motion produced changes
in the texture features that were larger than the mean intra-patient difference. Features that
changed less than the mean intra-patient difference passed this comparison. The number of
features that were reproducible decreased with increasing motion amplitude, Figure 6.7 and
Figure 6.8. Three features: LoG filtered kurtosis, gray-level nonuniformity from the run-length
matrix, and entropy from the histogram, were reproducible for motions of 6-8mm when
measured from the entire volume. At 4 mm of motion, 12 of the 37 features were reproducible
for the entire volume. When only the center image slice was used for feature calculation, seven
features were reproducible for up to 6-10 mm of motion. The most consistent features
measured from only the center slice were coarseness from the neighborhood difference matrix,
high gray-level run emphasis and gray-level nonuniformity from the run-length matrix, sumaverage and information measure correlation from the co-occurrence matrix, and scaled mean
and entropy from the histogram. At 4 mm of motion, 14 of the 37 features were reproducible for
the center slice measurements.
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Figure 6.7: The impact of motion on the reproducibility of radiomics features extracted from the
dense cork insert in the motion phantom using the full 3D ROI. Comparisons are between
different peak-to-peak amplitudes of motion (2mm to 25mm) and no motion. For each
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comparison and feature, the base 10 log ratio of the difference in phantom measurements to
the mean intra-patient difference is plotted. Negative values are highlighted in blue and imply
smaller differences in the phantom measurements than in the patient test-retest values and
thus a “pass.” Positive values are highlighted in red and imply that the phantom difference was
larger than the mean intra-patient difference and thus a “fail.”
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Figure 6.8: The impact of motion on the reproducibility of radiomics features extracted from the
dense cork insert in the motion phantom using a 2D ROI from an axial image slice.
Comparisons are between different peak-to-peak amplitudes of motion (2mm to 25mm) and no
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motion. For each comparison and feature, the base 10 log ratio of the difference in phantom
measurements to the mean intra-patient difference is plotted. Negative values are highlighted
in blue and imply smaller differences in the phantom measurements than in the patient testretest values and thus a “pass.” Positive values are highlighted in red and imply that the
phantom difference was larger than the mean intra-patient difference and thus a “fail.”
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Discussion
Patient Test-Retest
The goal of this study was to determine whether any radiomics features can be
reproducibly measured from CBCT images so that features could be tracked periodically
through treatment. In order to investigate this question, we initially considered a large number
of features. Two tests were used to eliminate features that were not reproducible in a patient
test-retest dataset or that were only reproducible due to their volume dependence. Features
that were not reproducible even for the same patient on the same machine are extremely
unlikely to be useful in future models and could lead to erroneous results. Features that are
volume dependent will appear to be reproducible especially in patient datasets where the
volume range is large. However because volume is already known to be prognostic and is easy
to extract from patient images without the rigor of a texture analysis, volume dependent
features would not add meaningful information to future models and could have led to
misleading results in this investigative study. Approximately half the features initially considered
passed both of these qualifying tests. Interestingly, at least one feature from every feature
category was successful in passing these tests. The large number and wide variety of features
that passed, offer preliminary support for the possibility of texture analysis in CBCT images.
This relatively high pass rate occurred despite the strict criteria for reproducibility (CCC≥0.9).
We deliberately adopted very strict and conservative cutoffs here in order to minimize the
possibility of false-positives in this analysis. Many of the excluded features had CCC values in
the 0.75-0.89 range representing medium reproducibility and thus we may have excluded
features that could potentially be useful in the future.
In order to determine the effects of scanner, scatter, and motion on this reproducibility,
phantom measurements were compared to the mean intra-patient difference for each feature.
This choice of threshold is one limitation of our study since it is partly arbitrary, and may not
accurately reflect the amount of variability in a texture that would significantly influence an
154 | P a g e

eventual prognostic model. However because the purpose of this study was only to introduce
the magnitudes of variability that are created by changes in scanner, motion, and scatter we
feel that our choice of threshold is justified. Furthermore by using the mean of the differences
measured from patient test-retest data rather than the maximum, it is more likely that our
choice of threshold is overly conservative than lenient.
Another limitation of this part of the analysis was the small number of patients with
available repeat images. A larger patient dataset may have increased the variability we saw in
patient test-retest values which in turn may have increased the number of features that passed
each test.
Inter-Scanner Analysis
The results of our inter-scanner analysis strongly indicated that radiomics values
obtained from different imaging protocols or different linac manufacturers should not be
compared. This is a useful result for anyone considering extracting radiomics features from
CBCT images in order to produce a model. The Elekta values may have differed from the
Varian values because of manufacturer differences in Hounsfield unit scaling. CBCT CT
numbers can be more variable than the CT numbers in regular CT images because CBCT
images include more scatter due to the 2D detector geometry and are acquired with less dose
since they are used primarily for image setup versus the primary goals of CT images which
include diagnosis, contouring, and dose calculation. Additionally differences between
manufacturers in HU mapping from CBCT images could play a role in the observed differences
seen between scans of the same phantom.
The inter-scanner analysis also revealed that more features were likely to pass when
measured from the dense cork cartridge than the shredded rubber cartridge. This is likely
because the dense cork cartridge is physically more uniform than the shredded rubber
cartridge. For the same scan, the dense cork standard deviation was typically one-half to onethird the value of the shredded rubber standard deviation. Thus even when magnitude shifts or
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varying levels of noise are introduced by using a different scanner or protocol, the dense cork
cartridge individual voxels are less varied than those of the shredded rubber cartridge. The
patients’ standard deviations fell within the range of both cartridges so the values from the
shredded rubber cartridge can be assumed to approximate the variability in a patient with
heterogeneous texture while the dense cork cartridge may approximate a patient with
homogenous texture.
Some features were not reproducible even when both the manufacturer and protocol
were kept consistent. These features may be overpowered by the noise in the image making
them essentially random. This is probably the reason why features such as the maximum value
from the histogram failed each comparison. In other cases, such as low gray-level run
emphasis from the run-length matrix, the texture values from the patient and phantom images
are essentially always zero because the feature searches for specific patterns that do not exist
in images of tumors (such as straight lines).
This analysis also demonstrated that reproducible features could come from any of the
feature categories, e.g. skewness from the histogram, cluster shade from the co-occurrence
matrix, normalized gray level non uniformity from the run length matrix, and the mean after LoG
filtration. This broad spectrum of reproducible features is helpful, because features from
different categories may provide independent information about an image and when combined,
may be able to provide a more complete picture than one feature alone.
Effect of Scatter
When the texture phantom was surrounded by scatter material, most of the texture
values changed more than the mean of the patient test-retest differences. This result was not
surprising, as we know that more surrounding material will result in more scatter and thus a
larger amount of noise in the image as well as artifacts from beam hardening and cupping. The
differences between 1 layer and 2 layers of scatter material were also in general larger than the
mean intra-patient difference. This is a problem because it suggests that two patients with
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physiologically alike tumors (i.e. similar levels of heterogeneity) could have very different values
for their computed textures if the patients are dissimilar in size. The impact of this problem may
be limited if texture features measured from CBCT images are used to observe how the
features change for a single patient over time. For that analysis, the relative difference in a
texture value could be measured for each patient. The change in the amount of scatter would
likely be substantially less than shown here if each patient acted as his or her own control. A
recent study investigating c-arm CBCT demonstrated that relative changes in mean Hounsfield
units were consistent when measured within patients93. Thus, it is possible that relative
changes in texture may still be used for future prognostic models despite the effect of changes
in scatter levels on the absolute value measured from any one patient.
Effect of Motion
Most of the features changed substantially with increasing motion of the tumor texture
insert. The main reason for this result was hypothesized to be the slices of the ROI at the edge
of the texture insert, where the density changes were greatest. This hypothesis was supported
by our data for many of the features which did not significantly change with small motion if only
the center slice was used for their calculation.
While a majority of features were no longer reproducible beyond 2 mm of motion when
the entire tumor volume was used, 12 of the 37 features did still pass at 4 mm of motion and 4
of these even passed at 6mm of motion. The number of reproducible features dropped to zero
at 10 mm when the entire tumor volume was used and to 1 when only the center slice was
used. Therefore, we recommend a threshold of at most 10 mm and potentially as low as 5mm
for future studies. This threshold is not unduly restrictive since a recent study showed a
majority of patients with NSCLC had tumor motion less than 5mm and only 10% had motion
greater than 10 mm49. Thus we think a future study limited to patients with little motion and
selecting only these most reproducible features for further investigation would be feasible.
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Additionally, either 4D CBCT or breath-hold CBCT could be used to mitigate tumor motion in
future studies and may be more successful than shrinking the tumor contour.
Several features, when measured from the center slice, were reproducible at large
motions while not being reproducible at smaller motions. For example sum entropy from the cooccurrence matrix was reproducible with 2-4mm and 20-25 mm but not with 6-15 mm of
motion. This inconsistency suggests that at large motions the feature may be returning
reproducible values by coincidence or because of artifacts. Thus we would not consider this
feature reproducible beyond 4 mm.
It should also be noted that while the motion phantom was larger than the texture
phantom (32 cm vs 10 cm diameter), it is still smaller than many patients. Thus in a clinically
realistic scenario the effects of motion and additional scatter would be combined and may
further reduce the number of features or the range of motion that could be considered
reproducible.
Overall Best Performing Features
From our results it appears that select features are reproducible under certain
circumstances. Several of these reproducible features have been found useful in studies using
CT or contrast-enhanced CT images. One study found skewness, which we showed to be
robust to scatter, may aid in identifying tumors with genetic mutations32 while another study
demonstrated it was prognostic for overall survival25. LoG filtered kurtosis was useful for
identifying tumors with genetic mutations32 and we showed it was robust to scatter and motion.
Gray-level nonuniformity from the run-length matrix was the feature we tested that was most
robust to the effects of motion and it has been shown to be useful for predicting survival in
NSCLC23 and differentiating between benign and malignant lymph nodes21. Cluster shade from
the co-occurrence matrix was able to pass all of the scatter tests for the dense cork material,
and recently was shown to be useful for prognosis when used in a radiomics signature of three
features for NSCLC patients28. These links are encouraging but an independent study will still
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be needed to determine if models built on CBCT features alone can be prognostic. However it
should be clear that the features which did change more dramatically when measured from a
phantom than the calculated mean intra-patient differences in our study are unlikely to be
useful in future analyses using CBCT images of NSCLC unless the patient cohort was highly
restricted to patients exhibiting low intrascan variability (e.g. negligible tumor motion and
minimal weight change).

Conclusions
The goal of this study was to determine if texture features could be reliably extracted
from CBCT images under a variety of conditions. A total of 68 features were originally
considered. However, 31 of these features were excluded from the analysis because they did
not have a high CCC value when measured from a test-retest dataset or had a strong volumedependence that might be responsible for their high CCC. The remaining 37 features included
at least one feature from each feature category that had been studied. These features were
then investigated for susceptibilities to differences in scanners, imaging protocols, scatter, and
motion. Features changed significantly if they were calculated from images acquired with
different protocols or with scanners from different manufacturers. Future studies should attempt
to keep their imaging protocols as uniform as possible to avoid this source of error. Almost
every feature changed more than the mean intra-patient difference with the addition of scatter.
Thus, values of features may not be comparable between patients of different sizes while
remaining insensitive to small changes in size of each individual patient. Lastly, no features can
be reliably measured if the tumor motion is greater than 1 cm. For motion less than 1 cm,
reproducibility is improved if the edges of the tumor are excluded from the ROI for texture
calculation. In summary, certain texture features can be reliably measured from CBCT images
as long as the imaging protocol is consistent, relative differences are used, and patients are
limited to those with less than 1 cm of tumor motion.
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Chapter 7 : Treatment Modality Dependence of Radiomics
Features
In this chapter we describe the results for Specific Aim 4: Compare the changes in
radiomics features from patients treated with intensity modulated radiation therapy (IMRT) to
those treated with passive scatter proton therapy (PSPT). Our working hypothesis for this aim
was that the changes in radiomics features measured from patients treated with protons would
occur earlier in treatment compared to those treated with photons due to the increased relative
biological effectiveness (RBE).

Introduction
If radiomics features change during treatment due to biological changes in the tumor,
then the rate or magnitude of their changes may also be affected by the radiation modality used
(protons vs. photons). The patients used through the majority of this thesis and described in
Chapter 3 were treated with either passive scatter proton therapy (PSPT) or intensity
modulated radiation therapy using photons. The clinical relative biological effectiveness (RBE)
for protons is assumed to be 1.1 for calculating equivalent dose; however, it is known to vary
with depth of penetration and possibly between different tissues94,95. The RBE is a complex
function of dose per fraction, linear energy transfer (LET), tissue, and cell type94. If the
radiomics features are measuring biological differences from the images than any deviation
from a RBE of 1 could translate to a slower or faster rate of change in those features measured
from tumors treated with protons compared to features measured from tumors treated with
photons.
This study had several goals. The first was to compare the distribution of values at the
beginning and end of treatment between the patients treated with the two modalities. We
hypothesized that the distributions would be the same at the beginning of treatment but would
have significantly diverged by the end. The second was to determine how early in treatment
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these changes begin to occur for each treatment modality. We hypothesized the radiomics
features for patients treated with protons would demonstrate significant changes earlier in
treatment compared to patients who received IMRT due to the increased RBE of protons.

Methods
Features
For this study, the same feature set that was designed in Chapter 5 was used. This
feature set included 31 features that were calculated with feature-specific image preprocessing,
Figure 7.1. The feature-specific image preprocessing was determined by selecting the
technique that resulted in a significant (p-value<0.1) univariate cox proportional hazards fit for
the feature using its pre-treatment values and a non-significant (p-value>0.05) result for the
Wilcox rank sum test comparing values from two different CT models (GE Discovery ST and
the GE Lightspeed RT16). The feature set included features from the histogram, cooccurrence matrix, neighborhood gray-tone difference matrix, run length matrix, and shape
categories. Volume was added to this feature set as a comparison metric, bringing the total
number of features to 32.
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Figure 7.1: List of features included in the analysis of modality dependence and the image
preprocessing used to calculate each. None=no extra image preprocessing after image
thresholding, Smooth=images are smoothed with a Butterworth filter with an order of 2 and a
cutoff frequency of 125 prior to image thresholding, and Both=images are smoothed with a
Butterworth filter with an order of 2 and a cutoff frequency of 125, then thresholded, and then
resampled to 8 bit depth.
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Patients
For this analysis the patient cohort described in Chapter 3 was used again. These
patients had been treated with passive scatter proton therapy (PSPT) or intensity modulated
radiation therapy (IMRT). All patients were treated with 2 Gy fractions to either 66 or 74 Gy.
Each patient had a 4DCT pre-treatment image acquired for treatment planning and weekly
4DCT images acquired during their treatment. Radiomics features were calculated from the
tumor GTV ROI on the end-of-exhale phase of each of these images. This patient set was
reduced by different criteria to form 3 different subsets which are described in the next section.
ANOVA Classification
Of the 110 patients in the main cohort, 68 were treated with photons and 42 were
treated with protons. The patients treated with photons were overwhelmingly imaged with a GE
Discovery (362 of 448 weekly images) while the patients treated with protons were mainly
imaged with a GE LightSpeed RT16 (222 of 282 weekly images). Thus there was a risk that by
comparing the two groups, a significant difference in the radiomics feature values could be
found that was attributable to a difference in the CT models rather than the tumors. While
certain tests had already been performed during the feature-specific image preprocessing
selection in Aim 2 to negate this possibility, even stricter criteria were implemented for this
analysis to ensure that any discovered changes between treatment modalities could not be
attributed to differences in the CT models. To circumvent this possibility, an ANOVA analysis
was performed for each feature to evaluate whether it changed as a result of treatment and
was independent of CT model. To balance these two factors, a subset of 17 patients was
identified that had been imaged on each of the two CT models both early and late in treatment.
Images were classified as early in treatment if they were acquired for treatment planning (week
0) or during treatment weeks 1 and 2; images were classified as late in treatment if they were
acquired during treatment weeks 4 through 6. Features were considered to be significantly
different based on treatment time if the p-value was < 0.01. Features were considered to be
163 | P a g e

significantly different between CT models if the p-value was <0.2. Using these two cutoff values
each feature was classified as either (i) treatment dependent, (ii) model dependent, (iii)
treatment and model dependent, or (iv) treatment and model independent. A tight cutoff was
used to classify a feature as treatment dependent to ensure that only features with particularly
large changes were investigated. This also helps reduce the penalty from multiplicity
corrections in later tests. Similarly the p-value cutoff for a difference between CT models was
large to ensure even features with a weak dependence on CT model were classified as model
dependent and thus reduce the number of features classified as independent of CT model.
Analysis
The treatment dependent and treatment & model dependent groups of features were
investigated independently to determine how early during treatment they began to exhibit
changes and whether those changes were ever different between patients treated with protons
and those treated with photons.
Paired Wilcoxon signed-rank tests were used to evaluate at what time point during
treatment the radiomics features first exhibited significant changes from baseline. The test was
performed between the values at each week of treatment and the values at baseline.
Radiomics features for patients with an eligible CT image at a particular week were compared
to the radiomics feature values at pre-treatment using the Wilcoxon test. The final p values for
all comparisons were corrected for multiple comparisons using the Bonferroni method because
in this case the multiple hypotheses were not independent. Corrected p values < 0.05 were
considered significant.
Wilcoxon rank sum tests were used to determine if the radiomics feature values at any
week in treatment were different between patients treated with protons versus photons. The
final p values were corrected using the Bonferroni method for multiple testing, and corrected p
values of <0.05 were considered significant.
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Wilcoxon rank sum tests were also used to determine if the net changes in radiomics
features from patients treated with proton therapy were significantly different from the net
changes for patients treated with IMRT. Net changes were calculated between each week of
treatment and baseline. The final p values were corrected using the Bonferroni method for
multiple testing, and corrected p values of <0.05 were considered significant.
The subset of images available for each test was different based on the classification of
the features being investigated. For the treatment dependent features, the dataset was reduced
so that each patient only had values from the CT scanner on which most of their images had
been acquired. For the treatment & model dependent features, the dataset was reduced so that
all patients only had values from the GE Discovery ST. This was done so that the impact of CT
model was removed from the analysis for these features. However using only images acquired
on one scanner substantially decreases the power of the test and thus for features that were
not model dependent it was preferable to use the larger set of images for each patient. The
different cohorts used in this analysis were,
(i)

Primary cohort: 110 patients with between 2-8 images each acquired on any CT
model. This was the full original patient cohort and was decreased to form the
ANOVA, secondary, and tertiary cohorts as outlined in the guidelines below.

(ii)

ANOVA cohort: 17 patients with 4 images each. These were the patients who
had received a 4DCT on each of the primary CT models both early in treatment
(weeks 0-2) and late in treatment (weeks 4-6). This dataset was only used to
classify features as treatment dependent, model dependent, treatment & model
dependent, or treatment & model independent.

(iii)

Secondary cohort: 81 patients with between 2-8 images each, where for a given
patient all of their images were acquired on either the GE Discovery ST or GE
LightSpeed RT16, they had an image acquired on their main scanner by week 1,
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and had at least 2 images remaining after these criteria were implemented. In
this case any net change that was measured would be between the same
scanner. This cohort was used for comparing features that were not significantly
dependent on CT model. The number of patients with an image available at
pre-treatment was heavily weighted towards photon patients (43 photon patients
vs 6 proton patients) thus for this dataset, baseline was defined as Week 1 of
treatment where the distribution was more even (31 photon patients vs 28
proton patients). This meant only 59 of the possible 81 patients were used in
calculations.
(iv)

Tertiary cohort: 73 patients with 2 images each, where all of the images were
acquired on a GE Discovery ST. Each patient had a pre-treatment (Week 0)
4DCT for treatment planning and a mid-treatment 4DCT acquired on the GE
Discovery ST. The mid-treatment 4DCT was acquired on weeks 4-6. If the
patient had more than one image available during this period, one was chosen
based in this order of preference: week 5, week 6, week 4. This cohort was used
for analyzing features that were significantly dependent on CT model (the
treatment & model dependent feature set). The mid-treatment 4DCTs were
grouped together into week 5 for calculations since each patient only had 1 midtreatment 4DCT.

The feature set of primary interest were those that were treatment dependent with no
significant dependence on CT model. However using the tertiary cohort we were also able to
analyze features that were treatment & model dependent in a way that controlled for the model
dependence. Features that did not exhibit a dependence on treatment in the ANOVA analysis
were not examined.
The number of patients treated with each modality with an image at each week of
treatment for each of the cohorts is presented in Table 7.1. Then in Table 7.2 the number of
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images at each week used in the calculations after taking into account the baseline shift for the
secondary cohort and the mid-treatment grouping of images for the tertiary cohort are shown.

Table 7.1: Number of patients with an image available at each week for each cohort.

Cohort

Modality

Week 0

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Week 7

Primary Cohort

Photon

68

38

59

59

62

57

58

47

(All images)

Proton

42

29

37

40

36

34

35

29

Total

110

67

96

99

98

91

93

76

Secondary Cohort

Photon

43

31

41

43

43

37

44

32

(1 CT model

Proton

6

28

27

30

23

17

23

19

Total

49

59

68

73

66

54

67

51

Photon

54

0

0

0

1

46

7

0

(1 CT model

Proton

19

0

0

0

4

11

4

0

in the cohort)

Total

73

0

0

0

5

57

11

0

per patient)
Tertiary Cohort

1

Table 7.2: Number of patients at each week in each cohort used in calculations.

Cohort

Modality

Week 0

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Week 7

Primary Cohort

Photon

68

38

59

59

62

57

58

47

(All images)

Proton

42

29

37

40

36

34

35

29

Total

110

67

96

99

98

91

93

76

Secondary Cohort

Photon

--

31

25

27

28

23

27

18

(1 CT model

Proton

--

28

25

28

21

15

21

18

per patient)

Total

--

59

50

55

49

38

48

36

Photon

54

0

0

0

0

54

0

0

(1 CT model

Proton

19

0

0

0

0

19

0

0

in the cohort)

Total

73

0

0

0

0

73

0

0

Tertiary Cohort

1

1

The baseline for the secondary cohort was set to Week 1 instead of Week 0 because the

number of patients with an image available at Week 0 were heavily biased to those treated with
photons. 2Values for the tertiary cohort from Week 4-6 were grouped together into Week 5 to
increase power in calculations leading to a total of 54 photon patients and 19 proton patients
for that analysis.
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Clinical Factors
Clinical factors were compared between patients receiving IMRT versus PSPT using
the full patient set of 110 patients. A chi-square test was used for categorical factors and a
Wilcoxon rank-sum test was used for continuous factors. The characteristics for each group are
tabulated in Table 7.3 and the test results are summarized in Table 7.4 and show that smoking
status was the only covariate significantly differed between the patients treated with photons
versus protons.
Table 7.3: Clinical characteristics of the patients treated with protons versus photons.
Proton Patients
(n=42)
66.8 (51-76)
15
27
6
14
22
0
3
39
2
19
21
58.6 (4-200)
23

Photon Patients
(n=68)
64.4 (47-80)
32
36
2
35
30
1
3
65
7
48
13
54.1 (5-180)
40

19

28

19
23
12
30
8
34
0

30
38
12
56
4
62
2

66

12

26

74

30

42

Clinical Factor

Values

Age
Sex

Mean (range)
Female
Male
70
80
90
100
0
>0
Never
Former
Current
Mean (range)
Adenocarcinoma
Squamous cell
carcinoma
0-1
2-3
0-1
2-3
II
III
IV

KPS

ECOG
Smoking

Pack years
Histology

T Stage
N stage
Stage

Prescribed
dose
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Table 7.4: Differences in clinical factors for patients treated with photons versus protons
(n=110).

Clinical Factor

Test Used
Mann-Whitney
Chi-square
Chi-square

P value
0.164
0.332
0.057

Age
Sex
KPS
ECOG performance
status
Chi-square
0.857
Smoking status
Chi-square
0.003
Pack years
Mann-Whitney
0.873
Histology
Chi-square
0.826
T category
Chi-square
1.000
N category
Chi-square
0.267
Overall stage
Chi-square
0.059
Prescribed dose
Chi-square
0.407
ECOG: Eastern Cooperative Oncology Group; KPS: Karnofsky Performance Status

Results
ANOVA Results
Of the 32 features tested, 10 demonstrated both a strong dependence on dose in the
ANOVA (p <0.01) and no significant dependence on the CT scanner model used to acquire the
images (p>0.2), Figure 7.2. These were classified as treatment dependent. Of the other 21
features, 18 were dependent on treatment and CT model, 3 were only dependent on the CT
model, and 1 was independent of both treatment and CT model. Scaled values for one feature
from each group are displayed as boxplots in Figure 7.3. The p-values for both covariates after
correction are in Table 7.5
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Figure 7.2: Results of the ANOVA analysis for each feature to determine dependence on
treatment and CT scanner model. Features were categorized as treatment (TX) dependent,
model dependent, model and treatment dependent, or model and treatment independent. The
p values for both treatment and model were corrected for multiplicity using the Benjamini-
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Hochberg correction. A feature was considered dependent on treatment if its p value was <0.01
and dependent on model if its p value was <0.2.
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Figure 7.3: Example features for each of the ANOVA results. Boxplots of one feature from each
category of the ANOVA results were plotted to demonstrate the relative difference in feature
values with treatment (early-TX versus late-TX) and CT scanner model (Discovery ST versus
LightSpeed RT16). Feature values were scaled for visualization in this figure by subtracting the
mean and dividing by the standard deviation.
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Table 7.5: P-values from the ANOVA analysis.

Feature
COMautocorrel
COMinfomc
COMinfomc2
COMsumavg
COMsumvar
RLMhglre
RLMlglre
RLMsrlgle
HISTenergynorm
HISTmean
HISTmed
SHAPEcompact
SHAPEcompact2
SHAPEconv
SHAPEround
SHAPEspheredis
SHAPEsphericity
SHAPEsurfareaden
NDMtexstr
COMcontrast
COMcorrel
COMdissim
COMinvdifmn
COMinvdifn
RLMglnunorm
HISTstd
HISTkurt
HISTvar
COMdifent
RLMsre
HISTentropy
Volume

Treatment
P-value
0.001
0.001
0.005
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.010
0.005
0.006
0.005
0.006
0.004
0.001
0.016
0.003
0.063
0.002
0.006
0.004
0.024
0.007
0.006
0.006
0.002
0.002
0.006
0.024

CT Model
P-value
0.040
0.011
0.018
0.040
0.246
0.045
0.045
0.333
0.045
0.045
0.108
0.492
0.125
0.675
0.308
0.481
0.142
0.948
0.108
0.000
0.001
0.000
0.471
0.040
0.127
0.308
0.125
0.481
0.000
0.011
0.156
0.848

Classification
Treatment & Model Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment Dependent
Treatment & Model Dependent
Treatment Dependent
Treatment Dependent
Treatment Dependent
Treatment & Model Dependent
Treatment Dependent
Model Dependent
Treatment & Model Dependent
Model Dependent
Treatment & Model Dependent
Treatment Dependent
Treatment & Model Dependent
Model Dependent
Treatment Dependent
Treatment & Model Dependent
Treatment Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment & Model Dependent
Treatment & Model Independent
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Treatment Dependent Features
The results of the Wilcox sign-rank test comparing patients’ radiomics feature values at
each week of treatment to their values at week 1 for the 10 treatment dependent features are
shown in Figure 7.4. Of these features, 6 began to show significant changes in their values by
week 2 and all of the subsequent weeks were also significantly different from the baseline. 3
features began to show significant changes by week 3 that were also consistent through the
remainder of treatment. While 1 shape feature, roundness, was different by week 3 and
throughout treatment with the exception of one mid-treatment week, week 5. Boxplots of the
feature values at each week of treatment are shown in Figure 7.5.

Figure 7.4: Results of Wilcox sign-rank test comparing patients’ radiomics feature values at
each week of treatment to their values at week 1 for the treatment dependent features. The
majority of these features began to significantly change by treatment weeks 2 and 3.
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Figure 7.5: Boxplots of the radiomics features values through treatment for the treatment
dependent features. The radiomics feature values were scaled by subtracting the mean and
dividing by the standard deviation. Each boxplot is colored based on whether the change from
treatment week 1 to that week was significant with red indicating that the change was not
significant and blue indicating the change was significant.
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When the values in the radiomics feature values at each week or when the net changes
from week 1 were compared for the two treatment modalities, no feature demonstrated a
significant difference between the two treatment modalities. Results for each test can be seen
in Figure 7.6 and Figure 7.7. Boxplots for the feature values at each time point in treatment are
in Figure 7.8.

Figure 7.6: Results of Wilcox rank-sum test comparing the patients’ radiomics feature values by
treatment modality at each week for the treatment dependent features. At no point in treatment
were the values in the two groups significantly different.
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Figure 7.7: Results of Wilcox rank-sum test comparing the net changes between the patients’
radiomics feature values at each week of treatment to their values at week 1 by modality for the
treatment dependent features. At no point in treatment were the net changes significantly
different for the two modalities.
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Figure 7.8: Boxplots of the radiomics feature values through treatment and by treatment
modality for the treatment dependent features. The radiomics feature values were scaled by
subtracting the mean and dividing by the standard deviation. At no point in treatment were the
differences between the two modalities significant.
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Treatment & Model Dependent Features
For the 18 treatment and model dependent features, the tertiary cohort was used for the
analysis. Thus changes were only evaluated between weeks 0 and week 5. The results of the
Wilcox sign-rank test comparing patients’ radiomics feature values at week 5 to their values at
week 0 are shown in Figure 7.9. All of these features, showed significant changes at week
Boxplots of the feature values at each week of treatment are shown in Figure 7.10.

Figure 7.9: Results of Wilcox sign-rank test comparing patients’ radiomics feature values at
week 5 to their value at week 1 for the treatment & model dependent features. All of the
features demonstrated a significant change by mid-treatment.
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Figure 7.10: Boxplots of the radiomics features values at weeks 0 and 5 for the treatment &
model dependent features. The radiomics feature values were scaled by subtracting the mean
and dividing by the standard deviation. Each boxplot is colored based on whether the change
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from treatment week 0 was significant with red indicating that the change was not significant
and blue indicating the change was significant.
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When the values in the radiomics feature values at week 0 and week 5 or when the net
changes from week 0 were compared for the two treatment modalities, no feature
demonstrated a significant difference between the two treatment modalities. Results for each
test can be seen in Figure 7.11 and Figure 7.12. Boxplots for the feature values at each time
point in treatment are in Figure 7.13.

Figure 7.11: Results of Wilcox rank-sum test comparing the patients’ radiomics feature values
by treatment modality at weeks 0 and 5 for the treatment & model dependent features. At no
point in treatment were the values in the two groups significantly different.

182 | P a g e

Figure 7.12: Results of Wilcox rank sum test comparing the net changes between the patients’
radiomics feature values at week 0 to week 5 by modality for the treatment & model dependent
features. At no point in treatment were the net changes significantly different for the two
modalities.
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Figure 7.13: Boxplots of the radiomics feature values through treatment and by treatment
modality for the treatment & model dependent features. The radiomics feature values were
scaled by subtracting the mean and dividing by the standard deviation.
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Discussion
The goal of this analysis was to determine which radiomics features exhibited significant
therapy-induced changes during treatment, how early in treatment these changes occurred,
and whether they differed between patients who received PSPT and those who received IMRT.
A subset of features that exhibited significant, consistent changes as early as 2-3 weeks into
treatment was found. This is the same treatment window reported by radiomics and imaging
biomarker studies in other imaging modalities including FDG-PET96,97, diffusion weighted MRI98,
kV CT-on-rails99, and perfusion-CT100. Thus this may be the earliest possible detection of tumor
response for conventionally fractionated radiotherapy. The fact that radiomics features
demonstrated changes early in treatment for all patients may indicate that radiomics features
are related to early biologic responses to radiation therapy. It is also possible that patients
whose radiomics features change substantially from baseline early in treatment may be
classified as having a better response to radiation therapy. However, we explored this
hypothesis in Chapter 5 with this same patient set and found that changes in radiomics
features were not more prognostic than the feature values at the beginning of treatment or
typical clinical factors.
Interestingly, there were no significant differences between feature changes for patients
treated with protons and those treated with photons. A hypothesis of this study was that the
tumors treated with protons would demonstrate changes earlier in treatment as a result of the
higher RBE. This negative result may indicate that the use of the value 1.1 for proton RBE
accurately accounts for differences in dose deposition characteristics of proton therapy
compared to photon therapy in the tumor. Additionally for passive scattering proton therapy, an
increase in RBE above 1.1 may only occur at distal edges of the beams which are almost
always beyond the distal edge of the target volume and into the surrounding normal tissues.
Further, the net changes in radiomics features throughout the course of treatment, while
statistically significantly different from baseline, were small and may not be sensitive enough to
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detect even smaller differences owing to radiation therapy modality. Other sources of
uncertainty, such as respiratory motion and inter-fractional anatomy changes, may also have
further obscured the differences if they exist.
In this study, we focused on radiomics features that demonstrated changes throughout
therapy. However, during the ANOVA analysis, a set of features that were consistent
throughout treatment was also identified. The fact that this set of features did not change during
therapy most likely means that they are not measuring anything meaningful from the tumor and
are likely dominated by image noise.
Strict criteria were used in the ANOVA analysis for the classification of features to
reduce the feature dimensionality in the subsequent analyses and thus the multiplicity
correction penalization. Thus it is possible that some of the features classified by the ANOVA
as treatment independent, do in fact change during treatment but that their changes are smaller
than those features that were classified as treatment-dependent. For example, Volume which is
well known to change during treatment101–103 was classified as both treatment & model
independent because its corrected p-value for treatment was 0.024 and for model was 0.85. If
our criteria for treatment dependence had been loosened to 0.05 instead of 0.01, Volume
would have been included in the treatment-dependent group and 2 of the model dependent
features would have been included in the treatment and model dependent group. Because the
main goal of this analysis was to determine whether features demonstrate modality-specific
differences, it was more important to reduce the feature dimensionality in order to allow for the
possibility of finding those small changes than to explore when in treatment each feature
changes.
This study had a few limitations. First, the dataset was relatively small. Also, the number
of patients with CT images at each dose point differed as a consequence of the data condition
used to eliminate variation introduced by CT scanner model. This difference in the number of
patients being compared at different points in treatment may have been a cause of the fact that
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some features demonstrated significant changes at certain points during treatment but not
throughout the treatment. Additionally while we controlled for differences between scanners,
there are also known variabilities in radiomics features measured from test-retest patients on
the same scanner104. Thus some of the measured differences in treatment could be due to
variability in the features and not changes in the tumor. However this possibility seems small as
for all the patients, the features changed in the same direction (increased or decreased) over
the course of treatment. If the values were different only because of test-retest variability then
some of the patients’ values should have decreased and some of the patients’ values should
have increased leading to a negligible net effect for the patient population.

Conclusions
A set of radiomics features that exhibited significant radiation-induced changes over the
course of treatment was identified. At no point in treatment did these changes significantly differ
between patients treated with IMRT and those treated with proton therapy. Thus if any changes
in tumor biology are different based on treatment modality, they may not be large enough to be
measured using radiomics features.
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Chapter 8 : Discussion

The main goal of this study was to determine whether radiomics features calculated
from computed tomography (CT) images of non-small cell lung cancer (NSCLC) patients
change over the course of treatment, and if those changes were prognostic for outcome. We
also independently investigated if those features were reproducible in CBCT images, and if the
changes in features were different based on treatment modality. To accomplish this, we began
in Aim 1 by evaluating the impact of different image preprocessing techniques on the radiomics
features. Then in Aim 2 we used the results of Aim 1 to curate a set of radiomics features with
feature-specific preprocessing and evaluated their significance in univariate and multivariate
models. In Aim 3, radiomics features were measured from CBCT images of a texture phantom
to determine the influence of different imagers, scatter, and motion on their reproducibility.
Finally in Aim 4, we pinpointed when the features first began to change and if that rate or
magnitude of change was ever different between patients treated with protons versus photons.
In Aim 1 we calculated radiomics features from the pre-treatment images using a
variety of different image preprocessing techniques. For each feature and image preprocessing
combination we calculated the feature’s dependence on volume, dependence on CT model,
and prognostic significance. While other groups have investigated the impact of gray-level
discretization on the reproducibility of features44, we believe we are the first to propose these
metrics for deciding which version of a feature is the most useful. We found that most features
were more likely to be prognostic and independent of CT model if images were smoothed
before feature calculation either alone or in conjunction with a bit depth resampling step.
However the individual response was feature specific even within a category of features such
as the co-occurrence matrix. In addition to this main result we also identified five features that
were inherently volume dependent and proposed corrective factors for each. These corrected
features can be of use for future studies or can serve as a precautionary tale of some of the
188 | P a g e

possible weaknesses in using features not designed for analyzing medical images. Then we
designed a set of digital phantoms that can be easily used to test a feature’s independence
from volume or evaluate a user’s own understanding of a particular feature.
In Aim 2, the results of Aim 1 were used to design a methodology for selecting featurespecific image preprocessing for each radiomics feature. Then this set of features was
calculated from weekly 4DCT images to evaluate the ability of delta-radiomics features to
predict overall survival, time until distant metastases, and time until local-regional recurrence in
univariate and multivariate studies. In contrast to previous studies using the relative net
changes in features, this study included the slope of a linear regression of the feature, and the
value at the end of treatment as independent covariates for analysis. While there was strong
evidence that the features changed during treatment, these changes did not translate into
strong prognostic factors in either univariate or multivariate models. The delta-radiomics
features were able to significantly improve the model fit for overall survival but did not
substantially improve its performance. For time until distant metastases, only clinical factors
and radiomics features measured at pre-treatment were significant for both model fit and
performance. For time until local-regional recurrence, the final model included only one
covariate and it was texture-strength measured from the neighborhood difference matrix at the
end of treatment. Using this univariate model resulted in significant stratification of high and
low-risk patients. While these results did not provide strong evidence of the prognostic potential
of delta-radiomics features they were the first to investigate these features in NSCLC.
Additionally a framework for model building was generated which could be used with different
features designed to measure tumor heterogeneity or to investigate features in different image
modalities such as contrast-CT. Finally, one pre-treatment feature, compactness 2, was
successful at improving the prognostic performance of models predicting overall survival or
time until distant metastases. This supports several other analyses which have also found this
feature to be useful23,105.
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In Aim 3, we investigated whether features could be measured from CBCT images
because this would facilitate the aggregation of larger datasets to measure delta-radiomics
features in future studies. Almost half of the features we studied were not reproducible even in
a patient test-retest cohort where the same patient was imaged on the same CBCT scanner on
the same day. We found that the remaining features were highly impacted by differences in
motion, scatter, and imaging equipment when measured from a radiomics phantom under
varying conditions. Thus it will be important for any future studies seeking to use radiomics
features calculated from CBCT images to keep their imaging protocols as uniform as possible
and minimize motion. This was the first, and to our knowledge only, study using a radiomics
phantom to evaluate variability in radiomics features for CBCT images. This is an important
landmark because when the different sources of uncertainty are understood they can be
accounted for within the setup or analysis.
In Aim 4, we pinpointed when in treatment the features first began to significantly
change from baseline and determined if there was any difference in the rate or magnitude of
the changes for patients treated with PSPT or IMRT. We established that a subset of features
showed significant changes after 2-3 weeks of treatment but that there was no difference in
either the rate or magnitudes of these changes between patients treated with protons versus
photons. While this was a negative result, it did support the choice of 1.1 for the RBE when
calculating equivalent dose for proton treatments.
One limitation that was prevalent through all of these studies was the patient cohort
size. This became an even larger limitation when we tried to remove some of the variability in
the dataset prior to performing measurements. For example, the initial cohort of 157 patients
was decreased to 107 patients after several exclusion criteria (images acquired with 4DCT not
breathhold, primary GTV available in the treatment plan, and tumor volume>5cc) were
implemented prior to each of the aims. But then in Aim 4, this set was even further reduced to
73 patients in order to control for the fact that different patients had been imaged on different
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CT scanners throughout their treatment. This removed variability from the scanners but also
reduced the power of each statistical test and thus made it more difficult to find a significant
difference if one existed. A similar limitation was the lack of an independent validation set which
would have been particularly useful for Aims 1 and 2 where univariate and multivariate cox
proportional hazard models were built. We balanced this limitation by performing leave-one-out
cross validation in these instances.
The segmentation of the lesions may also have been a weakness in this study. We
defined the tumor ROI on each of the weekly images by deforming the primary GTV contour
from the treatment plan to each of the weekly images using an in-house, clinically validated
deformation software called CT-Assisted Targeting. Then I went through each of the images
and modified the contour to ensure consistency. While the vast majority of contours required no
edits by hand, many of the deformed contours for tumors connected to the mediastinum would
stray into it and thus slight manual edits would be necessary. In these cases, I erred on the
side of caution and would decrease the volume encapsulated by the contour to what I was
positive was the same area that had been identified as tumor in the treatment planning images.
This step would have benefited from input from a trained radiation oncologist familiar with
thoracic tumors. The segmentation can impact all of the radiomics features but is especially a
concern for the shape-based features. As mentioned in Chapter 5, those features that bordered
the mediastinum often were edited to have one smooth side as it was not clear where the
tumor ended and the mediastinum began and this smooth side could affect the shape based
radiomics features to have values closer to smooth floating style tumors that are typically less
aggressive than spiculated tumors.
Another limitation of this study, is the uncertainty about which radiomics features should
be used and how they should be calculated. There are hundreds of radiomics features that are
currently being explored by different groups and a practically infinite number of ways in which
each can be calculated. So far none of these features have been directly linked to a ground
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truth such as a genetic mutation. Thus it is impossible to know whether the subset of features
used in a study are the best features that could be used or if they are being calculated in a way
that would make them useful. Many radiomics studies handle this uncertainty by beginning with
a large set of features and whittling them down to those that are reproducible and cover a large
dynamic range in a test-retest patient set10,42,55,106. These are important steps however
reproducibility does not guarantee that the feature is linked to biology or even that it is
independent from volume. In this study we attempted to shed some light on these uncertainties
by calculating each feature after multiple different image preprocessing techniques and
evaluating the impact on the feature’s volume dependence, CT model dependence, and
prognostic significance. We then developed a method for selecting the optimal feature
preprocessing for each feature that was based largely on its prognostic ability when calculated
from pre-treatment images. While this allowed us to establish a pseudo-ground truth it also may
have biased the remainder of our analyses which sought to find the prognostic significance of
the delta radiomics version of these features. The original requirement that used the pretreatment version of the features was chosen for two reasons: first, because several
publications have shown that pretreatment radiomics features have informative value and thus
changes in the features that are already prognostic may reflect actual biological changes in the
tumor, and second, if model building was limited to delta-radiomics features that were
significant in univariate analyses the results could also be biased and overly optimistic.

Future Directions
One avenue for future research would be the use of auto-segmentation to contour the
tumors in this analysis. A study by Parmar et al demonstrated that feature reproducibility
increased when contours were segmented using a semiautomatic region growing algorithm107.
This result is not unexpected as auto segmentation typically leads to more reproducible
contours and the radiomics features are all influenced by the specific voxels contained within
the contour. This reproducibility is of especial importance in longitudinal studies such as this
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one, to make sure that the weekly contours are all defined in a systematic and reproducible
way so that the measured changes in the features are true changes in the tumor and are not
due to changes in the contours.
In this analysis all of the studied features were calculated globally. What this means is
that the final value is representative of the entire 3D tumor ROI. Thus if the tumor is large and
mainly homogenous with one small area that is heterogeneous, the signal from the
heterogeneous area can be lost amongst all the signal from the substantially larger
homogenous area. In future studies, features could be calculated locally instead to prevent this
effect. When features are calculated locally a pre-defined window is established (such as a
5mm x 5mm window) and then this window is slid over the tumor and at each interval the
features are recalculated for only the voxels within the window. The maximum or minimum
value for the feature from any of the windows can then be calculated and compared between
patients. So if for example, the feature was entropy from the co-occurrence matrix, it could be
more meaningful to evaluate whether a patient has a single region with high entropy at the
beginning of treatment. Then if the entropy value of this region decreases during treatment, that
decrease could signify that the most heterogeneous region of the tumor was destroyed during
treatment.
In order for radiomics to move from retrospective analyses to prospective clinical trials
and eventually alter patient treatment, the features must be standardized. This is an important
area of research that has been largely neglected in the past ten years of radiomics publications
as mentioned in many recent review articles34,68,108–112. The image biomarker standardization
initiative was recently formed to help tackle this important challenge and has already begun by
defining a list of features and their algorithms in specific detail113. A future step could be the
development of a set of test images to be available for download online along with a table of
calculated values for each of these standard features from the test images. This would allow
different researchers to calculate these same features with their own software and ensure that
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they are obtaining the same values. Then multi-institutional studies could be performed that
aggregate feature values from those institutions that have shown they can correctly measure
these features.
Another interesting area of future research would be the designing of new features
specifically for the analysis of medical images in radiomics studies. The majority of the features
used in the work presented here were designed in the 1970’s or 1980’s for comparing satellite
images11–14. As a result they may not be sensitive enough to pick up the relatively smaller
differences in heterogeneity or homogeneity in different tumors. They also, as we demonstrated
in Aim 1, are more likely to be sensitive to differences in volumes between the two tumors
being compared. Recent work by Prasanna and Tiwari is perhaps the start of a new wave of
features designed and validated for use specifically in radiomics114. They designed a feature
they named co-occurrence of local anisotropic gradient orientations (CoLIAGE) and evaluated
its ability to distinguish benign and malignant phenotypes in T1 weighted MRIs of the brain
(classified radiation necrosis versus recurrent tumor), DCE-MRI of the breast (classified two
molecular sub-types), and non-contrast CT images of the lung (classified granulomas versus
adenocarcinomas)114. In every case, this feature outperformed classical radiomics features
including the Haralick co-occurrence matrix features analyzed in this study.
One effort that could aid in designing useful features would be to begin by imaging and
contouring healthy tissues and comparing the values. Ideally, a set of features that can
differentiate between tissues such as the liver, lungs, kidney, muscle, blood in the heart, and
brain would be identified. If a feature cannot differentiate between these tissues which we know
are very biologically different then it is very unlikely that it would be able to pick out the more
subtle differences in heterogeneity of two lung tumors. Additionally, the ROIs for this evaluation
could all be kept the same size so that there is no impact from volume and multiple ROIs of that
size could be drawn in each tissue in the patient to assess both intra- and inter- patient
variability. Once a set of features that can differentiate these or other tissues was found, the
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experiment could be repeated using different size ROIs up to encapsulating the entire healthy
tissue to evaluate the effect of volume on these now known values. Once the normal range of
feature values in healthy tissue is well characterized, similar ROIs could be drawn on tumor
tissue and compared. For example, values from healthy liver could be compared to liver
lesions. Taking this one step further, these features could possibly even be used to train a
machine learning algorithm to classify voxels as healthy or tumorous tissue and thus allow for
the eventual auto-segmentation of tumors using radiomics features as was demonstrated by
Markel et al using the classical features115.
In addition to designing features specifically for radiomics analyses, designing imaging
protocols with the sensitivity necessary to pick up the tumor heterogeneity differences we are
trying to measure could be useful. However one of the strengths of radiomics is that these
studies can make use of medical images that are already routinely acquired. This makes it
easier to collect the large patient datasets which are necessary for high-throughput feature
analysis. Additionally imaging protocols are already carefully designed to balance visualization
needs with minimum radiation dose to the patient and short acquisition times. Thus instead of
changing the actual imaging protocols, it would be more feasible to harmonize the resulting
images prior to radiomics analysis. In this study, we achieved this harmonization by filtering the
images with a smoothing algorithm or bit depth resample in order to remove differences
between the two main scanners in this study, a GE LightSpeed RT16 and GE Discovery ST.
However these images had still been acquired using the same protocol and from the same
manufacturer. When images in the future are collated between institutions using different
imaging protocols or a greater variety of scanners, the differences in the images will be
larger40,41 and more effort will be needed to make the images equivalent via post-processing.
Our group is currently evaluating this need by imaging a new radiomics phantom on over 100
CT scanners in Texas using the default imaging protocol at each clinic. The results could be
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used to calibrate the images so that the resulting radiomics features are standardized and open
the door for larger multi-institutional radiomics studies.
Finally, while this study demonstrated that delta-radiomics features are not significantly
prognostic for NSCLC when measured from CT images, a similar study using contrast-CT
images could have better results. Contrast-CT images are acquired after iodine is injected as a
contrast agent into the patient’s blood stream intravenously116. The resulting images highlight
the vascularity of the tumor and allow for regions of necrosis to be identified. Thus radiomics
features measured from these images may be more meaningful than features measured from
non-contrast CT where the inter-tumor differences are more subtle. Radiomics features from
contrast-CT images have been successfully used to predict tumor response for soft tissue
sarcomas39 and predict patient outcomes for NSCLC26 when measured at baseline. Additionally
many features have been shown to be reproducible to differences in time between injection and
scan acquisition in contrast-CT71,117. While no radiomics studies have used delta-radiomics
features from contrast-CT images yet, one study by Lind et al showed that significant
decreases in the blood flow within NSCLC tumors treated with anti-angiogenic chemotherapy100
could be measured from serial contrast-CT scans. Thus using more sophisticated metrics such
as radiomics features could further improve our understanding of the changes taking place in
NSCLC tumors over the course of chemoradiotherapy and aid in predicting prognosis. The
same analysis methods presented in our study could be applied to this scientific question for
both the development of features and evaluation of their utility.

Conclusions
In this study we carefully constructed a set of features that were not dependent on CT
model or volume through the use of different image preprocessing techniques to evaluate
whether changes in features, delta-radiomics, were prognostic for NSCLC patients. We found
strong evidence that radiomics features change over the course of treatment. These changes
began to be significant as early as the second or third week of treatment for many features and
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were independent of treatment modality. However, both in univariate and multivariate models,
changes in features were less likely to be significant prognostic factors than their counterparts
measured from pre-treatment images or than classical clinical factors. Two features that were
prognostic were compactness 2 measured at pre-treatment for overall survival and time until
distant metastases and texture-strength measured at the end of treatment for local-regional
recurrence. When features were measured from CBCT images they varied substantially with
the choice of imaging unit, amount of scatter, and range of motion. Our results demonstrate the
importance of establishing uniform imaging protocols for use in radiomics studies as well as
developing rigorous standards for model building in radiomics analyses.
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Appendix A: IBEX Parameter Sheets

When radiomics features are calculated using the IBEX software, the output includes three excel sheets. The first sheet has the
quantitative feature value for each image and feature, the second sheet has the image characteristics such as the voxel size, and the third
sheet includes all of the parameters that were used to calculate the features. The following two tables in this appendix are the parameter
sheets for the feature sets used in Aims 2-4. The parameter sheet is made up of 6 columns in the following order: Category, Parameters,
Feature, Parameters, Preprocess, and Parameters. The three ‘Parameters’ columns refer respectively to the parameters used for the
Category, Feature, and Preprocess columns. These columns are grouped under ‘FeatureItem’ because in IBEX, the user begins by
selecting a feature category such as Shape. This category becomes the ‘FeatureItem’ in the parameter sheet. Then under that particular
category a number of different features can be selected and calculated using the same category parameters and imaging preprocessing
parameters. This saves the user having to reselect these for each individual feature. Thus in Table A1, the 7 features listed under
‘FeatureItem-1’ are all shape features that were calculated with the ‘Threshold_Image_Mask’ preprocessing technique. For more details
please refer to the paper by Zhang et al on IBEX50.
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Table A1: The feature and parameters sheet produced by the radiomics analysis software IBEX for the calculation of the radiomics
features used in Aim 2 and 4.
FeatureItem-1
Category

Parameters

Shape

Feature

Parameters

Preprocess
Threshold_Image_
Mask

Compactness1

Parameters
ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

Compactness2
Convex
Roundness
SphericalDispropor
tion
Sphericity
SurfaceAreaDensit
y
FeatureItem-2
Category

GrayLevelCooccur
enceMatrix25

Parameters
Direction=0 45
90 135;
AdaptLimitLevel=1;
GrayLimits=0
4096;
NumLevels=4096;
Offset=1;
Symmetric=0;

Feature

InformationMeasur
eCorr1

Parameters

Preprocess

Threshold_Image_
Mask

Parameters

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

InformationMeasur
eCorr2
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FeatureItem-3
Category

GrayLevelRunLen
gthMatrix25

Parameters

Feature

Direction=0 90;
GrayLimits=1
4096;
NumLevels=4096;

GrayLevelNonunifo
rmity

Parameters

HighGrayLevelRun
Empha

Preprocess

Parameters
cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;
Threshold_Image_
Mask

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

LowGrayLevelRun
Empha
ShortRunLowGray
LevelEmpha
FeatureItem-4
Category

NeighborIntensityD
ifference25

Parameters

Feature

NHood=5;
NHoodSym=1;
IncludeEdge=0;
AdaptLimitLevel=1;
RangeMin=0;
RangeMax=4096;
NBins=4096;

TextureStrength

Parameters

Preprocess

Parameters
cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;
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Threshold_Image_
Mask

FeatureItem-5
Category

IntensityDirect

Parameters

Feature

ThresholdLow=1;
ThresholdHigh=80
00; ErosionDist=0;
OnlyUseMaxSlice=
0;

EnergyNorm

Parameters

Preprocess

Parameters
cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;
Threshold_Image_
Mask

GlobalMean

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

GlobalStd
Kurtosis
Variance
FeatureItem-6
Category

Parameters

Feature

Parameters

Preprocess

Parameters
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GrayLevelCooccur
enceMatrix25

Direction=0 45
90 135;
AdaptLimitLevel=1;
GrayLimits=0
4096;
NumLevels=4096;
Offset=1;
Symmetric=0;

AutoCorrelation

cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;

Contrast

Threshold_Image_
Mask

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

Dissimilarity
InverseDiffMoment
Norm
InverseDiffNorm
FeatureItem-7
Category

GrayLevelRunLen
gthMatrix25

Parameters

Feature

Direction=0 90;
GrayLimits=1 256;
NumLevels=256;

ShortRunEmphasi
s

Parameters

Preprocess

Parameters
cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;
Threshold_Image_
Mask

ThresholdLow=900
;
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ThresholdHigh=12
00; ErosionDist=0;

BitDepthRescale_
Range

FeatureItem-8
Category

IntensityDirect

Parameters

ThresholdLow=1;
ThresholdHigh=80
00; ErosionDist=0;
OnlyUseMaxSlice=
0;

Feature

Parameters

GlobalEntropy

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

FeatureItem-9
Category

Parameters

Feature

Preprocess

Parameters
cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;
Threshold_Image_
Mask

GlobalMedian

Parameters

RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;

BitDepthRescale_
Range

RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

Preprocess

Parameters
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GrayLevelCooccur
enceMatrix25

Direction=0 45
90 135;
AdaptLimitLevel=1;
GrayLimits=0 256;
NumLevels=256;
Offset=1;
Symmetric=0;

Correlation

cutoff=125;
order=2;
x_padded_size=51
2;
Butterworth_Smoot
y_padded_size=51
h
2;
draw_before_after
=0;
images_folder=;

DifferenceEntropy

Threshold_Image_
Mask

SumAverage

BitDepthRescale_
Range

ThresholdLow=900
;
ThresholdHigh=12
00; ErosionDist=0;
RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

SumVariance
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Table A2: The feature and parameters sheet produced by the radiomics analysis software IBEX for the calculation of the radiomics
features used in Aim 3.
FeatureItem-1
Category

IntensityDirect

Parameters
ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;
OnlyUseMaxSlice=
0;

Feature

Parameters

Threshold_Image_
Mask

Energy

GlobalEntropy

Preprocess

Parameters

ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

GlobalMax
GlobalMean
GlobalMedian
GlobalStd
GlobalUniformity

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Kurtosis
Skewness
FeatureItem-2
Category
IntensityDirect

Parameters
ThresholdLow=1;
ThresholdHigh=25
6; ErosionDist=0;

Feature
Energy

Parameters

Preprocess
Threshold_Image_
Mask

Parameters
ThresholdLow=850
;
205 | P a g e

OnlyUseMaxSlice=
0;
GlobalEntropy

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

BitDepthRescale_
Range

ThresholdHigh=12
00; ErosionDist=0;
RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

GlobalMax
GlobalMean
GlobalMedian
GlobalStd
GlobalUniformity

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Kurtosis
Skewness
FeatureItem-3
Category

GrayLevelCooccur
enceMatrix25

Parameters
Direction=0 45
90 135;
AdaptLimitLevel=1;
GrayLimits=0
2100;
NumLevels=100;
Offset=1;
Symmetric=1;

Feature

Parameters

Preprocess

AutoCorrelation

Threshold_Image_
Mask

ClusterProminence

BitDepthRescale_
Range

Parameters

ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;
RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

ClusterShade
ClusterTendendcy
Contrast
Correlation
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DifferenceEntropy
Dissimilarity
Energy
Entropy
Homogeneity
Homogeneity2
InformationMeasur
eCorr1
InformationMeasur
eCorr2
InverseDiffMoment
Norm
InverseDiffNorm
InverseVariance
MaxProbability
SumAverage
SumEntropy
SumVariance
Variance
FeatureItem-4
Category

Parameters

Direction=0 90;
GrayLevelRunLeng
GrayLimits=1 256;
thMatrix25
NumLevels=256;

Feature

Parameters

Preprocess

GrayLevelNonunifo
rmity

Threshold_Image_
Mask

HighGrayLevelRun
Empha

BitDepthRescale_
Range

Parameters
ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;
RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

LongRunEmphasis
LongRunHighGray
LevelEmpha
207 | P a g e

LongRunLowGrayL
evelEmpha
LowGrayLevelRun
Empha
RunLengthNonunif
ormity
RunPercentage
ShortRunEmphasis
ShortRunHighGray
LevelEmpha
ShortRunLowGray
LevelEmpha
FeatureItem-5
Category

NeighborIntensityD
ifference25

Parameters
NHood=5;
NHoodSym=1;
IncludeEdge=0;
AdaptLimitLevel=1;
RangeMin=0;
RangeMax=4096;
NBins=256;

Feature

Parameters

Preprocess

Parameters

ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;

Busyness

Threshold_Image_
Mask

Coarseness

BitDepthRescale_
Range

RangeMin=0;
RangeMax=4096;
RangeFix=1;
BitDepth=8;

Parameters

Complexity
Contrast
TextureStrength
FeatureItem-6
Category
IntensityDirect

Parameters
ThresholdLow=1;
ThresholdHigh=10
0; ErosionDist=0;

Feature

Parameters

Preprocess

GlobalEntropy

NBins=256;
RangeMin=0;

Threshold_Image_
Mask

ThresholdLow=850
;
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OnlyUseMaxSlice=
0;

RangeMax=4096;
RangeFix=0;
GlobalMean

Log_Filter

ThresholdHigh=12
00; ErosionDist=0;
Size=5; Sigma=1;
FillROIOutOn=1;
FillROIOutValue=5
000;

GlobalStd
GlobalUniformity

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Kurtosis
Skewness
FeatureItem-7
Category

IntensityDirect

Parameters
ThresholdLow=1;
ThresholdHigh=10
0; ErosionDist=0;
OnlyUseMaxSlice=
0;

Feature

Parameters

Preprocess

GlobalEntropy

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Threshold_Image_
Mask

GlobalMean

Log_Filter

Parameters
ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;
Size=7;
Sigma=1.5;
FillROIOutOn=1;
FillROIOutValue=5
000;

GlobalStd
GlobalUniformity

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Kurtosis
Skewness
FeatureItem-8
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Category

IntensityDirect

Parameters
ThresholdLow=1;
ThresholdHigh=10
0; ErosionDist=0;
OnlyUseMaxSlice=
0;

Feature

Parameters

Preprocess

GlobalEntropy

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Threshold_Image_
Mask

GlobalMean

Log_Filter

Parameters
ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;
Size=11;
Sigma=2.5;
FillROIOutOn=1;
FillROIOutValue=5
000;

GlobalStd
GlobalUniformity

NBins=256;
RangeMin=0;
RangeMax=4096;
RangeFix=0;

Kurtosis
Skewness
FeatureItem-9
Category

Shape

Parameters

Feature

Parameters

NumberOfVoxel

EdgeVoxelFraction
=0.5;

Volume

EdgeVoxelFraction
=0.5;

Preprocess
Threshold_Image_
Mask

Parameters
ThresholdLow=850
;
ThresholdHigh=12
00; ErosionDist=0;
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